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Abstract
Eukaryotic Translation Elongation Factor 1 Alpha (EEF1A) exists as two forms 
with different tissue specificities and encoded by separate loci: eEF1A1 on 6q13 and 
eEF1A2 on 20q13.3. eEF1A1 is ubiquitously expressed whereas eEF1A2 expression is 
normally limited to the heart, brain and skeletal muscles. eEF1A proteins are GTP-binding 
proteins that recruit an amino-acylated tRNA to the ribosome during the elongation phase 
of protein translation.
eEF1A2 mRNA and protein are highly expressed in 50–60% of primary human 
breast tumors and metastases but not in normal breast epithelium. Since it is also 
overexpressed in 30% of primary human ovarian tumors, transforms rodent fibroblasts and 
increases their tumorigenicity in nude mice, eEF1A2 is considered to be a potential human 
oncogene. The mechanism of eEF1A2 expression is yet to be determined. Studies showed
no gene mutation and no correlation between locus amplification or methylation and gene 
expression.
Phosphate Tyrosine Kinase-6 (PTK6) is also located on 20q13.3. It is 48kb 
upstream of EEF1A2. PTK6 is a non-receptor tyrosine-kinase that is normally expressed in 
epithelial linings, prostate, skin and oral epithelium but it is not detected in the normal 
human mammary epithelium.
PTK6 has been found to be expressed in many breast cancer cell lines and in 
approximately 60% of primary human breast tumors but it has not been detected in normal 
human breast tissue nor in fibroadenomas. Like other tyrosine kinases, PTK6 
phosphorylates and activates downstream substrates that would be predicted to lead to 
increased transcriptional activity and therefore mediates proliferation of breast cancer cells. 
PTK6 is considered a prognostic marker of metastasis-free survival in breast cancer 
independent of the classical markers of tumor size, lymph node involvement and HER2 
status.
xx
The aim of this project was to characterize for the first time the genomic region 
containing the two mentioned breast cancer oncogenes and understand their various roles-
whether they act in tandem or independently in breast tumorigenesis. 
Immunohistochemistry was performed on tissue microarrays from 300 breast cancer 
patients to detect the expression levels of eEF1A2 and PTK6. Tumors that showed a high 
co-expression were analyzed for the genes’ copy number. An increased copy number of 
PTK6 was detected but not of eEF1A2 nor of adjacent genes on the 20q13.3 amplicon. 
To understand the effect of EEF1A2 expression on other genes, microarray analysis 
was performed on NIH-3T3 cells stably transfected with EEF1A2. Many upregulated genes 
were associated with different types of cancers. This was further confirmed by real-time 
PCR. However, when the NIH-3T3 cells were transiently transfected with EEF1A2, the 
genes that were upregulated in the microarray study showed no change in expression.
In conclusion, EEF1A2 and PTK6 act independently and each acts through a 
different mechanism in breast tumorigenesis. 
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Chapter 1: Introduction 
 
1.1 Breast Cancer 
Breast cancer is a complex and heterogeneous disease. It is the most common 
form of cancer in women and the third leading cause of cancer death in Europe 
(Ferlay et al., 2007). According to a study published in 2007 by Ferlay, et al, in 
Europe in 2006, it was estimated that 3,191,600 patients were diagnosed with cancer 
and 1,703,000 died from it. The most common type of cancer was breast cancer 
(429,900 cases, 13.5% of all cancer cases), followed by colorectal cancers (412,900 
cases, 12.9%) and lung cancer (386,300 cases, 12.1%). Lung cancer was the most 
common cause of cancer death with an estimated 334,800 deaths (19.7% of total), 
followed by colorectal (207,400 deaths), breast (131,900 deaths) and stomach 
(118,200 deaths) cancers (Ferlay et al., 2007).  
According to the Cancer Research UK statistics, it is estimated that more than 
44,000 women and 300 men are diagnosed with breast cancer each year in the UK. 
While different modalities of treatment (i.e. chemotherapy, hormonal therapy, 
radiotherapy and surgery) have improved significantly in the past decade decreasing 
the mortality and morbidity rates, each year in the UK more than 12,000 women and 
around 100 men die from breast cancer. Of these women, around 1,400 are under the 
age of 50. 
 
1.1.1 Risk factors for Breast Cancer 
Many risk factors play an important role in developing breast cancer. Age is 
one of the best documented risk factors in breast cancer. The incidence is extremely 
low before the age of 30 and increases until the age of 80. Unlike the direct link of 
cigarette smoking to lung cancer, no factors of this kind have yet been identified that 
have a major effect on the risk of breast cancer. There are, however, several factors 
that have a more limited effect. Alcohol consumption might increase the risk of breast 
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cancer. Numerous studies have shown that consumption of one drink per day or less 
(approximately 12 g alcohol) does not significantly affect the risk of breast cancer 
(Harvey et al., 1987; Longnecker, 1999; Mannisto et al., 2000). However, Royo-
Bordonado et al. reported that the relative risk associated with alcohol consumption 
was higher for those with body mass (BMI) index above the median (Royo-
Bordonada et al., 1997). In premenopausal women, BMI was not a risk factor for 
breast cancer incidence whereas in post-menopausal women, the risk is increased 
(Tretli, 1989). This is attributed to adipose tissue being a source for extragonadal 
estrogens. It is also shown that that women who began menstruating before the age of 
12 had a relative risk for invasive breast cancer of 1.3 compared to those who began 
after the age of 15 (Kyriazis et al., 1988). Hormone replacement therapy (HRT) and 
oral contraceptive use also increase the risk of breast cancer whereas prolonged 
lactation and physical exercise are protective against the disease. Other factors that 
increase breast cancer risk include: exposure to radiation, benign breast disease and 
mammographic density, a positive family history, previous history of neoplastic 
disease or hyperplasia in the breast and a genetic predisposition.  
 
 
1.1.2 Breast cancer classification 
 
Breast tumors are classified as non-invasive and invasive (Figure 1.1). Most 
breast cancers occur in the ducts of the breast which supply milk to the nipple. Breast 
cancer in this region is called ductal carcinoma. The less common form of breast 
cancer occurs in the lobules - where breast milk is made and is called lobular 
carcinoma. 
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Figure 1.1 Breast cancer classification: Non-invasive (DCIS) and invasive (CancerHelp UK). 
1.1.2.1 Non-invasive breast cancer 
Non-invasive breast cancer is an abnormal growth of cells within the area in 
which it started. These cancer cells have not invaded the surrounding breast tissue. 
The two types of non-invasive tumors are ductal carcinoma in situ (DCIS) and lobular 
carcinoma in situ (LCIS). DCIS is a non-invasive breast cancer and referred to as 
stage 0. In the UK national health screening program for which figures are available 
annually, diagnosis of DCIS now form some 20% of all breast cancers diagnosed by 
screening. LCIS on the other hand is not considered a true cancer, but rather one 
whose presence indicates an increased risk of developing cancer in the future.  
 
1.1.2.2 Invasive breast cancer 
When breast cancer cells invade the surrounding breast tissue from the ducts 
or lobules, the cancer is called invasive. This increases the chance for cancer cells to 
metastasize to the lymph nodes. Inflammatory breast cancer (IBC) and Paget’s 
disease of the nipple are two rare types of invasive breast cancer. Other less common 
forms of invasive breast cancer are medullary, mucinous, papillary and tubular 
carcinoma.  
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1.1.3 Male breast cancer  
Male breast cancer accounts for 0.7% of all breast cancers (Jemal et al., 2004) 
and 0.17% of all cancers in men (Appelbaum et al., 1999). It is found to be on the rise 
with the increasing incidence of breast cancer in women (Jemal et al., 2004). The 
incidence of breast cancer in men has increased by approximately 26% over the past 
25 years, affecting approximately one per 100,000 men per year in the United States 
(Giordano, 2005). The average age for male breast cancer is 67 years at diagnosis 
which is 5 years older than the average age for women diagnosed with the same 
disease (Giordano et al., 2004).  
The etiology of breast cancer in men is unclear; it has been suggested that 
hormonal levels play a role in the development of this disease. Several medical 
conditions have been associated with the increased risk of breast cancer in men. This 
includes testicular abnormalities such as undescended testes, congenital inguinal 
hernia, orchiectomy, orchitis and infertility (Fentiman et al., 2006; Sasco et al., 1993; 
Thomas et al., 1992), and conditions that result in increased estrogen levels, such as 
advanced age, poor liver function and Klinefelter’s syndrome (Giordano, 2005; Yang 
et al., 2001a). Klinefelter’s syndrome, an XXY sex chromosome anomaly may 
predispose up to 7.5% male breast cancers. This rate is higher than the 3% rate 
previously reported with a 50-fold increased risk of developing breast cancer relative 
to normal men (Hultborn et al., 1997).  
Gynecomastia is not believed to be a risk factor for breast cancer (Fentiman et 
al., 2006), whereas radiation therapy to the chest in men –as in women- increases the 
risk for developing the disease (Jellici et al., 2005). Men with a family history of 
breast cancer in a female relative have 2.5 times higher odds of having breast cancer 
than men without a family history (Fentiman et al., 2006).  
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1.1.3.1 Male breast cancer genetics 
Male breast cancer is more commonly associated with germline mutations of 
BRCA2 than BRCA1 (Fentiman et al., 2006). In population-based series, it was shown 
that between 5% and 15% of men with breast cancer unselected for family history 
have BRCA2 mutations, while 0–4% have BRCA1 mutations (Basham et al., 2002; 
Frank et al., 2002). Men who inherit the germline BRCA2 mutation have around 6% 
higher risk of developing breast cancer. This type of mutation tends to present at a 
younger age and may be associated with poorer survival (Kwiatkowska et al., 2003).  
Other genes have also been linked to male breast cancer. Mutations in the 
androgen receptor gene (AR), PTEN tumor suppressor gene, and mismatch repair 
genes (i.e., hMLH1) have been reported in males with breast cancers (Boyd et al., 
1999; Fackenthal et al., 2001). Pich et. al have shown that in men with breast cancer, 
the overexpression of c-myc, c-erbB-2, and p53 proteins is associated with poor 
prognosis (Pich et al., 2000). 
 
 
1.1.4 Genes associated with breast cancer 
Although environmental factors, hormonal and reproductive factors such as 
pregnancy history, age at menarche and age at menopause, play an important role in 
increasing breast cancer risk (Colditz et al., 2006), there is also strong evidence for a 
genetic component. First-degree relatives of breast cancer patients have 
approximately a 2-fold increase in risk for developing breast cancer and most of the 
excess risk is likely to be caused by genetic factors rather than shared environment 
(Lichtenstein et al., 2000; Peto and Mack, 2000). 
 
1.1.4.1 Oncogenes 
MYC is a gene that encodes a transcription factor involved in cell growth, 
differentiation and cell apoptosis. MYC is amplified and overexpressed in 15-20% of 
breast cancers (Aulmann et al., 2006). Even though gene amplification is always 
associated with protein expression, Blancato et al. have shown that in human breast 
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tumor tissues, myc overexpression is not always associated with gene amplification 
(Blancato et al., 2004). Even though no explanation in the literature suggests the 
reason for the overexpression, many mechanisms could be attributed to protein 
overexpression with normal gene copy number. These include gene mutation, 
signalling pathways being activated by other mechanisms such as gene fusion, ligand 
stimulation cross-activation by other substrates, and epigenetic factors. (General 
mechanisms of overexpression without amplification discussed in section 3.3.2) 
ERBB2 or HER2/neu is a gene encoding a tyrosine-kinase transmembrane 
receptor. The products of this gene are either amplified and/or overexpressed. ERBB2 
is overexpressed in 20-40% of breast cancer patients (Paik et al., 1990) and amplified 
in 20% of invasive breast cancers (Clark and McGuire, 1991). In most cases, HER-2 
overexpression is caused by amplification of the HER-2 gene (Pauletti et al., 1996). 
However, Koo et al. reported that HER-2 protein overexpressed breast cancer was 
detected without HER-2 gene amplification (Koo et al., 2009). The overexpression of 
this oncogene in breast cancer cell lines has shown an increase in the invasion 
properties and metastatic activity of the transfected cells (Tan et al., 1997). 
CCND1 is another oncogene that encodes cyclin D1. It is overexpressed in 40-
50% of breast cancer patients and amplified in only 20% of cases (Buckley et al., 
1993). Reis-Filho et al. found a good correlation between CCND1 amplification and 
cyclin D1 overexpression. However, few breast cancers that lacked CCND1 
amplification still showed a high expression of cyclin D1 (Reis-Filho et al., 2006). 
The fibroblastic growth factors (FGFs) and their receptors are involved in cell 
transformation by deregulating tyrosine-kinase receptor activity. FGF1 and FGF2 are 
frequently co-amplified with CCND1 in breast cancer but are much more rarely 
expressed than cyclinD1. FGFR1 is amplified in 10% of breast cancers (Adnane et 
al., 1991) and overexpressed in 20% whereas FGFR4 is overexpressed in 30% of 
breast tumors (Penault-Llorca et al., 1995). 
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1.1.4.2 Tumor suppressor genes 
TP53 or p53 is a transcription factor that was first recognized when a germline 
mutation was found to be responsible for Li-Fraumeni Syndrome (Malkin et al., 
1990). Patients with this syndrome have an increased risk of several cancers with the 
most frequent being breast cancer (Hollstein et al., 1991). TP53 mutations are found 
in 15-35% of sporadic breast cancer cases and are often accompanied by loss of the 
wild-type allele (LOH) (Greenblatt et al., 1994). Most TP53 alterations found in 
breast carcinomas are point mutations leading to the synthesis of a mal-functional 
protein. 
RB1 is a retinoblastoma gene that regulates the cell cycle. In the absence of 
the gene, cells may undergo uncontrolled proliferation leading to tumour formation. 
RB1 showed a loss of expression in 20% of breast cancer cases (Varley et al., 1989).  
BRCA1 and BRCA2 are the most studied tumor suppressor genes associated 
with breast cancer. Mutations of these genes in sporadic breast cancers are rare but 
deletions of one or more exons have been found in the inherited form. A decreased 
expression of BRCA1 is due to hypermethylation (Dobrovic and Simpfendorfer, 
1997) whereas no hypermethylation of BRCA2 was reported (Collins et al., 1997). 
BRCA2 is overexpressed in 20% of breast cancers. This overexpression is correlated 
with poor prognosis (Bieche et al., 1999).  
PTEN is a tumor suppressor gene encoding a lipid phosphatase that negatively 
regulates the cell-survival signaling pathway. It dephosphorylates 
phosphatidylinositol 3,4,5-trisphosphate (PI-3,4,5-P3), the product of phosphatidyl 
inositol 3-kinase (PIK). Data suggests that the phosphatase activity of PTEN is 
essential for its function as a tumor suppressor. The activation of Akt/PKB is 
regulated by the phosphorylation of Akt on Thr308 and Ser473 by phosphoinositide-
dependent kinase (PDK) and integrin-linked kinase (ILK), respectively (Simpson and 
Parsons, 2001). Inactivation of PTEN allows constitutive and unregulated activation 
of the Akt/PKB signaling pathway. In addition to regulating the Akt/PKB signaling 
pathway, PTEN also inhibits growth factor (GF)-induced Shc phosphorylation and 
suppresses the MAP kinase signaling pathway. PTEN interacts directly with FAK and 
is able to dephosphorylate activated FAK. PTEN-induced down-regulation of 
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p130CAS through FAK results in inhibition of cell migration and spreading (Besson et 
al., 1999). Somatic mutations are rare in sporadic breast cancer (Rhei et al., 1997). 
However, a germ-line mutation in this gene is responsible for Cowden disease which 
is associated with a high risk of breast cancer (Lynch et al., 1997). 
ATM is a kinase that is activated by DNA damage which initiates the DNA 
damage checkpoint by phosphorylating a number of key proteins. Once activated, the 
checkpoint leads to cell cycle arrest and either DNA repair or apoptosis. Mutations of 
the ATM gene are responsible for Ataxia Telangiectasia, an autosomal recessive 
disorder characterized by cerebellar ataxia, telangiectasia, immunodeficiency and a 
predisposition to malignancies including breast cancers. Women with ATM mutations 
causing Ataxia Telangiectasia were found to have a 2-fold increase risk of developing 
breast cancer (Renwick et al., 2006). 
E-Cadherin (CDH1) is a cell adhesion molecule. It is mutated in 20-40% of 
cases of lobular breast carcinoma (Berx et al., 1995). In invasive breast cancer, no 
mutation has been reported but a decreased expression of CDH1 is observed (Rimm 
et al., 1995). The low expression could be due to the hypermethylation of the 
promoter region (Graff et al., 1995).  
The cyclin-dependant kinases inhibitors (Cdki) are cell cycle regulators that 
inhibit the cyclin/cdk complex. Some of these genes act as tumor suppressor genes 
such as p16 and p27. Mutations in p27 have been reported in breast cancer (Spirin et 
al., 1996). p27 is expressed at high levels in normal breast tissue but shows low 
expression in breast cancers and is associated with poor prognosis (Catzavelos et al., 
1997).  
1.1.5 Genomic regions altered in breast cancer  
Many regions have been frequently reported to be altered in breast cancer. 
These regions are either amplified or deleted. Many cancers have been analyzed in 
genome-wide array Comparative Genomic Hybridization (aCGH), these include both 
common cancer types, such as breast (Naylor et al., 2005) and colorectal cancers 
(Kim et al., 2006), as well as more rare cancer types such as gastrointestinal stromal 
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tumors (Assamaki et al., 2007). These studies analyzed copy number changes in 
various cancer types to understand the patterns of copy number alterations occurring 
during cancer development. A number of regions that are frequently involved in gains 
and losses have been identified (section 1.1.5.1 & 1.1.5.2). Naylor et al. compared the 
location, frequency and size of copy number changes in 47 primary breast cancers 
versus 18 breast cancer cell lines using aCGH (Figure 1.2). They identified gains on 




Figure 1.2 Array-based comparative genomic hybridization (aCGH) frequency plots of breast 
cancers and cell lines. Plots of primary breast cancers (light) overlaid onto breast cell lines (dark) with 
gains in green and losses in red (Naylor et al., 2005). 
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1.1.5.1 Amplification - Gain of genetic material  
Amplification can be due to gain of part of a chromosome or a whole 
chromosomal arm. The gain of an entire chromosome arm could be the result of 
mitotic non-disjunction whereas gene amplification could be the result of the 
dominant action of such genes.  
Hicks et al. have used Representational Oligonucleotide Microarray Analysis 
(ROMA) to detect genomic amplifications in breast tumors. They identified a pattern 
characterized by multiple closely spaced amplicons they called “firestorms” where 
tumors were profiled for copy number at a resolution of <50kb (Hicks et al., 2006). 
This term was given to amplified regions in the genome that were close to one 
another on the same region of the chromosome. The multiple amplifications on a 
single chromosome arm were highly correlated with aggressive disease and poor 
survival in patients. 
Comparative genomic hybridization (CGH) has shown frequent gain of 
chromosome arms of 1q and 8q (Tirkkonen et al., 1998) in approximately 40% of 
cases. The most frequently amplified regions in breast cancer are 16p11, 17q11.2, 
17q24 and 20q13. These amplifications are seen in over 15-20% of breast cancers 
(Kallioniemi et al., 1994).  
 
1.1.5.1.1 Amplification of 20q13 in cancer 
Amplification is an important mechanism for oncogene overexpression in 
breast cancers. Several amplified regions may participate to breast cancer initiation 
and/or progression. Of these regions, 20q13 - which is amplified in 8.5-10% of 
tumors- plays an important role in breast cancer (Letessier et al., 2006). High level of 
20q13 amplification was associated with short disease-free survival in lymph node-
negative patients (Tanner et al., 1995). In breast cancer and other types of 
malignancies, several potential oncogenes have been reported including EEF1A2 (Lee 
and Surh, 2009), BRK/PTK6 (Zhang et al., 2005), MYBL2 (Forozan et al., 2000), 
STK6/AURKA/Aurora A (Sen et al., 1997) and ZNF217 (Nonet et al., 2001). All these 
genes are within a 20Mb region (Figure 1.3).  
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Figure 1.3 20q13 region showing potential oncogenes in breast cancer. PTK6 (8.8kb), EEF1A2 
(11kb). AURKA (23kb), ZNF217 (16kb) and MYBL2 (49kb). All genes are within a 20Mb region. 
Arrows indicate the orientation of gene expression. 
 
 
In breast cancer, correlations between levels of amplification and gene 
expression have been reported. Xiang et al. have reported the associated co-
amplification and correlated overexpression of BRK and ERBB2 in breast cancer. 
They found that ERBB2 protein interacts with BRK protein, and increases its intrinsic 
kinase activity. Expression of Brk enhanced the ErbB2-induced activation of 
Ras/MAPK signalling and cyclin E/cdk2 activity resulting in proliferation of cultured 
breast cells (Xiang et al., 2008). These studies demonstrated the potential for genes 
located on distinct amplicons to co-operate in the induction of transformation. 
High level of 20q13 amplification was associated with faster cancer 
progression and worse patient survival in colon and ovarian cancer (Aust et al., 2004; 
Tanner et al., 2000). Amplification of the EEF1A2 gene at this locus have been 
reported in human lung adenocarcinoma (Li et al., 2006). siRNA knockdown 
inhibited proliferation and promoted apoptosis and expression of EEF1A2 protein 
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1.1.5.1.2 Mechanisms of gene amplification 
Gene amplification is likely to occur due to a DNA double-strand break, 
genome rearrangements and in cells lacking checkpoints. The initiation of 
amplification has been attributed to defects in DNA replication, telomere dysfunction 
and chromosomal fragile sites.  
 
1.1.5.1.2.1 DNA replication 
Eukaryotic cells normally replicate their DNA only once every cell cycle. This 
regulation is important because re-replication would threaten genome stability and 
therefore eventually lead to increased cell division and cancer development. This 
would explain the case of the ERBB2 gene for example. Due to the importance of 
DNA replication in cancer, many anticancer drugs target various aspects of DNA 
replication. Role of DNA replication in cancer proliferation has been reported in 
many malignancies such as the hereditary cancers of the colon, breast, ovary and skin. 
These can be caused by mutations in DNA replication genes, such as translation 
synthesis, intra- S-phase signaling or mismatch repair genes (Sancar, 1994; Marra and 
Boland, 1995; Bertwistle and Ashworth, 1998; Masutani et al., 1999). In somatic 
cancers, such early mutations would probably have a lesser effect as the disease 
progresses, therefore making the relationship less obvious.  
 
1.1.5.1.2.2 Telomere dysfunction 
Telomeres prevent the loss of DNA sequences that occurs due to incomplete 
replication of linear DNA at a chromosomal end. At the end of each replication, the 
DNA is shortened by 40-50bp. Telomeres are replicated by the enzyme telomerase 
which is inactive in somatic cells. When telomeres get shortened to a critical length, 
cells undergo senescence and therefore stop proliferating. In tumors, telomerase is re-
activated and cells maintain telomere length. However, before these tumor cells adapt 
to telomere dysfunction, they could have proliferated with such short telomeres 
risking the susceptibility of fusion and therefore abnormal cell division (Londono-
Vallejo, 2004).   
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Telomere dysfunction is one of the mechanisms leading to amplification 
through the breakage-fusion-bridge (BFB) where a chromosomal break or a 
dysfunctional telomere leads to chromosomal ends fusion resulting in a dicentric 
chromosome formation. During anaphase, a chromosomal break occurs which leads 
to the generation of an inverted duplication of terminal sequences. This process will 
be repeated in following cell divisions until the chromosomal ends are stabilized by 
addition of telomeric sequences probably by translocation to another chromosome. 
This BFB event will eventually result in generating an amplicon at the site of the gene 
where the units are arranged as inverted repeats. 
 
1.1.5.1.2.3 Fragile sites 
Fragile sites are chromosomal regions prone to breakage under conditions of 
replication stress such as exposing cells to agents interfering with DNA replication. 
More than 120 different fragile sites have been identified in the human genome 
(Lukusa and Fryns, 2008). These regions are likely to be flexible and therefore 
associated with high frequency of recombination leading to chromosomal aberrations 
associated with different types of cancer (Glover et al., 2005). In effect, they are 
regions prone to breakage that could initiate the amplification process. Miller et al. 
have reported that fragile sites participate in amplification in human cancers where 
they showed that the boundaries of MET amplicon map within the fragile site FRA7G 
in esophageal cancer (Miller et al., 2006).  
 
1.1.5.1.3 Overexpression due to amplification 
Overexpression is usually associated with gene amplification. An example of 
a gene overexpressed due to amplification –as mentioned in section 1.1.4.1- is HER-
2. HER-2 is a gene located on chromosome 17q12 that encodes a transmembrane 
protein with tyrosine kinase activity. Overexpression of HER-2 in breast cancer and is 
associated with poor prognosis, aggressive disease and poor response to hormonal 
therapy (Carr et al., 2000). 
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1.1.5.1.4 Overexpression without amplification 
Varis et al. have evaluated the amplification and expression levels of three 
target genes, HER-2, TOP2A and DARPP32, located on the 17q12 amplicon in gastric 
cancer. They showed that of the three genes, DARPP32 was the most highly 
overexpressed gene (Varis et al., 2004). Several cancers with gene overexpression 
were found but lacked DARPP32 amplification. This suggests that mechanisms other 
than gene amplification are responsible for DARPP32 upregulation. 
Another gene reported to be overexpressed in breast cancer but its 
overexpression was not correlated with amplification is PPM1D. PPM1D is one of 
the drivers of the 17q23.2 amplicon which is associated with several types of cancers. 
Lambros et al. reported that it is amplified in only 6% of cases and that PPM1D 
amplification was strongly associated with the mRNA expression levels (Lambros et 
al., 2010). However, they show that PPM1D overexpression is more prevalent than 
gene amplification. 
HDM2 gene, the human homologue of murine mdm2 is an oncogene that 
maps to chromosome 12q13. HDM2 blocks the function of p53 by binding to its 
transcriptional activation domain. Melanoma cell lines were reported to express 
HDM2 protein but there was no evidence of gene amplification (Polsky et al., 2001). 
The mechanisms driving HDM2 overexpression are yet to be investigated.  
Roles of EEF1A2 & PTK6 in Breast Cancer 
Chapter 1: Introduction 15
1.1.5.2 Deletion - Loss of genetic material 
Many deleted chromosomal regions have been associated with cancer. 
Deletion of the same loci in different tumors suggests the existence of tumor 
suppressor genes in this region. The loss of function of tumor suppressor genes 
requires the loss or inactivation of both copies of the gene. This usually occurs by 
mutation of one allele and LOH of the wild type one. The most frequently lost 
chromosomal arms that have been reported using CGH are 1p, 3p, 6q, 8p, 9p, 11p, 
13q, 16q, 17p. These deletions are observed in more than 20-25% of breast cancers. 
On the other hand, deletions at 1q, 7q, 11p, 17q, 18q and 22q have been reported in 
15–20% of breast cancers by LOH studies (Devilee et al., 1991).  
 
1.2 Mechanisms of gene expression 
Gene expression is modulated by many epigenetic markers that are involved 
in transcriptional and translational regulation. The nucleosome is the basic unit of the 
chromatin. It is composed of the four core histones H2A, H2B, H3 and H4 as well as 
146 basepairs of DNA wrapped around the histones (Luger et al., 1997). Each core 
histone is composed of a structured domain and a tail of unstructured amino-terminal 
of 25-40 residues. Histone tails provide sites for a variety of posttranslational 
modifications, including acetylation, phosphorylation and methylation (Figure 1.4). 
Such modifications of histone tails determine the interactions of histones with other 
proteins, which may in turn also regulate chromatin structure. MicroRNAs (miRNAs) 
are another class of mediators that are important in gene expression and cancer 
development. 
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Figure 1.4 Epigenetic gene silencing during tumourigenesis proceeds gradually. In normal tissue 
the CpG island is typically unmethylated and histones are acetylated. As tissue progresses from normal 
to pre-neoplastic and tumour state, gradual deacetylation and methylation at CpG island is 
accompanied by a progressive loss of gene expression (Vaissiere et al., 2008). 
 
1.2.1 Phosphorylation 
Histone phosphorylation has been shown to play an important role in 
processes such as transcription, DNA repair, apoptosis and chromosome condensation 
(Cheung et al., 2000). The mechanism by which phosphorylation contributes to 
transcriptional activation is not well understood. The addition of negatively charged 
phosphate groups to histone tails neutralizes their basic charge and therefore reduces 
their affinity for DNA. Phosphorylation of serine 10 (Ser-10) in histone H3 has been 
associated with gene activation in mammalian cells (Thomson et al., 1999). It has 
been reported that many acetyltransferases have increased HAT activity on serine 10-
phosphorylated substrates. Also, mutation of serine 10 decreases activation of Gcn5-
regulated genes (Lo et al., 2000). Therefore, phosphorylation may contribute to 
transcription through HAT activation on the same histone tail. Clayton et al. have 
reported that upon gene activation, histone H3 on the oncogenes c-fos- and c-jun-
associated nucleosomes becomes doubly-modified where the same H3 tail becomes 
both phosphorylated and acetylated (Clayton et al., 2000). Histone H3 
phosphorylation also occurs after activation of DNA-damage signaling pathways 
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whereas phosphorylation of H2A is associated with mitotic chromosome 
condensation (Cheung et al., 2000). 
 
1.2.2  Methylation  
1.2.2.1 DNA methylation and gene expression 
DNA methylation is one of the most commonly occurring epigenetic events 
that take place in the mammalian genome. It plays a critical role in the control of gene 
activity. DNA methylation occurs in CpG-rich regions known as CpG islands, which 
span the 5′ end of the regulatory region of many genes. These islands usually range 
from 0.5 to 5 kb, occurring on average every 100 kb and are unmethylated in normal 
cells (Weber et al., 2007). CpG islands are enriched in promoters or the first exon of 
the gene. They are found in the promoter regions of around 60% of protein-coding 
mammalian genes. They are normally unmethylated in transcriptionally active genes 
like housekeeping genes but developmental and tissue-specific genes appear to be 
methylated and silenced in differentiated tissues (Bird, 2002). Hypermethylation of 
repetitive genomic sequences prevents gross chromosomal changes, such as 
translocations or amplifications, which lead to chromosomal instability. In cancer, 
many unmethylated genes in the normal tissue become methylated in the tumor.  
DNA methyltransferases (DNMT) are a group of enzymes important in 
maintaining DNA methylation. Cells that lack the stabilizing effect of DNA 
methylation due to spontaneous defects in DNMTs have prominent nuclear 
abnormalities (Xu et al., 1999). It was reported that mice deficient in the 
methyltransferase gene die early in development or immediately after birth 
(Robertson, 2002). 
Several mechanisms have been shown to cause transcriptional repression by 
DNA methylation. The first mechanism involves direct binding of specific 
transcription factors to their recognition sites in their promoter regions. Many 
transcription factors such as AP-2, c-Myc/Myn, CREB, E2F, and NFkB, recognize 
and bind to sequences that contain CpG residues. The binding of each has been 
shown to be inhibited by methylation (Tate and Bird, 1993). The second mechanism 
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of transcriptional repression involves the binding of specific transcriptional repressors 
to methylated DNA. The DNA methylation signals are “read” by the methyl-CpG–
binding proteins (MeCP), that bind to the methylated CpG sequence (Prokhortchouk 
and Hendrich, 2002). Several proteins have been reported to bind to the methylated 
CpG region. These include MeCP1, MeCP2, MBD1, MBD2, MBD4, and Kaiso 
(Prokhortchouk and Hendrich, 2002).   
 
1.2.2.2 Hypermethylation in breast cancer 
Hypermethylation results in loss of expression of a variety of genes that are 
important in the development of breast cancer. These include steroid receptor genes, 
cell adhesion genes, and inhibitors of matrix metalloproteinases (Yang et al., 2001b). 
Many genes have been reported to be hypermethylated in breast cancer. These 
include p16, estrogen receptor (ER) alpha, progesterone receptor (PR), BRCA1, 
GSTP1, TIMP-3, and E-cadherin. Two of these genes, ER and PR are steroid receptor 
genes that have long been associated with breast cancer. Methylation studies have 
shown that the ER gene has a CpG island in its promoter region and first exon (Yang 
et al., 2001b). Even though the ER gene is unmethylated in normal cells, it is reported 
to be hypermethylated in more than half of primary breast cancers. The BRCA1 gene, 
which is a gene commonly associated with breast cancer was reported to have a 
reduced or absent protein product. This has been attributed to DNA methylation as a 
cause of its inactivation (Catteau and Morris, 2002). 
 
1.2.2.3 Hypomethylation in breast cancer 
Hypomethylation in breast cancers mostly occurs in repetitive DNA 
sequences and pericentromeric satellite DNA, which are normally heavily methylated 
in non-malignant cells (Bernardino et al., 1997). Unlike in ovarian cancers where 
increased satellite DNA hypomethylation is associated with tumor progression 
(Widschwendter et al., 2004), in breast cancer, satellite DNA hypomethylation is 
associated with early tumor development (Costa et al., 2006). Sat2 and Satα repeats 
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are frequently hypomethylated in ovarian and breast cancer (Costa et al., 2006; 
Widschwendter et al., 2004). Hypomethylation of Sat2 affects 50% of breast tumors 
whereas SatR-1 hypomethylation affects 86% (Costa et al., 2006; Narayan et al., 
1998). The melanoma associated cancer/testis antigens MAGE are methylated and 
silenced in adult tissues, but hypomethylated and expressed in several tumors and 
breast cancer cells (Weber et al., 1994). Other hypomethylated genes associated with 
breast cancer are the plasminogen activator uPA (PLAU) gene, the breast cancer 
specific protein 1/synuclein-γ gene (SNCG), and the multidrug resistance 1 gene 
(MDR1) (Guo et al., 2002; Gupta et al., 2003; Sharma et al., 2010). Even though it 
has been shown that in cancer cells there is no reduction of DNA methyltransferase 
activity (Girault et al., 2003), knockdown of the gene in animal models or 
deficiencies of DNMTs activity would lead to genome wide DNA hypomethylation 
and chromosomal instability (Gaudet et al., 2003).  
 
1.2.3 MicroRNAs (miRNAs) 
MicroRNAs are small non-coding double-stranded RNAs that play a major 
role in the expression regulation of many genes (Figure 1.5). It is estimated that 
miRNAs may target about 60% of mammalian genes (Friedman et al., 2009). As of 
May 2011, more than 1100 human miRNAs have been identified 
(http://www.microrna.org/). Mature miRNAs usually down-regulate gene expression 
by recognizing the target mRNAs complementary sequence. They bind to the 3’ 
untranslated region (UTR) or the open reading frame (ORF) of the target mRNA, or 
to 5’UTRs (Lee et al., 2009) resulting in inhibition of protein translation and/or 
degradation of the mRNA. Besides being involved in development and normal 
function, miRNAs have also been associated with many human diseases. Since 
miRNAs are important in regulating cellular differentiation and proliferation, any 
misregulation may be linked to tumorigenesis.  
 
 
Roles of EEF1A2 & PTK6 in Breast Cancer 
Chapter 1: Introduction 20
 
Figure 1.5 Models of miRNA function. The two-step model: Upon binding to the 3′-UTR of a target 
mRNA, the miRNP complex inhibits translation initiation, presumably by interfering with the 7mG 
cap function in recruiting eIF4E. Next, the repressed mRNA:miRNP complex is moved to the P-bodies 
(PBs) for storage. One-step model: Binding of the miRNP to the target mRNA directs the mRNA to 
the PBs. Disassembly of ribosomes on the message occurs prior to entry into the PBs. The mRNA can 
then be either degraded or stored for later reuse. 7mG, 7-methyl guanine; AAAA, polyadenosine tail; 
4E, eIF4E; 4G, eIF4G (Pillai, 2005). 
 
1.2.3.1 MicroRNAs and cancer 
miR15 and miR16 are the first two miRNAs that were linked to cancer in 
patients with chronic lymphocytic leukemia (CLL) (Calin et al., 2002). Both the 
miRNA genes are located at 13q14 and were found to be deleted or down-regulated in 
the majority of CLL cases (Calin et al., 2002). miRNAs function as regulatory 
molecules where they can act as oncogenes or tumor suppressors (Liang et al., 2007).  
 
1.2.3.1.1 MicroRNAs as oncogenes 
miRNAs can act as oncogenes when amplified or overexpressed. They can 
downregulate a tumor suppressor gene or other genes involved in cell differentiation 
and tumor development by stimulating proliferation, angiogenesis and invasion 
(Miska, 2005). Several miRNAs have been shown to act as oncogenes in pancreatic 
cancer. Increased expression of miR-103 and miR-107 were detected in pancreatic 
tumors (Lee et al., 2005). MiRNA-21 is more highly expressed in pancreatic cancer 
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when compared to benign tumors (Dillhoff et al., 2008). The miRNA miR-155 also 
acts on the activity of Tumor Protein 53-Induced Nuclear Protein 1 (TP53INP1) by 
inhibiting its antitumor actions (Gironella et al., 2007).   
MicroRNAs play an important role in colorectal cancer. Increased expression 
level of let-7f, miR-181b and miR-200c was detected in patients with colorectal 
cancer (Nakajima et al., 2006). It was also shown that miR-21 downregulates the 
tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in the 
human colon cancinoma cells Colo206f, indicating its oncogenic function (Asangani 
et al., 2008). 
Hayashita et al. have shown that the miR-17-92 cluster, which is composed of 
seven miRNAs and resides in intron 3 of the C13orf25 gene, is frequently 
overexpressed in lung cancers (Hayashita et al., 2005). The oncogenic effect of the 
miR-17-92 cluster results in inhibition of apoptosis in lung cancer cells (Matsubara et 
al., 2007). 
 
1.2.3.1.2 MicroRNAs as tumor suppressors 
MicroRNAs also function as tumor suppressors in different types of cancers. 
In pancreatic cancer cells, miR-34a, which is induced by the P53 tumor suppressor 
protein is frequently absent (Chang et al., 2007). Its expression is also silenced in 
several types of cancers due to the methylation of the CpG island of the promoter 
(Lodygin et al., 2008). The miR-34a responsive genes play a role in cell-cycle 
progression, DNA repair, apoptosis and angiogenesis.  
In colon cancer, as well as in colon cancer cells, miR-145 and miR-143 
expression levels were reported to be reduced (Akao et al., 2006; Michael et al., 
2003). The expression of the let-7 miRNAs have not only been shown to be reduced 
in both colon tumors and cancer cell lines but also in lung cancer. Members of the let-
7 family, which includes let-7b, let-7c, let-7d, let-7f, and let-7g are all down-
regulated in lung cancer and linked with shortened survival (Takamizawa et al., 
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2004). This has been attributed to their ability to inhibit the RAS oncogene (Johnson 
et al., 2005).  
Many other miRNAs have been reported to be reduced in expression in other 
types of cancers. These include miR-15a and miR-16-1 in chronic lymphocytic 
leukemia (Cimmino et al., 2005), miRNA-143 in human bladder tumor tissues (Lin et 
al., 2009) and miR-101 in progressive prostate and breast cancers (Varambally et al., 
2008). 
 
1.2.3.2 MicroRNAs and breast cancer 
Many miRNAs have been predicted to regulate important breast cancer genes 
like BRCA1/2, ATM, PTEN and CHEK2. These miRNAs can be divided into miRNAs 
that function as oncogenes and those that act as tumor suppressors. The miRNAs that 
act as oncogenes are: miR-27a which targets the transcriptional cofactor 
ZBTB10/RINZF, miR-10b overexpression was shown to promote cell migration and 
invasion and miR-21 knockdown in the breast cancer cell line MCF-7 and mouse 
xenograft tumors decreased cell growth and inhibited tumor proliferation (Zhu et al., 
2007b). miR-21 was also reported to down-regulate the tumor suppressor 
tropomyosin 1 (TPM1) therefore supporting the notion that these miRNAs function as 
oncogenes (Zhu et al., 2007b). 
Several other miRNAs act as tumor suppressors in breast cancer. mir-125a 
and miR-125b were reported to be significantly reduced in ERBB2-amplified breast 
cancers (Mattie et al., 2006) leading to cell migration and invasion through the AKT 
pathway (Scott et al., 2007). miR-206 is another miRNA that is decreased in 
expression in ER-α positive human breast cancer tissues (Adams et al., 2007). 
miRNAs play important roles in breast cancer metastasis. Ma et al. have 
shown that miR-10b is highly expressed in breast cancer metastatic cell lines when 
compared to nonmetastatic cells. Its overexpression was associated with invasion and 
metastasis but not proliferation (Ma et al., 2007). miR-373 and miR-520c have been 
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reported as metastasis-promoting miRNAs in MCF7 cells as they are also involved in 
tumour migration and invasion (Huang et al., 2008).  
 
1.2.4 Transcription 
The process of transcription is initiated when the RNA polymerase (RNA pol) 
enzyme binds to the template DNA strand and begins the production of 
complementary RNA. Three different types of RNA polymerase are reported: RNA 
pol I which transcribes genes encoding most of the ribosomal RNAs (rRNAs) and 
RNA pol III which transcribes the genes for one small rRNA and transfer RNAs 
(tRNAs) that play an important role in the translation process, as well as other small 
regulatory RNA molecules. RNA pol II is the key enzyme that transcribes the 
mRNAs that serve as templates for protein production. Transcription also requires 
transcription factors and proteins which specifically recognize short DNA sequences 
(cis-acting elements) in the non-coding region of the gene (Ptashne, 1986). These 
sequences could be upstream of the transcription start site, where they bind to the 
promoter for accurate and efficient initiation of transcription, or they could be several 
thousand bases upstream or even within introns or downstream of the gene, forming 





The mechanism of translation initiation can be divided into several steps 
(Figure 1.6). The pathway starts with the recycling of post-termination complexes 
where the separated 40S and 60S ribosomal subunits bind to form the 80S ribosomal 
initiation complex. The large subunit of the ribosome has three sites at which tRNA 
molecules can bind. The A (amino acid) site is where the aminoacyl-tRNA anticodon 
binds to the mRNA codon, ensuring that correct amino acid is added to the growing 
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polypeptide chain. The P (polypeptide) site is where the amino acid is transferred 
from its tRNA to the growing polypeptide chain. The E (exit) site is the location at 
which the tRNA -that is not carrying any amino acids- binds before being released 
back into the cytoplasm to bind to another amino acid and repeat the process. The 
initiator methionine tRNA is the only aminoacyl-tRNA that can bind in the P site of 
the ribosome, and the A site is aligned with the second mRNA codon. The ribosome 
is thus ready to bind the second aminoacyl-tRNA at the A site, which will be joined 
to the initiator methionine by the first peptide bond. 
The initiating Methionine (Met-tRNA Meti) is base paired with the initiation 
codon in the ribosomal P-site which is competent to start the translation elongation 
step. This is followed by the eukaryotic initiation factor 2 (eIF2)–GTP–Met-tRNAMeti 
complex formation. Next, formation of a 43S preinitiation complex comprising a 40S 
subunit, eIF1, eIF1A, eIF3, eIF2–GTP–Met-tRNAMeti and probably eIF5 takes place 
followed by mRNA activation, during which the mRNA cap-proximal region is 
unwound in an ATP-dependent manner by eIF4F with eIF4B. The 43S complex will 
be attached to this mRNA region. Scanning of the 5′ UTR in a 5′ to 3′ direction by 
43S complexes will take place. This is followed by recognition of the initiation codon 
and 48S initiation complex formation, which switches the scanning complex to a 
‘closed’ conformation and leads to displacement of eIF1 to allow eIF5-mediated 
hydrolysis of eIF2-bound GTP and Pi release. 60S subunits will bind to 48S 
complexes leading to displacement of eIF2–GDP and other factors (eIF1, eIF3, 
eIF4B, eIF4F and eIF5) mediated by eIF5B and GTP hydrolysis by eIF5B and release 
of eIF1A and GDP-bound eIF5B from assembled elongation competent 80S 
ribosomes. Termination follows elongation and leads to recycling, which generates 




The elongation phase is the second phase in translation. It is controlled by 
three main elongation factors: eEF1A (Discussed in section 1.3), eEF1B, and eEF2. 
The ribosome moves along the mRNA in the 5' to 3' direction with the help of the 
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elongation factor eEF2. The tRNA that corresponds to the second codon binds to the 
A site. This step requires the elongation factors eEF1A and eEF1B, as well as 
guanosine triphosphate (GTP) as an energy source for the process. Upon binding of 
the tRNA-amino acid complex to the A site, GTP is cleaved to form guanosine 
diphosphate (GDP), then released along with eEF1A to be recycled by eEF1B for the 
next round.  
Peptide bonds are now formed between the first and second amino acids. 
After the bond formation, the ribosome translocates again, therefore causing the 
tRNA to occupy the E site. The tRNA is then released to the cytoplasm to bind to 
another amino acid whereas the A site is now empty and ready to receive another 
tRNA for the next codon. 
This process is repeated until all the codons in the mRNA have been read by 
tRNA molecules, and the amino acids attached to the tRNAs are linked together in 
the growing polypeptide chain in the appropriate order. At this point, translation must 
be terminated, and the protein must be released from the mRNA and ribosome 
complex. 
1.2.5.3 Termination 
There are three termination codons that are employed at the end of a protein-
coding sequence in mRNA: UAA, UAG, and UGA. tRNAs do not recognize these 
codons. Therefore, in the place of these tRNAs, one of several release factors binds 
and facilitates release of the mRNA from the ribosome and subsequent dissociation of 
the ribosome back into the cytoplasm.    
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Figure 1.6 Pathway of eukaryotic translation regulation. 1) Recycling of post-termination 
complexes (post-TCs; 1) to yield separated 40S and 60S ribosomal subunits, and result in the 
formation of an 80S ribosomal initiation complex, 2) eIF2 ternary complex formation, 3) 43S complex 
formation, 4) mRNA activation, 5) Attachment of the 43S complex to the mRNA, 6) scanning of the 5′ 
UTR in a 5′ to 3′ direction by 43S complexes, 7) Initiation codon recognition, hydrolysis of eIF2-
bound GTP and Pi release, 8) Joining of 60S subunits to 48S complexes and concomitant displacement 
of eIF2–GDP and other factors (eIF1, eIF3, eIF4B, eIF4F and eIF5) mediated by eIF5B, 9) GTP 
hydrolysis by eIF5B and release of eIF1A and eIF5B (Jackson et al., 2010). 
Roles of EEF1A2 & PTK6 in Breast Cancer 
Chapter 1: Introduction 27
1.3 Breast cancer genes studied in this project 
 
1.3.1 EEF1A2 
The elongation phase of protein synthesis can be divided into two stages: a) 
amino-acylated tRNA recruitment to a ribosome where eEF1A2 plays a major role 
(Figure 1.7) and b) ribosome translocation along the RNA as amino acids are added 
to the polypeptide chain (Thornton et al., 2003).  
 
 
Figure 1.7 The role of eEF1A in the elongation phase of translation. eEF1A recruits the aa-tRNA 
to the A site of the ribosome where peptide elongation takes place. This requires the release of GDP. 
The eEF1A:GDP complex binds to eEF1B to allow for the exchange of GDP back to GTP. eEF1B is 
released again for eEF1A:GTP complex to bind to another aa-tRNA (Thornton et al. 2003). 
 
Eukaryotic translation elongation factor 1 alpha 2 (EEF1A2) is a 11kb gene 
consisting of 8 exons and encoding a 463 amino acid protein with a molecular weight 
of 50.5kD. eEF1A2 is one of the two members of the eEF1A family of proteins, 
eEF1A:GDP 
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eEF1A1 and eEF1A2. eEF1A1 and eEF1A2 share 98% amino acid homology but are 
encoded by different chromosomes (EEF1A1 in 6q14 and EEF1A2 in 20q13) (Lund 
et al., 1996).  
eEF1A proteins -as shown in figure 1.7- are GTP-binding proteins that recruit 
an amino-acylated tRNA to the ribosome during the elongation phase of protein 
translation (Thornton et al., 2003). While eEF1A1 is ubiquitously expressed, eEF1A2 
expression is limited to the normal brain, heart and skeletal muscles (Knudsen et al., 
1993). Their translational elongation activities are similar but there is a difference in 
their binding affinity for GDP and GTP where eEF1A2 binds GDP more strongly 
than GTP and the opposite is true for eEF1A1 (Kahns et al., 1998). 
 
1.3.1.1 eEF1A2 in wasted mice 
In 1972, the autosomal recessive mutation wasted (wst) arose spontaneously 
in the Jackson Laboratory in an inbred mouse colony (Shultz et al., 1982). Wasted 
mice have a 15.8 kb deletion that abolishes the expression of eEF1A2 and is therefore 
responsible for the mutant mouse phenotype (Chambers et al., 1998). Mice 
homozygous for this mutation are born completely normal but show loss of muscle 
bulk, tremors and gait abnormalities at 20 days of age and die by 4 weeks. Such a 
phenotype resembles many of the signs seen in motor neuron disease in humans, but 
with early onset and a quick disease progression (Chambers et al., 1998). 
 
1.3.1.2 eEF1A2 and cancer 
eEF1A2 plays an important role in carcinogenesis, possibly by acting as a 
tumor oncogene. eEF1A2 is overexpressed in several types of cancers. Anand et al. 
have reported that eEF1A2 is overexpressed in 30% of ovarian tumors (Anand et al., 
2002). They have shown that the overexpression of Eef1a2 in the mouse fibroblasts 
cell line NIH-3T3 results in oncogenic activity and also increases the growth rate of 
ovarian cancer cells ES-2 when overexpressed in xenograft nude mice. Tomlinson et 
al. reported a similar figure where at the RNA level, 33% of ovarian tumors showed 
overexpression of eEF1A2 (Tomlinson et al., 2007). The authors reported that 
EEF1A2 copy number does not correlate with the expression level of the gene, the 
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EEF1A2 gene is unmethylated in both normal and tumor DNA and that no mutations 
were detected. This indicates that overexpression is not dependent on genetic or 
epigenetic modifications at the EEF1A2 locus. The expression of eEF1A2 has also 
been measured using tissue microarray from 500 ovarian tumors. This showed 
eEF1A2 overexpression in about 30% of all primary ovarian tumors (Pinke et al., 
2008).  
Tissue microarray analysis showed that eEF1A2 was overexpressed in lung 
cancer patients. Elevated protein expression correlated with the increased level of 
both DNA and mRNA transcripts (Li et al., 2006; Zhu et al., 2007a). High expression 
of eEF1A2 correlates with increased expression of Ki-67 and is associated with poor 
prognosis (Li et al., 2006).  
Even though little or no expression of eEF1A2 was detected in normal human 
pancreatic tissue, overexpression was detected in 83% of pancreatic tumors (Cao et 
al., 2009). Cao et al. have shown that overexpression of eEF1A2 promoted cell 
growth, survival, and invasion in pancreatic cancer.  
eEF1A2 was also reported to be amplified and overexpressed in about 50% of 
hepatocellular carcinomas (Schlaeger et al., 2008). The same group also inhibited 
EEF1A2 expression using small interfering RNAs (siRNA) in two hepatocellular 
carcinoma cell lines; HepG2 and Hep3B. Gene silencing led to reduced cell viability 
and proliferation and increased apoptosis rates in those cells. 
Most studies have shown that miRNAs downregulate gene expression by 
binding to the 3’UTR and either degrading the mRNA or binding to the mRNA and 
therefore inhibiting translation. However, in 2008, Dahiya et al. have reported the 
overexpression of eEF1A2 in the ovarian cancer cell line BG-1 when transfected with 
the miRNA let-7f (Dahiya et al., 2008).  
 
 
1.3.1.3 eEF1A2 and breast cancer 
It was shown that eEF1A2 is expressed at low levels in the normal breast 
epithelium but was overexpressed in 60% of primary human breast tumors 
(Tomlinson et al., 2005). This overexpression tends to be associated with ER-positive 
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tumors. Kulkarni et al. have reported a similar figure where eEF1A2 mRNA and 
protein were highly expressed in 50–60% of primary human breast tumors and 
metastases but not in normal breast epithelium (Kulkarni et al., 2007). Since it is also 
overexpressed in 30% of primary human ovarian tumors, transforms rodent 
fibroblasts and increases their tumorigenicity in nude mice, eEF1A2 is considered to 
be a potential human oncogene (Anand et al., 2002).  
Furthermore, eEF1A2 was shown to be overexpressed in rat metastatic 
mammary adenocarcinoma cell lines when compared to non-metastatic cell lines 
(Edmonds et al., 1996). High expression level of eEF1A2 in primary breast tumors is 
associated with a significantly increased 20-year survival in patients when compared 
to those whose tumor does not express substantial eEF1A2. This is thought to be due 
to the effect of the high expression of eEF1A2 in reducing the aggressiveness of 
breast tumors (Kulkarni et al., 2007). They also reported that eEF1A2 protein 
overexpression predicts increased survival probability in those breast cancer patients 
independent of HER-2 protein expression, ER status, tumor size and lymph node 
involvement. Their study suggests that high eEF1A2 expression could be a significant 
prognostic marker of breast cancer.  
In 2001, Ruest et al. also showed that continuous expression of eEF1A2 
protects differentiated myotubes from apoptosis by delaying cell death, therefore 




1.3.1.4 Effect of eEF1A2 overexpression/knockdown  
eEF1A2 is a translation elongation factor that seems to be involved in 
different pathways and affects the expression of a number of proteins. Amiri et al. 
reported that eEF1A2 is an activator of the protein kinase Akt in a 
phosphatidylinositol-3 kinase (PI3K)-dependant manner (Amiri et al., 2007). The 
same group showed that the expression of eEF1A2 in BT549 cells stimulated the 
formation of filopodia in these human breast cancer cell lines and in non-transformed 
Rat2 cells. Filopodia production enhances cell invasion and migration and therefore 
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indicates the importance of eEF1A2 in promoting tumor development through 
phosphatidylinositol signalling, actin remodeling and cell motility (Amiri et al., 
2007). However, even though Amiri et al. suggested the involvement of eEF1A2 in 
tumorigenesis, other groups reported that high eEF1A2 protein expression was 
associated with increased survival (Pinke et al., 2008; Ruest et al., 2002). EEF1A has 
been shown to be a component of the acting cytoskeleton (Edmonds et al., 1996) 
therefore these results correlate with the results published by Edmond et al. who 
reported that the eEF1A protein is overexpressed in rat metastatic cells compared to 
the nonmetastatic cells and whole tumors (discussed on page 30). In both types of 
tumors, eEF1A binds to F-actin but eEF1A from metastatic cells has a reduced 
affinity for actin. The authors reported that a weak association between eEF1A and 
actin could be related to the metastatic process through a different organization of the 
actin cytoskeleton and the differential translation of mRNAs associated with the 
cytoskeleton (Edmonds et al., 1996). 
Even though normal mouse and human plasma cells do not express eEF1A2, 
it has been reported to be overexpressed in plasma cell neoplasms of both mice and 
humans (Li et al., 2010). Mouse plasmacytomas (PCT) expressing eEF1A2 
contributes to cell transformation by cell cycle progression and inhibiting apoptosis. 
A previous study showed that non-PCT cell lines overexpressing eEF1A2 enhanced 
cell growth and resisted apoptosis (Ruest et al., 2002). Li et al. showed that 
knockdown of Eef1a2 expression in PCT cell lines affected the JAK/STAT pathway 
and the PI3K-AKT-mTOR pathway. They reported that phosphorylation of STAT3 
and AKT was delayed and that PI3K expression was reduced (Li et al., 2010). These 
data indicate that eEF1A2 may play an important role in the induction or progression 
of plasma cell neoplasms in mice and humans.  
Many genes showed altered expression with the knockdown of eEF1A2. Of 
these genes were ones involved in tumor invasion (Tgfbr2, Mmp13, Itgal), 
proliferation (Pik3cg, Fosb, Fos, Mapk1, Flt3, Wnt1, Cdk6, Ccnd2), survival (Ifi202b, 
Tnfsf13b, Bcl2, Bcl2l1), and cytokine and interferon signaling (Jak2, Stat1, Stat2, 
Stat3, Irf2, Irf8, Socs3) (Li et al., 2010). Some of these genes (JAK2, STAT1, STAT2, 
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STAT3, SOCS3, FYN, LYN, PIK3CG) contain both the SH2 and SH3 domains which 
are the protein domains to which eEF1A2 is reported to bind (Kim et al., 1999; 
Panasyuk et al., 2008).  
 
1.3.2 PTK6 
Phosphate Tyrosine Kinase-6 (PTK6), also known as Brk/Sik or Brinker, is 
encoded by a gene consisting of 8 exons giving rise to a protein of 451 amino acids 
with a predicted molecular weight of 52kD. It encodes a non-receptor tyrosine kinase 
that contains SH2, SH3 and catalytic domains. The Src homology (SH3) domain bind 
proline-rich sequences and is involved in significant pathways that regulate kinase 
activity, protein-protein interactions and cellular localization. The SH2 domain on the 
other hand is essential in controlling interactions. It recognizes and binds to 
phosphorylated tyrosine residues. The intracellular localization of PTK6 is flexible 
and can be found to be present in the nucleus as well as the cytoplasm or at the 
membrane (Haegebarth et al., 2004). PTK6 is normally expressed in epithelial 
linings, prostate, skin and oral epithelium but it is not detected in the human normal 
mammary epithelium (Mitchell et al., 1994). 
 
1.3.2.1 PTK6 and cancer 
PTK6 expression has been detected in many different types of cancers. It is 
not expressed in normal ovaries but has been detected in 70% of human ovarian 
tumors (Schmandt et al., 2006). It has also been detected in primary and metastasized 
colon tumors (Llor et al., 1999), prostate tumors (Derry et al., 2003), head and neck 
squamous cell carcinoma (Lin et al., 2004), B- and T-cell lymphomas (Kasprzycka et 
al., 2006), and the HeLa cervical cancer cell line (Shen et al., 2008). PTK6 gene 
expression has been detected in the cancers of the lung (Rikova et al., 2007), bladder 
(Ruhe et al., 2007), pancreas (Kubo et al., 2009a), and gastric cancer (Kubo et al., 
2009b).  
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PTK6 mutations have also been detected in human melanomas (Prickett et al., 
2009), human bladder carcinoma cell lines and lung cancer cell lines (Ruhe et al., 
2007).  
 
1.3.2.2 PTK6 and breast cancer 
PTK6 has been found to be expressed in many breast cancer cell lines and in 
approximately 60% of primary human breast tumors but it has not been detected in 
normal human breast tissue nor in fibroadenomas (Barker et al., 1997). Like other 
tyrosine kinases, PTK6 phosphorylates and activates downstream substrates (i.e. 
Sam68, SLM-1, SLM-2, STAP-2, paxillin, STAT3, STAT5a and STAT5b) that 
would lead to the increased transcriptional activity and therefore mediates 
proliferation of breast cancer cells (Weaver and Silva, 2007).  
Amplification of the PTK6 gene has been correlated with the amplification of 
ERBB2 in human breast cancers (Xiang et al., 2008). The co-amplification induces 
prolonged activation of the Ras/MAPK pathway and promotes cell proliferation.   
Aubele et al. have also demonstrated that PTK6 is a prognostic marker of 
metastasis-free survival in breast cancer and that it is independent of the classical 
markers of tumor size, lymph node involvement and HER2 status (Aubele et al., 
2007). This has also been reported regarding eEF1A2 where authors showed that high 
eEF1A2 protein expression was associated with increased probability of 20-year 
survival in ovarian tumors (Pinke et al., 2008). 
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1.3.2.3 PTK6 signaling 
PTK6 plays an important role as a mediator for many signaling pathways 
(Figure 1.8). It can lead to activation of substrates, the EGF pathway and the 
PIK3/Akt pathway.  
Multiple PTK6 substrates have been identified. These can be divided into the 
RNA-binding proteins like Sam68 (Lukong et al., 2005), SLM-1 and SLM-2 
(Haegebarth et al., 2004), transcription factors such as STAT3 (Liu et al., 2006) and 
STAT5a/b (Weaver and Silva, 2007) and different signalling molecules that include 
paxillin (Chen et al., 2004), Akt (Zhang et al., 2005) and KAP3A (Lukong and 
Richard, 2008). PTK6 phosphorylation of reported substrates has been shown to 
promote cell division and migration. 
PTK6 was found to phosphorylate and negatively regulate the RNA-binding 
protein Sam68 (Derry et al., 2000) and the Sam68-like mammalian proteins SLM-1 
and SLM-2  (Haegebarth et al., 2004).  
 
Figure 1.8 PTK6 acts as a mediator for many signaling pathways. a) Tyrosine phosphorylation by 
PTK6 decreases Samm68 RNA-binding activity. b) PTK6 phosphorylation enhances Stat3 and Stat5 
transcriptional activity. c) PTK6 signaling downstream of ErbB receptors activates multiple signalling 
pathways which can lead to changes in the gene programs expressed by cells (Li et al., 2010). 
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Many reports have shown that the overexpression of PTK6 in normal 
mammary epithelial cells increase EGR-induced proliferation (Kamalati et al., 1996). 
It was further shown that PTK6 interacts and binds to the ErbB family members 
(Figure 1.8), ErbB2, ErbB3 and ErbB4 (Aubele et al., 2008). This in turn would 
enhance EGR-induced PTK6 autophosphorylation which then phosphorylates the 
downstream substrate paxillin leading to Rac1 activation and cell migration (Chen et 
al., 2004).  
PTK6 overexpression also activates the PI3K pathway (Kamalati et al., 2000). 
It limits the Akt activity in normal cells but interacts with it in breast cancer cell lines 
leading to the activation of the PI3K/Akt pathway. As described in section 1.3.1.4, 
Eef1a2 knockdown in PCT cells lines also affected the PI3K/AKT pathway where 
phosphorylation of AKT was delayed and the expression of PI3K was reduced (Li et 
al., 2010).  
PTK6 has also been shown to play a role in the activation of the STAT 
signaling pathways. The expression of PTK6 phosphorylates STAT3 and STAT5 
leading to increasing transcriptional activity (Weaver and Silva, 2007). 
 
1.3.3 EEF1A2 & PTK6 similarities 
EEF1A2 and PTK6 are two genes located on 20q13.3. Several studies reported 
the amplification of this region in a various number of tumors including breast cancer. 
EEF1A2 and PTK6 are less than 50kb apart and share many common properties. Both 
are reported to be potential oncogenes (Lee and Surh, 2009; Zhang et al., 2005), 
overexpressed in 60% of breast cancers (Barker et al., 1997; Kulkarni et al., 2007), 
they promote cell growth, migration and inhibit apoptosis by activating the 
PI3K/AKT pathway (Kamalati et al., 2000; Li et al., 2010) and both were reported to 
be associated with increased survival (Aubele et al., 2007; Pinke et al., 2008). Being 
on the same amplicon and sharing all the characteristics mentioned, it is hypothesized 
that EEF1A2 and PTK6 act in tandem through the same mechanism in breast cancer 
and that one of these genes could be the driver in this amplicon.  
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1.4 Main project aims 
Many studies have shown that EEF1A2 and PTK6 are overexpressed in 60% 
of breast cancer patients. The aim of this project was to understand the various roles 
of the two genes mentioned- whether they act in tandem or independently, and how 
they contribute to breast cancer development and disease progression. The study 
focused on characterising for the first time the genomic region those two breast 
cancer oncogenes are located on and study their role in tumorigenesis. The ultimate 
aim is to identify new biomarkers and/or therapeutic targets for the treatment of 
breast cancer. 
 
The main specific aims of this project are: 
• To relate the copy number changes in the genes encoding EEF1A2 and 
PTK6 to their expression levels in human breast tumors to determine 
whether one of the genes is the driver in this amplicon. 
• To assess the extent of the region on 20q13.3 commonly amplified in 
breast tumors. 
• To assess the effect of eEF1A2 overexpression on PTK6 and other 
breast cancer associated genes. 
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Chapter 2: Materials & Methods 
2.1 Materials 
2.1.1 Buffers and solutions 
All buffers and solutions used are listed in table 2.1 below. 
Table 2.1 All buffers and solutions used in the methods described in this chapter 
RIPA Buffer 1.752g NaCl, 2ml NP-40, 1g deoxycholic acid, 1ml 20% SDS, 6.67ml 
1.5M tris pH 8.0, up to 200ml dH2O 
Phosphate Buffer 
Saline (PBS) 
1 PBS tablet dissolved in 100ml of dH2O and autoclaved 
PBS-Tween-20    
(PBS-T) 
1 PBS tablet dissolved in 100ml of dH2O and 0.1% (v/v) Tween-20 
added after autoclaving 
0.5M Tris HCL 3g Tris HCl, 50ml dH2O, pH 6.8 
1.5M Tris HCL 9g Tris HCl, 50ml dH2O, pH 8.8 
25% AMPS 25g Ammonium Persulfate (AMPS), 100ml dH2O 
2X Laemmli loading 
buffer 
60nM Tris HCl (pH 6.8), 2% SDS, 0.1% bromophenol blue, 10% 
glycerol 
10X Laemmli running 
buffer 
250nM Tris HCl (pH 8.3), 1.9M glycine, 10% SDS 
Transfer Buffer (10x) 30.3g Tris base, 144.2g glycine, up to 1L dH2O, pH 8.3 
TBE                       
(Tris Borate-EDTA) 
108g Tris, 55g Boric acid, 9.3g Na4EDTA in 1L dH2O, pH 8.3 
Luria-Bertani (LB) 
medium 
1% tryptone, 0.5% yeast extract, 1% NaCl, pH 7.0, medium autoclaved 
and allowed to cool down before adding the antibiotic 
LB Agar Plates As above with adding additional 15g/L agar before autoclaving 
Peroxidase Blocking 
Solution 
2ml 30% dH2O2, 10% sodium azide, up to 400ml dH2O 
10x DNA sample 
loading buffer 
20g sucrose, 100mg of Orange G, up to 50ml dH2O 
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2.1.2 Antibodies 
Antibodies used in this project are mentioned in table 2.2 below along with 
their different concentrations for different methods. All primary antibodies are 
monoclonal whereas the secondary antibodies (HRP labeled) are polyclonal. 
Table 2.2 List of antibodies used and conditions under which they were used for Western Blots 
(WB), Immuohistochemistry (IHC) and Reverse Phase Protein Array (RPPA).  
Name Specificity Species Source Dilution 
Western Blots (WB) 
eEF1A2-3 eEF1A2 Sheep  Helen Newbery1 1:2000 
PTK6 (C-17) PTK6 Rabbit Santa Cruz Biotechnology 1:200 
Serpine2 (Y-20) Serpine2 Rabbit Santa Cruz Biotechnology 1:200 
ALDH3A1 (M-19) Aldh3a1 Rabbit Santa Cruz Biotechnology 1:200 
TPD52 (K-17) Tpd52 Rabbit Santa Cruz Biotechnology 1:200 
MKP-3 (C-20) Dusp6 Rabbit Santa Cruz Biotechnology 1:200 
Egr1 Egr1 Goat R&D Systems2 1:2000 
GAPDH GAPDH Mouse Chemicon 1:30,000 
HRP Rabbit-anti-mouse Mouse Ig Rabbit Dako cytomation 1:1000 
HRP Goat-anti-rabbit Rabbit Ig Goat Dako cytomation 1:1000 
HRP Rabbit-anti-goat Goat/Sheep Ig Rabbit Dako cytomation 1:1000 
Immunohistochemistry (IHC) 
eEF1A2-3 eEF1A2 Rabbit Helen Newbery1 1:15 
PTK6 (C-17) PTK6 Rabbit Santa Cruz Biotechnology 1:150 
Reverse Phase Protein Array (RPPA) 
eEF1A2-3 eEF1A2 Sheep Helen Newbery1 1:150 
eEF1A2-3 (14.1.05) eEF1A2 Rabbit Helen Newbery1 1:50 
                                                 
1 Medical Genetics, Molecular Medicine Centre, University of Edinburgh 
2 Given by Gráinne Gernon, MRC Human Genetics Unit, University of Edinburgh 
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2.1.3 Cell lines 
Experiments were done on many cell lines. Table 2.3 shows a list of cell lines 
used in this project. 
 
Table 2.3  List off cell lines, species, cell type, source and media in which cells were grown. 
Cell line Species Cell Type Source Medium 
MCF7 Human Breast adenocarcinoma John Bartlett1 DMEM + 10% FBS 
T47D Human  Breast ductal carcinoma John Bartlett1 DMEM + 10% FBS 
MDA-MB-231 Human  Breast adenocarcinoma John Bartlett1 DMEM + 10% FBS 
MDA-MB-453 Human Metastatic breast carcinoma John Bartlett1 DMEM + 10% FBS 
BT549 Human Breast ductal carcinoma Elad Katz2 DMEM + 10% FBS 
HeLa Human Cervix adenocarcinoma Justyna 
Janikiewicz3 
Given as pellet 
NIH-3T3 Mouse Embryonic fibroblast Yuan Cao3 DMEM + 10% NBCS 
NIH-3T3 stable 
cell lines 




DMEM + 10% NBCS 
+ Zeocin 
                                                 
1 Edinburgh Cancer Research UK Centre, University of Edinburgh 
2 Breakthrough Research Unit, Cancer Research Centre, University of Edinburgh 
3 Medical Genetics, Molecular Medicine Centre, University of Edinburgh 
 
 
2.1.4 Primers  
Oligonucleotide primers used for this project are listed in table 2.4. DNA 
primers were used for gene copy number detection while cDNA primers were used 
for gene expression analysis. Primers were designed using the primer design tool 
Primer3 unless clearly stated and purchased from Sigma-Aldrich. All primers were 
stored in TE buffer in -20oC at a concentration of 100µM and were diluted to 0.5µM 
in dH2O as a working dilution unless otherwise specified. 
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Table 2.4 List of primers’ names and sequences used in RT-qPCR 
Target Primer Sequence 5’ to 3’ Product Source 
DNA Primers 
EEF1A2 EEF1A2-5F GGCATCTCTGTGTGCACTGT 134bp Designed 
EEF1A2-5R TACTGGGTCTCCACCCTCAC 
PTK6 PTK6F2-7 GTCCCCACTGTCCCTGACT 144bp Designed 
PTK6-R2-7 CACACCTGCACCATTCTCTG 
KCNQ2 KCNQ2-2F GCTGTAACTCAGCCCTCACC 129bp Designed 
KCNQ2-2R TCTCCGGCTCCAGAGATAAA 
SRMS SRMS-3F AGTGGGGAAAGGAGACCTGT 149bp Designed 
SRMS-3R CAGGTGCAGCATCTTGTGAT 
D5S478 D5S478-F CCGTTTGCACATTTGAGGCT 121bp Ginzinger et al., 
D5S478-R CTGAAAAAGAAGGCAACGTC 2000 
D11S913 D11S913-F CTAGATTTCTGAAACTCAAATGCA 164bp Ginzinger et al., 
D11S913-R TAGGTGTCTTATTTTTTGTTGCTT 2000 
cDNA Primers (Human) 
EEF1A2 EEF1A2 AGGACGTGTACAAGATTGGC 155bp Tomlinson,(Tomlinson
 EEF1A2 CACCTCAGTGGTGATGTTCA 2007 
PTK6 PTK6 qPCR GGACTTCGGGTTAGCCAGG 118bp Zhao et al., 
 PTK6 qPCR GGATTTGGTGGAGTAATGGCC 2003 
PUM1 PUM1qPCR TGAGGTGTGCACCATGAAC 187bp Szabo et al., 
PUM1 CAGAATGTGCTTGCCATAGG  2004 
TBP TBP qPCR TGCACAGGAGCCAAGAGTGAA 132bp Yamagata et al., 
TBP qPCR CACATCACAGCTCCCCACCA  2009 
cDNA Primers (Mouse) 
Eef1a2 Q m1A2 F GCTCCAGGACACCGAGACTT 141bp Justyna  
Q m1A2 R GAGTGCGTGTTCCCGGGTT Janikiewicz1 
Ptk6 mPTK6 F CTGGCTTCTTCCTCCCTTCT 118bp Designed 
mPTK6 R TGTGGACAGTCAAGCTCCAA 
Serpine2 Serpine2 F CATCAAGTCACGGCCTCATG 112bp Designed 
Serpine2 R CGTGGAGAGCTGCTTCTTTGT 
Egr1 Egr1 F AACACTTTGTGGCCTGAACC 118bp Designed 
Egr1 R AGGCAGAGGAAGACGATGAA 
Aldh3a1 Aldh3a1 F CCCCTGGCACTCTATGTGTT 116bp Designed 
Aldh3a1 R GTGGGCACAGTGATGTGAAC 
Tpd52 Tpd52 F CCTCGCTTCAGGAGTTCAAG 138bp Designed 
Tpd52 R CTGAGCCAACCGATGAAAAT 
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Dusp6 Dusp6 F GGCAAAAACTGTGGTGTCCT 106bp Designed 
Dusp6 R CATCGTTCATGGACAGGTTG 
Tbp mTBP F CCCCACAACTCTTCCATTCT  103bp Justyna 
mTBP R GCAGGAGTGATAGGGGTCAT  Janikiewicz1 
B2M mB2MG F CATGGCTCGCTCGGTGACC  166bp Justyna 
mB2MG R AATGTGAGGCGGGTGGAACTG  Janikiewicz1 
18s m18S F CGGACAGGATTGACAGATTG  89bp Justyna 
rRNA m18S R CAAATCGCTCCACCAACTAA  Janikiewicz1 
miRNA Primers 
Let-7f Let-7f FP GCCCCTGAGGTAGTAGATTGTATAGTT - Invitrogen 
U6 U6 FP CGCTTCGGCAGCACATATAC 48bp Perkins et al., 2007 
U6 RP TTCACGAATTTGCGTGTCAT 2007 
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2.2 Methods 
2.2.1 Western Blots 
 
2.2.1.1 Preparation of protein lysates 
Protein lysates from cells were prepared from cells plated in 10cm2 culture 
plates. Media was removed from the cell culture plate and the cells washed with 
10ml of pre-chilled PBS twice. The plate was put on ice and 1ml of pre-chilled RIPA 
buffer was added for five minutes. Cells were harvested with a cell scraper and 
disrupted using vortex. After 10 minutes on ice, cells were centrifuged at 12,000rpm 
at 4°C for 20 minutes. Supernatant was transferred into a new tube and stored at -
20oC. The sample was heated at 100oC for 10 minutes before loading to denature the 
proteins and disrupt protein-protein interactions. 
2.2.1.2 Protein concentration measurement 
The concentration of total protein lysates was measured using the Lowri 
method using the Protein Assay Kit from BioRad following the manufacturer’s 
protocol. Before measuring the lysate concentration, a standard curve of a serial 
dilution of BSA from 0 to 4.0mg/ml in RIPA buffer was carried out. Reagent A’ was 
created by adding 20µl of reagent S to 1ml of reagent A. In triplicate, 10µl of each 
dilution was added to a 1.5ml tube along with 50µl of reagent A’ and mixed. Next, 
200µl of reagent B was added to each tube and kept in room temperature for 15 
minutes. Absorbance readings were measured at 750nm and plotted against the 
protein concentration to create a standard curve. This curve was then used to 
determine the protein concentrations of all protein lysates.   
 
2.2.1.3 SDS-PAGE gel electrophoresis 
The BioRad Mini TransBlot Cell apparatus was used according to the 
manufacturer’s protocol. First, a 10% acrylamide separating gel (enough for two 
gels) was made as follows:
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30% Acrylamide 5.2ml 
1.5M Tris pH 8.8 4ml 
dH2O 6.68ml 
20% SDS 80µl 
TEMED 10µl 
25% AMPS 40µl 
 
The gel components were mixed and poured in between two BioRad glass plates. 
The separating gel was overlaid with dH2O to disperse bubbles and prevent the upper 
part of the gel from drying out. It was kept for 30 minutes to set. The water was 
removed and replaced by the 4.3% stacking gel as follows: 
 
30% Acrylamide 1.45ml 
0.5M Tris pH 6.8 2.5ml 
dH2O 5.95ml 
20% SDS 50µl 
TEMED 5µl 
25% AMPS 50µl 
 
The stacking gel was then poured on top of the separating gel, 10 or 15 wells combs 
(BioRad) were inserted and the gel was allowed to set for 15 minutes. The plates 
were placed in the gel tank apparatus which was filled with 1x Tris-Glycine-SDS 
buffer (BioRad). The combs were removed from the gels and the wells were washed 
out with a pipette. 20µg of protein was mixed with 2x Laemmeli loading buffer and 
loaded into the wells along with a protein size marker (Fullrange Rainbow - BioRad). 
The gels were then run at 120V for about 45 minutes.
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The gel was removed from the plates and soaked in transfer buffer along with two 
filter papers (Whatman) and two sponges. A Hybond-P PVDF membrane 
(Amersham) was soaked in methanol and then soaked in transfer buffer. A sponge, 
one piece of filter paper, the membrane, the gel, another piece of the filter paper and 
the second sponge were placed on the transfer cell and assembled into the apparatus. 
The tank was filled with the transfer buffer and run at 400A at 4oC for one hour in 
order for the proteins and protein marker to transfer from the gel to the membrane. 
After an hour, the blots were removed and the non-specific sites on the membrane 
were blocked with 5% powdered milk in PBS-T overnight at 4oC. 
 
2.2.1.4 Western Blotting 
After blocking, the membranes were incubated for one hour with the primary 
monoclonal antibody and 5% milk at room temperature. The membranes were then 
washed 3 times, each for 10 minutes with PBS-T. This was followed by incubating 
the membranes with the HRP-labeled secondary antibody (dilution shown in table 
2.2) in 5% milk for one hour at room temperature. The membranes were again 
washed 3 times for 10 minutes with PBS-T. Protein detection was performed using 
the enhanced chemiluminescence (ECL) detection kit (Amersham). 
 
2.2.2 Immunuhistochemistry (IHC) 
2.2.2.1 Tissue MicroArrays (TMAs) 
To visualize the expression pattern of both EEF1A2 and PTK6 in breast 
tumors, commercial tissue arrays of both normal human breast tissues and cancers 
(AccuMax Array, Stretton Scientific) were stained with different monoclonal 
antibody dilutions before deciding on the best dilution shown in table 2.2. This was 
followed by performing IHC on breast tumor tissue arrays in triplicate from 300 
patients obtained from the tissue bank provided by John Bartlett at the Edinburgh 
Cancer Research UK Centre, University of Edinburgh. 
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2.2.2.2 IHC on breast tissue arrays 
At room temperature, parrafin embedded sections of human breast tumors 
were deparaffinised with xylene, rehydrated in 75% and 100% ethanol and 
microwaved in citric acid pH 6. Slides were washed in dH2O, treated with 3% 
hydrogen peroxidase, washed with PBS and loaded into a sequenzer. Three drops of 
Protein Block Serum-Free (Dako) were added and kept for 10 minutes. 100µl of the 
primary antibody was added overnight at the dilution mentioned in table 2.2. Slides 
were washed with PBS for five minutes, incubated in three drops of Biotinylated 
Link Universal (Dako) for 30 minutes, washed with PBS and incubated in 
Streptavidin-HRP (Dako) for another 30 minutes. After washing with PBS for five 
minutes, the slides were removed from the sequenzer and treated with 3, 3-
Diaminobenzidine (DAB) for two minutes. Finally, the slides were washed in dH2O, 
counterstained in haematoxylin, stained with lithium carbonate, dehydrated in 100% 
and 75% ethanol, cleared in xylene and mounted in pertex. The slides were left to dry 
overnight and sections were viewed by light microscopy using the DP software 
(Olympus) on Olympus BX51. 
 
2.2.2.3 Immunohistological scoring 
Cores on the breast tumors TMAs were scored based on the protein 
expression as shown below: 
 
Expression Histoscore Intensity 
Negative 0 0 
Weak 1-100 1 
Moderate 101-200 2 
Strong 201-300 3 
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Sections were histoscored using a score of 1 to 3 for staining intensity multiplied by 
the percentage of tumor tissue staining, therefore giving a maximum score of 300 per 
core. Blind scoring was carried out by two researchers. 
2.2.2.4 Statistical Analysis 
After scoring all the breast TMAs, histoscore analysis was carried out to 
check for the correlation between EEF1A2 and PTK6 using the SPSS analytical 
program (IBM). A two sample paired t-test was carried out as it has greater power 
when compared to unpaired tests. P values of 0.05 or less were considered to be 
statistically significant. A pearson correlation of 0.3 – 0.5 would signify a positive 
moderate association whereas a correlation of 0.6 – 1.0 would signify a positive 
strong association.   
 
2.2.3 RT-PCR 
2.2.3.1 mRNA extraction from cell lines 
Cells were washed with PBS, trypsinised and centrifuged. The supernatant 
was removed and cells were stored in -70oC until used. RNA was extracted using the 
RNeasy Mini Kit (Qiagen) according to the manufacturer’s protocol.  
2.2.3.2 miRNA extraction from cell lines 
Total RNA (miRNA and mRNA) was extracted from peletted cells using the 
mirVana miRNA Isolation Kit (Ambion) according to the manufacturer’s protocol. 
2.2.3.3 RNA concentration measurement 
Concentration of RNA was measured using the NanoDrop™ 1000 
spectrophotometer (Thermo Scientific). A nanodrop is a spectrometer that passes a 
beam of narrow-band light through a droplet of water and measures the intensity of 
light transmitted through the sample. It measures the absorbance reading at 260nm 
giving an RNA concentration in ng/µl. The ratio of absorbance at 260nm and 280nm 
is used to assess the purity of RNA. A ratio of ~2.0 is generally accepted as “pure” 
for RNA. RNA concentration of 10ng/µl was used as a working dilution. 
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2.2.3.4 cDNA synthesis 
cDNA was produced from RNA using two different kits depending on the 
experiment it will be used in. To produce cDNA for mRNA reactions, the First 
Strand cDNA Kit (Roche) was used as follows: 
 
Reaction +RT -RT 
RNA 10ng 10ng 
10X reaction buffer 2µl 2µl 
25mM MgCl2 4µl 4µl 
dNTP mix 2µl 2µl 
Oligo (dT) 2µl 2µl 
RNase Inhibitor 1µl 1µl 
AMT Reverse Transcriptase 






The reaction is kept at room temperature for 10 minutes, followed by 42oC for 1 hour 
and then 5 minutes at 99oC. The reaction was kept at -20oC until used. 
 
As for cDNA synthesis from miRNA, the NCode VILO miRNA cDNA Synthesis Kit 
(Invitrogen) was used as per manufacture’s protocol. The following reaction was 
carried out:  
5X Reaction Mix 4µl 
10X  SuperScript Enzyme Mix 2µl 
Total RNA (10ng) Xµl 
DEPC-treated water To 20µl 
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The reaction mix was gently mixed by vortexing and centrifuged briefly to collect 
the contents. It was incubated at 37oC for 60 minutes and terminated at 95oC for 5 
minutes. The cDNA was then stored at -20oC until used. 
 
2.2.4 Patient Samples 
2.2.4.1 DNA extraction from Paraffin Embedded Tissue (PET) 
Breast tumors were obtained from the tissue bank provided by John Bartlett, 
PET sections was cut by Ria Kishen and the DNA extraction protocol was provided 
by Vicky Sabine, all from the Edinburgh Cancer Research UK Centre, University of 
Edinburgh. PET samples were cut and put in 1.5ml tubes. 200µl of 5% Tween 20 
was added to the 1.5ml tube containing the sample and spun briefly to collect the 
material at the bottom of the tubes. To remove the paraffin wax, the tubes were 
agitated by inverting them and heating them to 90oC for 10 minutes in a heating 
block. Tubes were cooled to 55oC by transferring them to a separate heating block 
for five minutes. 4µl (10mg/ml) of Proteinase K was added to the mixture and 
incubated at 55oC for one hour. This step was repeated four times. Next, 4µl 
(10mg/ml) of Proteinase K was added again and incubated at 55oC overnight. 300µl 
of 1X PBS was added and mixed by vortexing for ten seconds. The mixture was 
heated to 99oC for ten minutes in a heating block. The hot tubes were transferred 
briefly to ice to cool, placed into a microfuge at 4oC and spun at 10,500rpm for 15 
minutes. After spinning, the sample was placed on ice again for five minutes to 
further harden the paraffin wax. The liquid was aspirated from below the now hard 
wax layer and transferred to a clean pre-labelled 1.5ml centrifuge tube. Next, the 
DNA extraction was carried out using the QIAamp DNA Mini Kit (QIAgen) as per 
the manufacturer’s protocol and stored at -20oC. 
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2.2.4.2 DNA concentration measurement 
Measuring DNA concentration was carried out the same way as the RNA 
(section 2.2.3.3). A 260/280 ratio of ~1.8 is generally accepted as “pure” for DNA. 
DNA concentration of 10ng/µl was used as a working dilution.
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2.2.5 Real-Time PCR 
The double delta Ct (∆∆Ct) method (Livak and Schmittgen, 2001) was used to 
detect the gene copy number for EEF1A2, PTK6, SRMS and KCNQ2 and the 
expression level of several genes using the Bio-Rad MyiQ iCycler (Discussed in 
section 3.2.3).  The amplification efficiency was first determined on the breast cancer 
cell lines MCF7, T47D, MDA-MB-231 and MDA-MB-453 (Standard curves shown 
in Appendix A). Primers with efficiencies between 90% and 110% were used for the 
copy number analysis as well as detecting the expression level. As shown in table 2.4, 
primers were designed to amplify a product of the size between 100-200bp with no 
secondary structure and no primer-dimer formation. All genes were normalized 
against two reference genes (copy number analysis) or three reference genes 
(expression level analysis). Normal human blood (provided by Pippa Thomson at the 
Molecular Medicine Centre, Edinburgh) was used as a control for the copy number 
analysis as it should contain normal two copies of the genes studied. Samples were 
done in triplicate and the mean Ct value was taken for the final analysis. For the 
qPCR reaction, the DyNAmo Flash SYBR Green qPCR Kit (New England Biolabs) 
was used as follows: 
 
Master Mix 10µl 
Forward Primer 0.5nM 
Reverse Primer 0.5nM 
DNA or cDNA 10ng 
dH2O To 20µl 
 
Normal control DNA was extracted and provided by Pippa Thomsons. It was 
extracted from 10ml whole blood using a Nucleon™ BACC Genomic DNA 
Extraction kit (GE Healthcare Life Sciences). 
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The cycling program used is shown below: 
 
Step Cycles Temperature Time 
Step 1 1x 95oC 5 minutes 
Step 2 40x 95oC 45 seconds 
  60oC 30 seconds 









Step 5 80x 60oC 10 seconds 
 
 
2.2.6 Cell Transfection  
 
2.2.6.1 Cell culture and cell count 
Cells were grown in T175cm2 flasks at 37oC in a 5% CO2 incubator to a 
confluency of around 80%. The media was aspirated, cells washed with PBS and 5ml 
trypsin was added. After 2-3 minutes, the medium was added and the cell suspension 
was transferred into a 50ml Falcon™ tube. Cell suspension was centrifuged at 
2000rpm for 5 minutes. Supernatant was aspirated, 5ml media was placed in a 50ml 
tube and it was added and mixed with the cells. For cell counting, 200µl of the 
mixture was placed into the counting chamber of the cell counter Cellometer Auto T4 
(Nexcelom). 
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2.2.6.2 EEF1A2 construct preparation 
To produce bacteria containing the EEF1A2 construct, 80mls LB agar was 
heated in the microwave for 6 minutes and left to cool for 15 minutes, 2µl of Zeocin 
(100mg/µl) was then added. 10mls of the LB agar with Zeocin was poured into 10cm2 
plates and left to cool. The bacteria containing the pcDNA3.1/GS-EEF1A2 construct 
from Invitrogen (Figure 2.1) was placed on ice. A loop was dipped in the frozen 
bacteria and spread on the LB agar with Zeocin plate and the plate was sealed with a 
paraffin tape. Plates were incubated at 37oC overnight. 4mls of LB with 1µl of Zeocin 
(100mg/µl) was placed in a 10ml tube. One colony from the plate was picked and 
inoculated the 4ml LB starting culture. This was then incubated at 37oC with shaking 
at 180rpm for two hours in an Innova 4300 incubator/shaker (New Brunswick 
Scientific). 150mls of LB with 37.5µl Zeocin (100mg/µl) was prepared for the next 
step. To dilute the starting culture 1:1000, 4µl of it was added to the 150ml 
LB/Zeocin and left in the shaker overnight. A maxi prep was then performed using 
the HiSpeed Plasmid Maxi Prep Kit (QIAgen) to produce high copy plasmid DNA as 
per the manufacturer’s protocol. The presence of the EEF1A2 DNA construct was 
confirmed by loading 5µl of DNA with 5µl of loading buffer on a 0.8% agarose gel. 
The correct band size was detected (Figure 2.2). The DNA was stored at -20oC. Both 
BT549 and NIH-3T3 cells were transfected with the EEF1A2 DNA construct. 
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Figure 2.1 EEF1A2 expression construct (Invitrogen). Vector pcDNA3.1/GS for expression in 
mammalian cells includes the CMV promoter and enhancer sequences for stable expression; and the 
Zeocin antibiotic for selection of bacterial transformants and of stably transfected mammalian cells. 
Vector also includes the V5 epitope tag after the insert to allow detection of proteins for which 
antibodies are not available, a carboxy-terminal polyhistidine tag (His)6 to allow metal-affinity protein 
purification, and the T7 promoter to enable in vitro transcription and translation of the target gene.  
 
Figure 2.2 Agarose gel showing the 6kb EEF1A





2 expression construct band. 3µl of the EEF1A2 
d size after extraction. 
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2.2.6.3 Let-7f miRNA 
BT-549 cells were transfected with the microRNA Let-7f to check if the 
EEF1A2 expression level is affected by the presence of Let-7f. The mature hsa-let-7f 
was purchased from Invitrogen. 6µl (30nM) of let-7f was used for each reaction.  
 
2.2.6.4 Transfection using a nucleofector 
A nucleofector (Amaxa) was used for the transfections into BT549 and NIH-
3T3 cells. BT549 cells were transfected with the EEF1A2 DNA construct to check for 
the change in PTK6 expression. BT549 cells were also transfected with let-7f miRNA 
to check for its effect on EEF1A2. NIH-3T3 cells were transfected with the EEF1A2 
DNA construct to check for its effect on the expression level of PTK6 and the 
expression level of the top genes in the microarray study (chapter four): Serpine2, 
Egr1, Aldh3a1, Tpd53 and Dusp6. After cell counting (section 2.2.6.1), 1 x 106 cells 
were centrifuged at 900rpm for 5 minutes and the pellet resuspended in 300µl of the 
appropriate nucleofector solution (Amaxa) to perform the experiment in triplicate. 
BT549 cells were suspended in solution T whereas NIH-3T3 cells were suspended in 
solution R as recommended and provided in the Cell Line Nucleofector® Kit 
(Amaxa). 10µl/reaction (3µg) of DNA vector was added to 100µl of the solution 
which was transferred to a cuvette. Cells were electroporated in the nucleofector 
using the appropriate program. Program A-023 was used for BT549 whereas program 
U-030 was used for NIH-3T3 cells. These are programs that have been pre-
configured by Amaxa. The cuvette was removed immediately after electroporation 
from the nucleofector and 500µl of medium was added. The cells were then 
transferred with a pipette into a 10cm2 plate containing 10ml of medium. The same 
was done with the remaining 200µl of solution as every plate required 3 reactions. 
Controls included cells with no electroporation and cells with the nucleofector 
solution but lacking DNA. 
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2.2.7 Microarrays 
 
2.2.7.1 RNA preparation 
Total RNA was extracted using the AllPrep DNA/RNA/Protein Mini Kit 
(QIAgen) according to the manufacturer's instructions. An aliquot of 150ng of total 
RNA was converted to single-stranded cDNA using an oligo (dT) tagged with a 
phage T7 promoter to enable in vitro transcription (Ambion). Single-stranded cDNA 
was converted to produce double-stranded cDNA. This was followed by transcription 
in vitro where the now cRNA is amplified and labelled by an in vitro transcription 
reaction that incorporates biotin UTP. This was done using the TotalPrep RNA 
Amplification kit (Ambion) recommended by Illumina. All twelve RNA samples 
were quantified and monitored with the Agilent 2100 Bioanalyzer (Agilent) to check 
the high-quality RNA. 
 
2.2.7.2 Sample processing 
Samples were processed and data acquired by Louise Evenden at the 
Wellcome Trust Clinical Research Facility/Genetics Core of Edinburgh University 
using two mouse WG-6 v2.0 Expression BeadChips for the analysis of more than 
47,000 probes. From each of the twelve samples, 1.5µl of labelled cRNA was 
aliquoted into 0.2µl tubes prior to the Agilent procedure. Once the concentrations are 
measured, decision is made whether to dilute or concentrate down the sample to get 
the 1500ng (10µl of 150ng/µl) needed for the Mouse WG-6 arrays. The sample was 
diluted or concentrated down and resuspended with RNase free water (SIGMA). The 
sample needed is 10µl of 150ng/µl and this is what was used for the Gene Expression 
protocol. The twelve cRNA targets were hybridised to the BeadChips, which were 
scanned on an Illumina BeadStation. Image processing and raw data extraction were 
performed using the Illumina Beadstudio software. A number of pre-processing steps 
including background adjustment, probe filtering, normalization and quality control 
checks were performed using the R package, lumi (www.bioconductor.org). Boxplots 
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of the microarray data before and after quantile normalization demonstrate how the 
distributions of the intensities are scaled to have equal means and variances across 
samples (Chapter 4, figure 4.6). To determine pathways affected by the 




2.2.8 Reverse Phase Protein Array (RPPA) 
The protocol for the RPPA was created by Peter Mullen from the 
Breakthrough Research Unit, Edinburgh. 
 
2.2.8.1 EEF1A2 antibody optimization 
2.2.8.1.1 EEF1A2 antibody incubation 
A FAST-slide (Whatman) was placed in a suitable container in x1 Whatman 
wash buffer for five minutes on a rocking platform (All buffers and reagents were 
provided by Peter Mullen). Wash buffer was replaced with LiCor Blocking Buffer 
diluted 50:50 in PBS and incubated for 1 hour at room temperature on a rocking 
platform. Two monoclonal EEF1A2 antibodies were tested: one raised in sheep and 
the other in rabbit. 125µl of each of the EEF1A2 primary antibodies was prepared in 
LiCor Blocking Buffer diluted 50:50 in PBS at the serial dilutions: 1:50, 1:100, 1:250, 
1:500 and 1:1000 and kept on ice. Slides were mounted in the FAST Frame slide 
holder (Whatman) so that a tight seal is formed between the slide and the incubation 
chamber. Residual buffer was removed from wells and 80µl of the EEF1A2 
antibodies was added to the respective wells. Slide and chamber were placed into a 
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2.2.8.1.2 Secondary antibody incubation  
At room temperature, the EEF1A2 antibodies were carefully removed from 
each well. 80µl of PBS-T was added to the wells and slides were washed on a rocking 
platform at room temperature for five minutes. The wash was repeated three times. 
The fluorescently-labelled polyclonal secondary antibodies were prepared by diluting 
them in Odyssey Blocking Buffer (diluted 50:50 in PBS) with 0.01% SDS at 1:2000 
dilution (1µl/2ml). The sheep-derived EEF1A2 antibody is detected using an anti-
goat fluorescently-labelled secondary antibody (either 680nm or 800nm wavelength) 
whilst the rabbit-derived EEF1A2 antibody is detected using an anti-rabbit 
fluorescently-labelled secondary antibody (either 680nm or 800nm wavelength). By 
combining a sheep primary and a rabbit primary along with their respective secondary 
antibodies (one of 680nm and the other of 800nm), dual-labelled RPPA Fast-Slides 
can be obtained. After preparing the secondary antibodies, the buffer was removed 
from the wells, 80µl of the fluorescently-labelled secondary antibodies were added to 
the respective wells and incubated at room temperature in the dark for 45 minutes 
with gentle shaking. Secondary antibodies were removed from the wells and briefly 
washed three times in 80µl PBS-T at room temperature. Slides were further washed 
in excess PBS-T for 15 minutes in the dark. PBS-T was removed and the membrane 
was washed with PBS at room temperature in the dark for 15 minutes to remove 
residual Tween 20. FastSlides were dried in a 50oC oven for ten minutes and then 
scanned on the Li-Cor Odyssey scanner. 
 
2.2.8.1.3 Determining efficient antibody dilutions for RPPA 
Based on the results of the antibody optimization, it was decided that the anti-
sheep EEF1A2 should be used at a dilution of 1:150 whereas the anti-rabbit EEF1A2 
should be used at a dilution of 1:50.  
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2.2.8.2 RPPA protocol 
2.2.8.2.1 EEF1A2 antibody incubation 
A FAST-slide (Whatman) was placed in a suitable container in LiCor 
Blocking Buffer diluted 50:50 in PBS and incubated for 1 hour at room temperature 
on a rocking platform. EEF1A2 antibodies were prepared in LiCor Blocking Buffer 
diluted 50:50 in PBS at the desired concentrations and kept on ice. Slides were 
mounted in the Fast Frame slide holder (Whatman). Residual buffer was removed 
from wells and 700µl primary antibody was added to the respective wells. Slides and 
chamber were placed into a sealed wet box and incubated on a rocking platform.  
 
2.2.8.2.2 Secondary antibody incubation 
At room temperature, the EEF1A2 antibodies were carefully removed from 
each well. 700µl of PBS-T was added to the wells and slides were washed on a 
rocking platform at room temperature for five minutes. The wash was repeated three 
times. The fluorescently-labelled secondary antibodies were prepared by diluting 
them in Odyssey Blocking Buffer (diluted 50:50 in PBS) with 0.01% SDS at 1:2000 
dilution (1µl/2ml). The buffer was removed from the wells, 700µl of the 
fluorescently-labelled secondary antibodies were added to the respective wells and 
incubated at room temperature in the dark for 45 minutes with gentle shaking. 
Secondary antibodies were removed from the wells and briefly washed three times in 
700µl PBS-T at room temperature. Slides were further washed in excess PBS-T for 
15 minutes in the dark. PBS-T was removed and the membrane was washed with PBS 
at room temperature in the dark for 15 minutes to remove residual Tween 20. 
FastSlides were dried in a 50oC oven for ten minutes and then scanned on the Li-Cor 
Odyssey scanner. 
 
2.2.8.3  RPPA analysis 
All data obtained from the scanned membrane were analyzed on Microsoft Excel. 
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Clinical parameters are mostly assessed and analyzed for the diagnosis or 
prediction of breast cancer outcome. This is usually done by either FISH or IHC on 
tumor TMAs. Protein expression is correlated with clinical markers such as grade 
and size of tumors, ER status, PR status, HER-2 status lymph node involvement, 
treatment modality and disease free survival which are typically assessed. 
Retrospective studies can be performed on archival breast cancer samples from 
patients with long follow-up and then compared to the protein expression. 
Overexpression is usually the result of gene amplification. However, several studies 
have reported protein overexpression without amplification. This might be due to the 
role miRNAs play in the translation process as intermediates in different types of 
cancers, but many other causes are possible. 
In this part of the project, I focused firstly on the clinical correlations in 
breast cancer in regards to EEF1A2 and PTK6. Clinical correlations were assessed 
for each protein separately on breast tumor TMAs. Secondly, I analyzed the copy 
number of both genes to further understand the correlation between their protein 
overexpression and gene amplification. Finally, the role of miRNAs in regards to 





3.2.1 Significant correlation between eEF1A2 and PTK6 in breast 
cancer TMAs 
Concentrations of the EEF1A2 and PTK6 antibodies were first optimized for 
IHC using different dilutions on breast cancer cell lines, normal human breast tissues 
and tumor sections. EEF1A2 antibody concentration was decided at 1:15 whereas the 
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concentration for PTK6 was 1:150. In order to assay the level of expression of both 
eEF1A2 and PTK6 in breast cancer, around 300 different breast tumors on two slides 
were stained in triplicate for eEF1A2 and another set of the same identical TMA 
slides were stained for PTK6 (i.e core A1 for example was scored 6 times on 
identical TMA slides; 3 times for eEF1A2 and 3 times for PTK6). As shown in 
figure 3.1, slide A has 146 primary breast tumors from patients treated with 
chemotherapy after the biopsy was taken whereas slide B has 152 primary breast 
tumors from patients treated later with both chemotherapy and hormonal treatment. 
Figures 3.2 and 3.3 Show the breast conservation series array maps for both 
slides A (breast tumors from patients treated with chemotherapy only after the biopsy 
was taken) and slides B (breast tumors from patients treated with both chemotherapy 
and hormonal therapy after the biopsy was taken). 
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Figure 3.1 Breast conservation series array maps of both EEF1A2 & PTK6. Slide A has 146 
breast tumors from patients treated with chemotherapy only whereas slide B contain 152 breast 
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IHC was performed as described in section 2.2.2. Each core on the TMA 
slide was then scored for the intensity of the expression level in the cytoplasm. Cores 
were scored by two researchers using a histoscore method which involves scoring the 
intensity at a level of 0 to 3 and then multiplying it by the percentage of tumor cells 
stained at that level; stromal tissue was discounted. This should give a maximum 
score of 300. Cores were then assigned to a category based on their histoscores. 
Tumors with a histoscore of 0 were considered “negative”, 1-100 were defined as 
“weak”, 101-200 were defined as “moderate” and histoscores of 201-300 were 
labeled as tumor with a “strong” expression (Figure 3.4). Since scoring was done in 
triplicate, the average of the 3 histoscores was calculated to get the final score for the 
expression level of each tumor on the TMA slide.  
Differences in the histoscores between eEF1A2 and PTK6 were analysed by 
Student’s t-test and showed a significant correlation (p-value 0.006) between the two 
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3.2.2 Expression of eEF1A2 and PTK6 in breast tumors is not 
associated with any clinicohistopathological parameters 
 
To determine whether the expression of eEF1A2 and/or PTK6 was correlated 
with any histopathological parameters, tumors were divided into the ones with low 
expression (scores of 0 and 1) and tumors with high expression (scores of 2 and 3). 
All scoring classifications were determined based on the Allred scoring method 
(which is based on staining intensity and proportion of positive cells) (Allred et al., 
1998). The parameters that were looked at were: grade and size of tumors, ER status, 
PR status, lymph node involvement, treatment modality (chemotherapy alone or 
chemotherapy and hormonal therapy) and disease free survival.  
In the case of this database that contained all the above mentioned 
parameters, all markers were scored by John Bartlett’s lab (Edinburgh Cancer 
Research UK Centre, University of Edinburgh) using the AllRed method of scoring. 
As mentioned in section 1.3, both EEF1A2 and PTK6 are proteins expressed 
in the cell cytoplasm. Different monoclonal antibody dilutions were carried out 
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3.2.2.1 Correlation of eEF1A2 and PTK6 expression with tumor 
size 
 
Tumor size was divided into tumors <20mm and tumors ≥20mm. No 
association was found between tumor size and EEF1A2 (p-value 0.221) nor with 
PTK6 (p-value 0.155).  
 
       EEF1A2 
Tumor size Weak expression High expression Total 
0 (<20mm)      Count 







1 (≥20mm)      Count 







Total               Count 








       PTK6 
Tumor size Weak expression High expression Total 
0 (<20mm)      Count 







1 (≥20mm)      Count 







Total               Count 
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3.2.2.2 Correlation of eEF1A2 and PTK6 expression with tumor 
grade 
 
Tumor grade was classified as grade 1 (well differentiated), grade 2 
(moderately differentiated) and grade 3 (poorly differentiated). EEF1A2 showed no 
significant correlation with tumor grade (p-value 0.55) whereas increased expression 
of PTK6 was associated with low grade tumors (p-value 0.003). 
 
 
        EEF1A2 
Tumor grade Weak expression High expression Total 
1                      Count 







2                      Count 







3                      Count 







Total               Count 










        PTK6 
Tumor grade Weak expression High expression Total 
1                      Count 







2                      Count 







3                      Count 







Total               Count 
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3.2.2.3 Correlation of eEF1A2 and PTK6 expression with the 
estrogen receptor status 
 
Estrogen receptor was another marker examined. Tumors were divided into 
estrogen receptor positive (code = 1) and estrogen receptor negative (code = 0). 
There was no association between estrogen receptor status and EEF1A2 (p-value 
0.64). However, there was a statistically significant association between PTK6 
overexpression and the estrogen receptor positive tumors (p-value 0.037). 
 
 
       EEF1A2 
Estrogen receptor status Weak expression High expression Total 
0 (ER-)               Count 







1 (ER+)              Count 







Total                   Count 










       PTK6 
Estrogen receptor status Weak expression High expression Total 
0 (ER-)               Count 







1 (ER+)              Count 







Total                   Count 
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3.2.2.4 Correlation of eEF1A2 and PTK6 expression with the 
progesterone receptor status 
 
Another marker was the progesterone receptor. Tumors were either 
progesterone receptor positive (code = 1) or negative (code = 0). There was no 
association between EEF1A2 and the progesterone receptor (p-value 0.08) nor was 
there an association with PTK6 (p-value 0.74).    
 
 
       EEF1A2 
Progesterone receptor 
status 
Weak expression High expression Total 
0 (PR-)               Count 







1 (PR+)              Count 







Total                   Count 










       PTK6 
Progesterone receptor 
status 
Weak expression High expression Total 
0 (PR-)               Count 







1 (PR+)              Count 







Total                   Count 
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3.2.2.5 Correlation of eEF1A2 and PTK6 expression with the 
lymph node status 
 
To look at the association of EEF1A2 and PTK6 with lymph node status, 
breast tumors were categorized as 0, 1, 2 and 3 based on the number of lymph nodes 
involved where 0 is node negative, 1 = 1 to 3 nodes involved, 2 = 4 to 9 nodes 
involved and 3 = 10+ lymph node involvement. There was no association between 
EEF1A2 and lymph node involvement (p-value 0.15) nor was there an association 
with PTK6 (p-value 0.08). 
 
       EEF1A2 
Lymph node status Weak expression High expression Total 
0                      Count 







1                      Count 







2                      Count 







3                      Count 







Total               Count 








       PTK6 
Lymph node status Weak expression High expression Total 
0                      Count 







1                      Count 







2                      Count 







3                      Count 







Total               Count 
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3.2.2.6 Correlation of eEF1A2 and PTK6 expression with distant 
relapse-free survival (DRFS) 
 
Distant relapse-free survival (DRFS) was also examined. There was no 
association between overexpression of EEF1A2 and DRFS (p-value 0.6) nor was 
there an association between PTK6 overexpression and DRFS (p-value 0.55) (Figure 
3.5). There was also no association between the overexpression of both EEF1A2 and 


















































































































































































Figure 3.5 Kaplan-Meier curve showing no association between distant relapse-free survival and 
EEF1A2/PTK6 overexpression over 20 years of follow-up. Green line indicates tumors with high 
expression whereas the blue line indicates tumors with low expression. 
 
To check if patient survival is affected based on the treatment received 
patients were split into two groups: those treated with chemotherapy only and those 
treated with chemotherapy and hormonal therapy. There was no association between 
survival in patients treated with chemotherapy alone and EEF1A2 overexpression (p-
value 0.2) nor was there an association with chemotherapy/hormonal treatment (p-
value 0.7) (Figure 3.6).  
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Figure 3.6 Kaplan-Meier curve showing patients treated with either chemotherapy and 
hormonal or chemotherapy alone with overexpression of EEF1A2. There is a slight trend towards 
increased survival in patients treated with chemotherapy and high EEF1A2. Green line indicates 
tumors with high expression whereas the blue line indicates tumors with low expression. 
 
 
As for PTK6, there was also no association between survival in patients 
treated with chemotherapy alone and PTK6 overexpression (p-value 0.3) nor was 
there an association with chemotherapy/hormonal treatment (p-value 0.9) (Figure 





















































































































































































Figure 3.7 Kaplan-Meier curve showing patients treated with either chemotherapy and 
hormonal or chemotherapy alone with overexpression of PTK6. There is a slight trend towards 
increased survival in patients treated with chemotherapy and PTK6 overexpression. Green line 
indicates tumors with high expression whereas the blue line indicates tumors with low expression. 
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  Next, the correlations of both EEF1A2 and PTK6 combined were assessed in 
all patients and then in patients treated with chemotherapy alone and the 
chemotherapy/hormonal group. Overall, there was no association between the 
overexpression of both EEF1A2 and PTK6 combined and DRFS in both groups of 
patients (p-value 0.9) nor was there an association between the overexpression of 
those two proteins and the treatment modality: chemotherapy/hormonal group (p-
value 0.9) and the chemotherapy only group (p-value 0.6) (Figure 3.8). 
 In figure 3.9, the axis was truncated at 10 years to get a better indication of 
the trend. The chemotherapy only graph shows that patients with overexpression of 
both EEF1A2 and PTK6 have an increased survival. This is decreased slightly by 
having either protein, whereas the worst prognosis is in patients with neither at 10 
years. However, in the previous figure (Figure 3.8), the graph shows that as patients 
approach 25 years after diagnosis, survival is increased with both proteins 











































































































































































































































































































































































































































































































































































































































































































































































Figure 3.8 Kaplan-Meier curve showing the association of EEF1A2 and PTK6 combined in all 
patients, in patient treated with chemotherapy/hormonal and in patients treated with 
chemotherapy alone in relation to disease free survival. 
Roles of EEF1A2 & PTK6 in Breast Cancer 









































































































































































Figure 3.9 Same Kaplan-Meier curve as above but with axis truncated to give a better indication 
of the trend. The chemotherapy only graph shows patients with overexpression of both EEF1A2 and 
PTK6 have an increased survival. This is decreased slightly by having either protein, whereas the 
worst prognosis is in patients with neither at 10 years. 
 
3.2.3 Gene copy number analysis in cell lines 
To assay the gene copy number of EEF1A2 and PTK6, primer optimization 
was first carried out on the breast cancer ER positive cells MCF7 and T47D and the 
ER negative cells MDA-MB-231 and MDA-MB-453 along with the cervical cancer 
cell line HeLa (Figure 3.10 & Table 3.1). Optimal primer concentration was 
determined to be 0.5µM and the gene copy number analysis was carried out on those 
cell lines. As discussed in section 2.2.5, normal human blood was used as a 
calibrator/control as it normally has two copies of each gene. The microsatellite 
markers D5S478 (5p15.2) and D11S913 (11q13.1) were used as reference genes 
(Ginzinger et al., 2000) as these loci are located in regions of the genome that usually 
did not show alterations in human breast tumors. To detect the copy number changes, 
the double delta Ct method (2−∆∆Ct) was used where first the difference between the 
mean Ct value of the genes in the control sample and ∆Ct of the reference gene in the 
control sample was determined to get ∆Ct. To get ∆∆Ct, ∆Ct would be subtracted 
from the same value and therefore it equals zero and 20 equals one which is 
equivalent to the number of copies in a haploid cell. This number would be 
multiplied by 2 to get the gene copy number in a diploid cell (Livak and Schmittgen, 
2001). For the tumor samples, evaluation of 2−∆∆Ct indicates the gene copy number 
difference relative to the control sample where the same calculations were used. No 
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copy number changes were detected for both the genes in all the breast cancer cell 
lines as they all showed normal two copies but HeLa cells showed an increased copy 
number of both EEF1A2 and PTK6 (Table 3.1 and Figure 3.10). 
 


























Figure 3.10 EEF1A2 and PTK6 gene copy number in cancer cell lines. EEF1A2 and PTK6 were 
normalized to the reference genes (PUM1 and TBP). Normal human blood was used as a calibrator. 
 
 
Table 3.1 Gene copy number analysis in cancer cell lines using the 2−∆∆Ct method. 
 EEF1A2 
 ∆CT ∆∆CT 2-∆∆Ct 
Normal Blood 0.15 0.00 2 
MCF7 -0.05 -0.20 3 
T47D 0.09 -0.06 2 
MDA-MB-231 0.16 0.01 2 
MDA-MB-453 0.04 -0.11 2 
HeLa -1.61 -1.76 7 
 PTK6 
 ∆CT ∆∆CT 2-∆∆Ct 
Normal Blood 3.97 0.00 2 
MCF7 3.77 -0.20 2 
T47D 4.33 0.36 2 
MDA-MB-231 4.31 0.34 2 
MDA-MB-453 4.04 0.07 2 
HeLa 3.15 -0.82 4 
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3.2.4 PTK6, but not EEF1A2, is amplified in breast cancer 
 
After scoring the breast tumor TMAs and dividing them based on the 
expression level of eEF1A2 and PTK6 into tumors with weak, moderate and strong 
expressions (section 3.2.1), tumors that showed a weak, moderate and strong co-
expression of both genes were selected (Table 3.2), DNA was extracted from the 
original breast tumors’ paraffin embedded tissue (PET) from which the cores were 
obtained, DNA concentration was measured and copy number analysis was carried 
out using real-time PCR. Normal blood was also used as a calibrator along with the 
same reference genes used for the copy number detection in cell lines as described in 
section 3.2.3. 
In total, 55 breast tumors were analyzed for copy number changes in the 
EEF1A2 and PTK6 genes. More tumors were initially selected which were later 
excluded as not enough tumor material was found in the paraffin blocks. Analysis 
using the 2−∆∆Ct method showed an increased copy number of PTK6 in all tumors 
when compared to EEF1A2 (Table 3.3). This was observed for all the three tumor 
categories: weak, moderate and strong, and all showed a significant correlation 
between EEF1A2 and PTK6 gene copy number especially in the tumors with the 
strong co-expression (all p-values were <0.05). In those tumors that showed a strong 
co-expression, copy numbers of PTK6 ranged between 8 and 92 copies whereas the 
copy numbers for EEF1A2 were surprisingly between 2 and 14. In the tumors with 
moderate co-expression, PTK6 copy number was lower than that seen in the tumors 
with strong expression (between 2 and 27), yet still higher that EEF1A2 copy number 
(between 2 and 19 copies). In the tumors with weak expression, PTK6 copies were 
between 2 and 20 whereas EEF1A2 copies were the same as in the tumors that 
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Table 3.2 Breast tumors co-expressing EEF1A2 and PTK6. 
Weak Moderate Strong 
Core ID Tumor ID Core ID Tumor ID Core ID Tumor ID 
B9C 1722 A4 1104 A5 1118 
B14W 1705 A6C 1126 A7 1146 
B18 970  A9 1127 D1 1478 
C17 1511 B15 1712 E3 901 
E8C 238 D10 725 D14 1119 
F8 255 E1 1112 F5 192 
G6 537 E6 1333 G1 543 
G11 212 E10 207 G2 535 
G13 77 F4 194 H1S 554 
G16 443 G4 567 H5 476 
G17 448 H4 986 B1 1103 
A12 1137 A1 953 F2 1783 
A17 1096 A6H 1023 H2 1102 
B6 1158 B14M 1219 I2S 1611 
B9H 1185 C10 1370     
C9 1372 D18 1618     
C12 882 E2 867     
D11 1674 F9 1665     
E8H 1726 G6 1499     
E17 1617 H1 1345     
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Table 3.3 EEF1A2 and PTK6 gene copy number in breast tumors. Copy number analysis was 
carried out on breast tumors that showed weak, moderate and strong co-expression of EEF1A and 
PTK6. 
Weak  Moderate  Strong 
Tumor EEF1A2 PTK6  Tumor EEF1A2 PTK6  Tumor  EEF1A2 PTK6 
B9C 7 10  A4 5 13  A5 4 16 
B14W 9 8  A6C 7 7  A7 5 13 
B18 9 9  A9 3 15  D1 2 8 
C17 7 7  B15 3 6  E3 1 8 
E8C 2 5  D10 4 12  D14 4 10 
F8 4 6  E1 9 27  F5 3 8 
G6 3 9  E6 3 8  G1 14 92 
G11 5 11  E10 2 8  G2 6 53 
G13 5 15  F4 5 11  H1S 4 35 
G16 4 11  G4 3 8  H5 3 23 
G17 6 10  H4 2 8  B1 4 37 
A12 3 8  A1 4 8  F2 3 8 
A17 3 7  A6H 2 15  H2 7 15 
B6 7 20  B14M 8 18  I2S 4 12 
B9H 3 9  C10 6 13  Average 5 24 
C9 3 10  D18 5 7     
C12 4 11  E2 5 8     
D11 4 8  F9 4 10     
E8H 2 5  G6 3 4     
E17 3 6  H1 4 9     
I5 3 10  Average 4 11     
Average 4 9 
 
As shown in Table 3.3, the average number of EEF1A2 gene copies is almost 
the same in all tumors with weak, moderate and strong expression at the protein level 
(4, 4, and 5 gene copies respectively). However, the average copy number for PTK6 
was the highest in the tumors with strong expression. PTK6 amplification could 
explain its overexpression at the protein level. This leads to phosphorylation of its 
substrates which in turn increases cell division and breast tumorigenesis. As for 
EEF1A2, having an average of 4-5 gene copies does not explain the high expression 
at the protein level detected from the breast tumors TMAs. Therefore it is suggested 
that other modulators –such as miRNAs, a strong promoter, an enhancer within the 
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3.2.5 SRMS and KCNQ2 have normal copy numbers 
It was shown in the previous section that PTK6 showed a copy number 
increase higher than EEF1A2. Since 20q13.3 is a region known to be amplified in 
breast cancer, the hypothesis was that many genes in this region will also show an 
increased copy number. Therefore both genes that flank EEF1A2 and PTK6 were 
analyzed for copy number changes: SRMS and KCNQ2 (Figure 3.12). Src-related 
kinase lacking C-terminal regulatory tyrosine and N-terminal myristylation sites 
(SRMS) is a non-receptor tyrosine kinase that is involved in proliferation or 
differentiation of keratinocytes in the skin. KCNQ2 (Potassium voltage-gated 
channel subfamily KQT member 2) is a gene important in the regulation of neuronal 
excitability. Mutations in the KCNQ2 gene was shown to be associated with epilepsy 





Figure 3.12 20q13.3 amplicon showing the two genes flanking EEF1A2 and PTK6: SRMS and 
KCNQ2 (Ensembl). 
 
To detect the copy number changes in SRMS and KCNQ2, real-time PCR was 
carried out on seven of the tumors that showed an increased copy number of PTK6 in 
the strong co-expression category. Since this is a region known to be amplified in 
breast cancer, SRMS and KCNQ2 might be expected to have an increased gene copy 
number, especially if PTK6 and EEF1A2 were part of a single amplicon. However, 
when copy number analysis was carried out, both genes showed normal two copies 
with no sign of amplification (Table, 3.4, Figure 3.13, 3.14 and 3.15). 
 
 






Tumor ID KCNQ2 EEF1A2 PTK6 SRMS 
Calibrator 2 2 2 2 
A5 2 4 16 1 
A7 1 5 13 1 
G2 2 6 53 3 
H1S 2 4 35 3 
H5 1 3 23 2 
B1 2 4 37 2 
I2S 1 4 12 2 
Table 3.4 qPCR analysis showing copy number changes in KCNQ2, EEF1A2, PTK6 & SRMS. 
 
Figure 3.13 Real-time
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 PCR product run on an agarose gel after analysis.  KCNQ2 and SRMS 
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KCNQ2, EEF1A2, PTK6 & SRMS 
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Figure 3.15 Copy number analysis of KCNQ2, EEF1A2, PTK6 and SRMS based on their 
location on the 20q13.3 amplicon. Only PTK6 appears to be amplified amongst those genes. The 
four genes were normalized to the reference genes. Normal human blood was used as a calibrator. 
 
Since EEF1A2 gene copy number did not correlate with the protein 
overexpression detected in the breast tumors TMAs (section 3.2.4), one hypothesis 
was that miRNAs might play a role in its overexpression. Most studies have shown 
that miRNAs downregulate gene expression by binding to the 3’UTR and either 
degrading the mRNA or inhibiting translation. However, in 2008, Dahiya et al. 
reported the overexpression of eEF1A2 in the ovarian cancer cell line BG-1 when 
transfected with the miRNA let-7f (Dahiya et al., 2008). 
Alexey Larionov (Breakthrough Breast Cancer Research Unit, Western 
General Hospital, Edinburgh) has kindly provided the figure below (Figure 3.16) 
where he looked at the association between eEF1A2 mRNA and Let-7f miRNA in 60 
breast tumors. His analysis was based on data obtained with Illumina HT-12 mRNA 
microarrays and Illumina miRNA arrays. There was no association between eEF1A2 
mRNA and Let-7f miRNA expression in those breast tumors. 
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Figure 3.16 Microarray study analyzing the association between eEF1A2 mRNA and Let-7f 
miRNA in 60 breast tumors. No significant correlation between eEF1A2 mRNA and let-7f miRNA 
in breast tumors (Alexey Larionov, Breakthrough Breast Cancer Research Unit, Western General 
Hospital, Edinburgh). 
 
The graph shows many breast tumors expressing let-7f but not eEF1A2 
indicating that let-7f alone is not sufficient to increase the expression level of 
eEF1A2, at least at the RNA level. On the other hand, tumors expressing eEF1A2 
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3.2.6 EEF1A2 expression in breast tumors and breast cancer cell 
lines using RPPA 
Reverse Phase Protein Array (RPPA) is a technique used to detect the 
presence or absence of a certain protein in a large set of tumors and/or cells lines in a 
single slide. This was carried out on 107 breast tumors along with 26 breast cancer 
cell lines to detect the presence of EEF1A2 at the protein level. Protein extraction 
and slides’ generation was carried out by Peter Mullen from the Breakthrough 
Research Unit, Edinburgh. Before carrying out the RPPA, antibody optimization was 
carried out for two EEF1A2 antibodies to determine the best concentration to be used 
(described in section 2.2.8). eEF1A2 anti-sheep antibody was used at a concentration 
of 1:150 while eEF1A2 anti-rabbit antibody was used at a concentration of 1:50.  
EEF1A2 is not usually expressed in normal breast tissue. However, it was 
shown to be increased in 60% of breast tumors. As shown in figure 3.17, eEF1A2 is 
expressed in all breast tumors with exceptionally increased expression in two breast 
tumors detected by the anti-sheep antibody. The anti-rabbit antibody showed similar 
results of increased eEF1A2 expression in all breast tumors, it also showed a 
significant increase in the same tumors as the ones detected by the anti-sheep 
antibody along with 2 other tumors (Figure 3.18). EEF1A2 showed increased 
expression in all 26 breast cancer cell lines as shown in figure 3.19 and 3.20. This 
was detected using both the anti-sheep and anti-rabbit antibodies. 
STAT3 is one of the intermediates affected by the downregulation of 
EEF1A2. Even though Li et al. reported that knockdown of Eef1a2 expression 
resulted in delayed phosphorylation of STAT3 in PCT cell lines, the actual level of 
STAT3 was not affected (Li et al., 2010). In this RPPA study, Peter Mullen has been 
working on STAT3 and has kindly provided figures 3.21, 3.22, 3.23 and 3.24 where 
he used two STAT3 antibodies: STAT3 and pSTAT3 (Tyr705) (Cell Signaling 
Technology®). As shown in figures 3.21 and 3.22, using both antibodies, many 
breast tumors show an increased expression of STAT3. Interestingly, both tumors 
that showed an exceptionally increased expression of EEF1A2 also show a high 
expression of STAT3. However, when pSTAT3 (Tyr705) antibody was used to 
detect the phosphorylated form of STAT3, it was noticed to be expressed in all 107 
Roles of EEF1A2 & PTK6 in Breast Cancer 
Chapter 3: EEF1A2 & PTK6 expression in breast cancer cell lines/tumors 85
breast tumors. As for the 26 breast cancer cell lines, all showed an increased STAT3 
and pSTAT3 (Tyr705) level but lower than the expression detected in breast tumors 
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3.3 Discussion 
 
3.3.1 EEF1A2 and PTK6 correlation with histopathological 
parameters in breast cancer 
EEF1A2 and PTK6 are two oncogenes mapping to the 20q13.3 amplicon. Both 
eEF1A2 and PTK6 are overexpressed in 60% of breast tumors and since these genes are 
located on a region known to be amplified in many different types of cancers, it was 
thought that these genes might have an increased copy number due to co-amplification, 
resulting in overexpression. Co-expression of PTK6 in conjunction with eEF1A2 has not 
previously been analyzed in breast cancer tissue. We found a significant correlation 
between PTK6 and eEF1A2 expression at the protein level (p-value 0.006) when IHC 
was carried out on breast tumor TMAs. 
In 2007, Aubele et al. demonstrated that PTK6 is a prognostic marker of 
metastases-free survival in 193 breast tumors, and that it is independent of the classical 
morphological and molecular markers of lymph node involvement and tumour size 
(Aubele et al., 2007). In 2008, the same group reported that PTK6 protein expression in 
426 breast tumors showed significant statistical correlation with the disease-free survival 
of patients but no correlation with lymph node status and tumor size (Aubele et al., 2008). 
However, when I analyzed 300 breast tumors to study the association of the 
histopathological parameters and PTK6, PTK6 overexpression was associated with only 
low grade tumors and the estrogen receptor positive tumors. No correlation was found 
with tumor size, lymph node status or with disease-free survival of patients. This could be 
attributed to the small number of tumors that I studied or those discrepant findings may 
be caused by different compositions of the tumor cohorts. This may influence and change 
the statistical results. Analysis of a larger set of tumors would give a better result of the 
correlation with those histopathological parameters.   
Kulkarni et al. have reported that high eEF1A2 expression is a significant 
predictor of outcome. Individuals with tumors which display eEF1A2 protein 
overexpression have an increased probability of 20-year survival compared to those 
women whose tumors do not express substantial eEF1A2. Therefore they concluded that 
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eEF1A2 protein expression predicts increased survival probability in breast cancer 
patients (Kulkarni et al., 2007). In the 300 breast tumor that I analyzed, no significant 
statistical correlation was found between eEF1A2 and any of the histopathological 
parameters studied. This could be due to the usage of an eEF1A2 antibody different than 
the one used by their group as our antibody is not commercial (detecting both EEF1A1 
and EEF1A2) but generated in our lab and therefore detecting only EEF1A2. However, a 
study with a larger number of tumors might give a better indication of any trend. 
 
3.3.2 EEF1A2 and PTK6 copy number analysis in breast tumors 
Protein overexpression usually correlates with increased gene copy number. 
However, a few reports showed that overexpression can be detected in the absence of 
gene amplification as shown with the PPM1D, HDM2 and DARPP32 genes (Lambros et 
al., 2010; Polsky et al., 2001; Varis et al., 2004). Real-time PCR showed that PTK6 has 
an increased copy number in breast tumors with a high expression in the TMAs. PTK6 
amplification would therefore explain the mechanism by which the protein is 
overexpressed. PTK6 stimulates ErbB receptor tyrosine kinase signaling in cancer cells. 
Overexpression of PTK6 sensitizes mammary epithelial cells to mitogenic effects of EGF 
(Kamalati et al., 1996) and therefore its coexpression with ErbB3 enhances EGF 
signaling through AKT and PI-3 kinase pathways (Kamalati et al., 2000). Different ErbB 
receptor ligands such as EGF and heregulin, stimulate PTK6 activity (Kamalati et al., 
2000; Ostrander et al., 2007).  
However, since EEF1A2 was thought to be located on the same amplicon, the 
hypothesis was that it would have a similar increase in gene copy number. When these 
same tumors were analyzed for copy number changes, EEF1A2 did not show copy 
numbers as high as PTK6. Therefore other factors/modulators might effect EEF1A2 
leading to high protein expression. Tomlinson et al. reported that at the RNA level, 33% 
of ovarian tumors showed overexpression of eEF1A2 (Tomlinson et al., 2007). The 
authors reported that EEF1A2 copy number does not correlate with the expression level 
of the gene, the EEF1A2 gene is unmethylated in both normal and tumor DNA and that 
no mutations were detected. This indicates that overexpression is not dependent on 
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genetic or epigenetic modifications at the EEF1A2 locus at least in ovarian tumors. This 
has not been tested in breast tumors. However, another hypothesis for the overexpression 
of EEF1A2 is attributed to the roles miRNAs play in gene expression. Most studies have 
shown that miRNAs downregulate gene expression by binding to the 3’UTR and either 
degrading the mRNA or binding to the mRNA and inhibiting translation. However, in 
2008, Dahiya et al. have reported the overexpression of eEF1A2 in the ovarian cancer 
cell line BG-1 when transfected with the miRNA let-7f (Dahiya et al., 2008). As 
mentioned, miRNAs usually repress translation by either binding to the mRNA or 
degrading it. In the case of EEF1A2, it is thought that let-7f binds to an inhibitor that 
deactivates EEF1A2 mRNA, leading to a high expression level. Another hypothesis is 
that EEF1A2 has a strong promoter that affects its expression and therefore would not 
require many copies of the gene. Bischoff et al. analyzed the promoter activity of 
EEF1A2 in the human amnion AMA cells and delineated a minimal promoter region that 
is sufficient to drive transcription of the gene (Bischoff et al., 2000). They have shown 
that the myocyte enhancer factor-2 (MEF2) site did not affect promoter activity in AMA 
cells. However MEF2 has been reported to participate in the activation of genes 
specifically expressed in skeletal muscle, heart, somatic muscle, and neuronal tissues 
(Black and Olson, 1998). Since eEF1A2 is expressed in equivalent tissues, the authors 
suggested that MEF2 might act as a factor that activates the expression of eEF1A2.  
On the other hand, several other factors including enhancers might affect the 
expression of eEF1A2. Newbery et al. carried out percentage identity plot (PIP) analysis 
of the human and mouse regions surrounding the gene encoding eEF1A2 (Newbery et al., 
2007). This analysis was based on the region contained in a human PAC clone. Figure 
3.25 shows a line-up of human and mouse gene sequences covering the whole region 
between eEF1A2 and PTK6 where the black line shows homology between human and 
mouse genes between 50 and 100%. No significant region of human/mouse homology 
was detected other than within known genes, with the exception of a 100 bp region 
upstream of EEF1A2 that showed 70% homology between human and mouse (circled in 
red). Homology suggests conservation due to functional elements in the 3kb upstream of 
eEF1A2 but –as shown in the figure- there is absolutely no homology up until the 
C20orf149 (Novel gene 2) coding sequence. Also, there is no homology until the 3' end 
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of Ptk6. These data do not conclude that there are no enhancers, but if there are any, they 
are not conserved and that EEF1A2 amplification is most probably not the mechanism 




Figure 3.25 Percentage identity plot (PIP) of the region surrounding the wasted locus of Eef1a2. The 
nucleotide positions for the mouse sequence are shown on the x axis, and the percent identity with the 
corresponding human sequence is shown on the y axis (50-100%). Genes are labeled according to known 
cDNA sequences. Black lines indicate homology between human and mouse genes suggesting conservation 
due to functional elements in the 3kb or so upstream of eEF1A2 (circled in red). As shown, there is no 
homology up until the C20orf149 (Novel gene 2) coding sequence. Also, there is no homology until the 3' 
end of Ptk6. These data do not conclude that there are no enhancers, but if there are any, they are not 
conserved (Newbery et al., 2007).  
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SRMS and KCNQ2 are two genes flanking EEF1A2 and PTK6, therefore located 
on 20q13.3. Since these genes are within a 200kb distance and located on a region known 
to be amplified in breast cancer, the hypothesis was that both would show an increased 
gene copy number as was observed with PTK6. Surprisingly, both genes showed normal 
copies leading to the conclusion that only PTK6 is amplified in this region. 
 
3.3.3 Effect of Let-7f on EEF1A2 in breast cancer cell lines 
EEF1A2 gene copy number did not correlate with high expression of the gene at 
the protein level detected in the breast tumor TMAs (section 3.2.4) and nor were the copy 
numbers as high as PTK6. Tomlinson et al. reported that EEF1A2 copy number does not 
correlate with the expression level of the gene in ovarian tumors, it is unmethylated in 
both normal and tumour DNA and that no mutations were detected (Tomlinson et al., 
2007). This was not determined in breast cancer, however one of the hypothesis proposed 
was that miRNA might be involved in the overexpression of eEF1A2. miRNAs usually 
degrade mRNA or bind to it resulting in inhibition of translation and therefore decreasing 
protein expression. However, with eEF1A2, the only miRNA that has been directly 
demonstrated to affect its expression is let-7f, and this increases rather than decreases 
levels of eEF1A2 mRNA. The hypothesis is thus that the miRNA let-7f probably 
increases its expression by deactivating an inhibitor that binds to its mRNA. This is a 
different mechanism by which miRNAs usually repress translation by binding directly to 
the mRNA. 
Dahiya et al. have shown that overexpression of the miRNA let-7f in ovarian 
cancer cell lines was associated with a high expression of eEF1A2 (Dahiya et al., 2008). 
EEF1A2 expression showed a 600 increase fold-change in the BG-1 let-7f transfected 
cells.  To establish whether this was also true in a breast cancer cell line, I transfected 
BT549 –a breast cancer cell line that does not express eEF1A2 under normal conditions- 
with let-7f precursor. Unfortunately, these data were not conclusive (Details and results 
of the experiment are given in Appendix B). 
The microarray results provided by Alexey Larionov (Figure 3.16) also differ 
from the results Dahiya et al. have shown where they reported an overexpression of 
Roles of EEF1A2 & PTK6 in Breast Cancer 
Chapter 3: EEF1A2 & PTK6 expression in breast cancer cell lines/tumors 99
EEF1A2 in ovarian cancer cell transfected with let-7f (Dahiya et al., 2008). It is entirely 
possible that let-7f is not the only miRNA responsible for the overexpression of eEF1A2 
in breast cancers. On the other hand, since let-7f is probably deactivating an inhibitor 
binding to eEF1A2, this intermediate could differ in breast cancer cells and therefore 
would show a difference in expression in ovarian tumors versus breast tumors. 
In conclusion, PTK6 overexpression in breast cancer is the result of gene 
amplification leading to phosphorylation/activation of downstream substrates (i.e. 
Sam68, SLM-1, SLM-2, STAP-2, paxillin, STAT3, STAT5a and STAT5b) that would 
lead to the increased transcriptional activity and therefore mediates proliferation of breast 
cancer cells (Weaver and Silva, 2007). However, even though EEF1A2 is mapped to the 
same 20q13.3 region, its overexpression is not associated with gene amplification. Other 
mechanisms/intermediates appear to play a role in its overexpression. This could be 
attributed to the hypothesis of the roles of miRNAs in binding to an inhibitor that 
deactivates eEF1A2 translation leading to an increased expression of eEF1A2 at the 
protein level or it could be due to the effect enhancers have on EEF1A2. Another 
hypothesis is that EEF1A2 has a strong promoter that does not require several copies of 
the gene (Discussed in section 3.3.2).   
Knockdown of Eef1a2 expression in PCT cell lines affected the JAK/STAT 
pathway and the PI3K-AKT-mTOR pathway (Li et al., 2010). The authors reported that 
phosphorylation of STAT3 and AKT was delayed and that PI3K expression was reduced. 
This correlates well with previous studies showing that eEF1A2 appears to be upstream 
of AKT and PI3K (Amiri et al., 2007). These data indicate that eEF1A2 may play an 
important role in the induction or progression of plasma cell neoplasms in mice and 
humans. These mechanisms might also be true in breast cancer where induction of those 
pathways might increase cell division and lead to breast tumor development through 
activating several modulators, one of which might be the miRNA involvement. In 
contrast to our initial hypothesis that EEF1A2 and PTK6 act in tandem to increase the 
risk of developing breast cancer through similar mechanisms, it appears from the work 
done so far that both genes act independently and that each protein is overexpressed in 
breast cancer through a different mechanism.  
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3.3.4 EEF1A2 expression in breast tumors and breast cancer cell 
lines 
As shown in figures 3.17 and 3.18, RPPA was carried out to detect the expression 
of EEF1A2 in 107 breast cancers using two different eEF1A2 antibodies. One was raised 
in sheep and the other antibody raised in rabbit. RPPA showed that EEF1A2 was detected 
in all breast cancers with two cancers having exceptionally high levels of EEF1A2.   
Li et al. showed that knockdown of Eef1a2 expression in Plasmacytoma (PCT) 
cell lines affected the JAK/STAT pathway suggesting that eEF1A2 may play an 
important role in the induction or progression of plasma cell neoplasms in mice and 
humans (Li et al., 2010). Peter Mullen has been working on STAT3 and pSTAT3 and has 
kindly provided the RPPA results shown in figures 3.21 and 3.22. Surprisingly, the same 
two cancerous tumors that showed an exceptionally high levels of EEF1A2 also showed 
high levels of STAT3 (Figure 3.17). Li et al. reported these finding in PCT cells whereas 
our results confirm the effect of EEF1A2 on STAT3 in breast cancers.  
EEF1A2 was also expressed in all breast cancer cell lines on these RPPA slides 
but expression levels varied between different cell lines (Figures 3.19 and 3.20). STAT3 
and pSTAT (Tyr705) have also been detected in all breast cancer cell lines and as 
EEF1A2, their expression level varied between cells (Figures 3.23 and 3.24). 
 In conclusion, as EEF1A2 is not usually known to be expressed in normal breast 
tissue, based on all the RPPA data mentioned above, it is clear that EEF1A2 protein is 
expressed in all the breast cancers studied in this experiment. Surprisingly, two of the 
cancerous tumors which showed an exceptionally high level of EEF1A2 have also 
detected high levels of STAT3. This supports a previous study published by Li et al. 
indicating that EEF1A2 affects the expression of STAT3 in PCT cells (Li et al., 2010).
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The development and progression of cancer are accompanied by complex 
changes in the pattern of gene expression. Gene expression microarrays provide a 
powerful tool for studying these complex changes. Illumina BeadChips were used to 
analyze global gene-expression changes during transformation of NIH-3T3 mouse 
fibroblast cells by EEF1A2.  
Results from the previous chapter showed that EEF1A2 and PTK6 are 
overexpressed at the protein level. Even though PTK6 was amplified in those breast 
tumors, therefore explaining the overexpression pattern, EEF1A2 overexpression did 
not correlate with the gene copy number.  
In this part of the project, I focused on the effect of EEF1A2 expression on 
cancer-related genes. This was carried out by using microarrays to assess a network 
of up-regulated and down-regulated cancer genes in NIH-3T3 mouse fibroblast cell 
lines stably transfected with EEF1A2. 
In addition, to start to address the question of which gene -EEF1A2 or PTK6- 
is the cancer driver and which one is the passenger, I carried out EEF1A2 and PTK6 
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4.2 Results 
 
4.2.1 Effect of EEF1A2 expression in NIH-3T3 stable cell lines 
 
4.2.1.1 Generation of NIH-3T3 stable cell lines 
NIH-3T3 cells are mouse fibroblasts that do not express eEF1A2 under 
normal conditions. Justyna Janikiewicz –a previous PhD student in our lab- has 
generated NIH-3T3 stable cell lines expressing eEF1A2 (Janikiewicz, 2010). The 
usage of these stable cell lines was critical to my work and therefore has been 
described below: 
To generate a stable cell line that expresses the protein of interest (eEF1A2) 
from a mammalian expression construct (section 2.2.6.2, figures 2.1 and 2.2), a 
killing curve was first established. The minimum concentration of selection antibiotic 
required to kill the NIH-3T3 untransfected host cell line was determined. Cells were 
plated for 24 hours after which the medium was removed and replaced by DMEM 
containing varying concentrations of ZeocinTM. The medium was replenished every 
3-4 days and the percentage of cells was determined every time. A concentration of 
450µg/ml of ZeocinTM was established as the minimal concentration that kills the 
majority of cells within two weeks of culturing. 
Cells were harvested, counted and transfected with the EEF1A2 construct as 
described in section 2.2.6. Medium (DMEM + 10% NBCS + Zeocin) was replaced 
24 hours later. This was repeated every 3-4 days until distinct cell colonies were 
observed after 2-4 weeks. Once colonies developed, cells from every individual 
colony were transferred and cultured in a separate plate. The cells were then 
collected and the presence of the insert was confirmed by PCR as well as by Western 
blots. Out of many stable cells generated, three that showed different expression 
level of eEF1A2 were chosen to examine the effect of EEF1A2 on cancer pathways. 
These three stable cell lines were named after the plate and colony number they were 
taken from where the first number is the plate number whereas the second number is 
the colony number: 7.2, 9.6 and 10.2. NIH-3T3 cells that were transfected with the 
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empty vector pcDNA3.1 GS was used as a negative control whereas EJTF2 cells that 
stably express the H-RasG12V oncogene were used as a positive control.  
To determine the oncogenic potential of these three cell lines, Justyna 
Janikiewicz used the focus formation assays where cells that showed multi-layers 
and crisscrossed growth of spindle shapes were considered transformed (Figure 4.1). 
NIH-3T3 cells that express EEF1A2 resulted in an increased level of foci formation 
when compared to the negative control cells. The number of foci in the 7.2, 9.6 and 
10.2 cells was 36, 37 and 39 respectively when compared to the NIH-3T3 negative 
control cells (Janikiewicz, 2010).  
 
 
Figure 4.1 Effects of  EEF1A2  overexpression  on  cellular  morphology within the stable cell 
lines 7.2, 9.6 and 10.2. NIH-3T3 cells stably transfected with the EEF1A2 construct were cultured in 
zeocin-supplemented DMEM for determination of their capacity to produce foci. Three weeks later 
cells were fixed, stained with crystal violet and their morphology was photographed. Size bars are 




Roles of EEF1A2 & PTK6 in Breast Cancer 
Chapter 4: Pathways affected by the overexpression of EEF1A2 104
The other assay conducted by Justyna to examine the oncogenic potential of 
these cells was the anchorage independent growth assay (Figure 4.2). The same 
control cells were used as described above. After three weeks in culture, it was 
noticed that all EEF1A2 overexpressing cells developed colonies in soft agar 
whereas no colonies were detected in the negative control cells. The number of 
colonies detected for the 7.2, 9.6 and 10.2 cells was 119, 131 and 207 respectively 
compared to the zero number of colonies formed by the NIH-3T3 negative control 
cells (Janikiewicz, 2010).  
 
Figure 4.2 Ectopic expression of all EEF1A2 variants in NIH-3T3 cells induces anchorage 
independent growth. Following 21 days of culture in 0.3% layer of agar, colonies were counted and 
photographed (magnification 10x). NIH-3T3 cells stably transfected with empty vector were used as a 
negative control and 3 weeks after plating, single cells were observed within these wells. In contrast, 
substantial numbers of colonies were detected in dishes of EJTF2 positive control and cell lines stably 
expressing EEF1A2 (Janikiewicz, 2010). 
 
Cellular proliferation of these cells was also assessed and compared to the 
control cells (Figure 4.3). Justyna has shown that the proliferation rates of all the 
three stable cell lines 7.2, 9.6 and 10.2 were considerably higher than that of both 
control cell lines (Janikiewicz, 2010). 
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Figure 4.3 Effect of EEF1A2 overexpression on NIH-3T3 cells proliferation. The stable cell lines 
were subjected to determination of growth rate under standard culture conditions. Proliferation of 
EEF1A2 clones (7.2, 9.6, 10.2) was compared to the stable lines of empty-vector or EJTF2 cells.  
AlamarBlue® dye was applied to the culture media of the cells and fluorescence was measured up to 
8 days after seeding. The results of growth magnitude are represented as the average fluorescence 
intensity at indicated time point ±SEM calculated from three separate experiments, each performed in 
five replicates (Janikiewicz, 2010).  
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It was critical to assess for continued maintenance and expression of EEF1A2 
in these cells and to check the primers before carrying out the experiments mentioned 
in this chapter, therefore PCR was carried out on the NIH-3T3 control cells, 7.2, 9.6 
and 10.2. As shown in figure 4.4, the right EEF1A2 155bp band size was detected in 
all the stable cells lines but not in the control cells nor in the –RT control reaction. 
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 blots detecting V5 tag that is binding to eEF1A2, indicating the presence of 
 in NIH-3T3 cells stable cells lines: 3T3, 7.2, 9.6 and 10.2.  The experiment 
iplicate hence the three lanes for each stable cell line. 
rforming the analysis on the microarray data, a number of pre-
including background adjustment, probe filtering, normalization and 
ecks were performed using the R package, lumi 
tor.org). Boxplots of the microarray data before and after quantile 
monstrate how the distributions of the intensities are scaled to have 
 variance across samples (Figure 4.6)   
tware was also used to give an unsupervised overview of gene 
 the three cell lines stably expressing EEF1A2: 7.2, 9.6 and 10.2 
re 4.7a shows a heatmap generated from the analysis of all probes 
0 probes) whereas figure 4.7b shows a heatmap of the 500 most 
s shown, the heatmaps produced from the R software allowed us to 
erential action of these genes between the three stable cell lines. It is 
table cells can be distinguished from each other in terms of gene 
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Figure 4.6 Boxplots of microarray intensities a) before normalization, b) after normalization. 
The experiment was carried out in triplicate on each stable cell lines: 3T3, 7.2, 9.6 and 10.2 hence the 
numbers 1, 2 and 3 following each stable cell line in the figure. 
a. 
b. 
Stable cell lines 
Stable cell lines 
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Figure 4.7 Heatmaps produced by the Bioconductor function (R software) from the microarray 
data of all stable cell lines showing a) a heatmap generated from the analysis of all probes and b) a 
heatmap of the 500 most variable genes. Red represents the strongest correlation, white the weakest 
with shades of yellow/orange in between. The experiment was carried out in triplicate on each stable 
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Microarray analysis comparing NIH-3T3/pcDNA3.1 cells with the stably 
transfected cells (7.2, 9.6 and 10.2 that express eEF1A2) resulted in a long list of 
genes that were upregulated (Table 4.1 & 4.2) and downregulated (Table 4.3 & 4.4), 
potentially due to the expression of EEF1A2.  Table 4.1 shows a list of the top 33 
upregulated genes, where the cutoff point was an average fold-change increase of 1.9 
and higher, whereas table 4.2 shows the same genes along with their individual fold-
change increases and the significance in the three stable cell lines compared to the 
control. As shown in table 4.1, 14 of those 33 upregulated genes are associated with 
different types of cancers. Since this project is focusing on breast cancer, five of the 
upregulated genes that are associated with human breast cancer have been chosen for 
further analysis. These genes are Serpine2, Egr1, Aldh3a1, Tpd52 and Dusp6.  
SERPINE2 is located on 2q36.1. It is a serine protease inhibitor gene that has 
been linked to many cancers especially breast cancer and breast cancer metastasis 
(Candia et al., 2006). It showed the highest average fold-change increase (FC 19.6) 
in the microarray list of genes affected by the overexpression of EEF1A2 with a 
statistically significant p-value of 0.0004 and 0.0009 in both 7.2 (FC 24.7) and 10.2 
(FC 35.3) stable cell lines respectively (Table 4.2). In the stable cell lines 9.6, there 
was no significant correlation between Serpine2 and EEF1A2 expression (p-value 
0.1). 
Early growth response factor 1 (EGR1) is a nuclear protein mapped to 5q31.1 
that functions as a transcriptional regulator. The products of target genes it activates 
are required for differentiation and mitogenesis. It has also been reported to act as a 
tumor suppressor gene (Krones-Herzig et al., 2005). It showed an average 2.9-fold 
change (FC) increase which was statistically significant in the two stable cells lines 
7.2 (p-value 0.01, FC 1.7) and 9.6 (p-value 0.02, FC 3.5) (Table 4.2). 
Aldehyde dehydrogenase 3 family, member A1 (ALDH3A1) is another gene 
associated with breast cancer. It is mapped to 17p11.2. It is involved in the 
detoxification of alcohol-derived acetaldehyde and in the metabolism of 
corticosteroids, neurotransmitters, and lipid peroxidation. It showed an average fold 
change increase of 2.4 in the microarray upregulated gene list that was significant in 
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all three stable cell lines 7.2 (p-value 1.21E-06, FC 3.6), 9.6 (p-value 0.02, FC 1.5) 
and 10.2 (p-value 0.01, FC 2) (Table 4.2). 
Tumor protein D52 (TPD52), identified in the 8q21 amplicon, is a gene 
amplified and overexpressed in many different types of cancers including breast 
cancer. It is potentially involved in vesicle trafficking. TPD52 showed an average 
2.2-fold change increase on the gene list. Its upregulation was statistically significant 
in all three stable cell lines: 7.2 (p-value 0.001, FC 1.1), 9.6 (p-value 7.11E-06, FC 
1.5) and 10.2 (p-value 4.15E-06, FC 4.1) (Table 4.2). 
Dual specificity phosphatase 6 (DUSP6) –also known as MKP3- negatively 
regulates members of the MAP kinase family which are associated with cellular 
proliferation and differentiation. DUSP6 is located on 12q21.33 and showed an 
average fold-change increase of 2 in the stable cell lines. Its overexpression was 
statistically significant in all stable cell lines: 7.2 (p-value 0.001, FC 1.7), 9.6 (p-
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Stable cells NIH-3T3/1A2 7.2 NIH-3T3/1A2 9.6 NIH-3T3/1A2 10.2 
Average FC 
Gene Symbol FC p-value FC p-value FC p-value 
Serpine2 24.7 0.0004 -1 0.1 35.3 0.0009 19.6 
Srpx2 1.9 0.0004 5 0.00004 3.4 0.0007 3.5 
Mgp 3.2 0.0001 2.1 0.02 4.3 0.02 3.2 
Egr1 1.7 0.01 3.5 0.02 3.4 0.07 2.9 
Saa3 1.2 0.05 2.9 0.02 4.2 0.02 2.7 
Pkia 1.6 0.0003 2.5 0.002 3.6 0.04 2.5 
Actg2 1.5 0.01 1.3 0.03 4.5 0.005 2.4 
Prelp 1.1 0.07 1.7 0.01 4.3 0.05 2.4 
Slc12a2 1.4 0.02 3.5 0.05 2.3 0.08 2.4 
Aldh3a1 3.6 0.000001 1.5 0.02 2 0.01 2.4 
Anxa8 2.9 0.0003 1.6 0.0003 2.2 0.01 2.2 
Tpd52 1.1 0.001 1.5 0.000007 4.1 0.000004 2.2 
Slc12a2 1.4 0.02 2.8 0.001 2.3 0.000003 2.2 
Ctgf 1.8 0.03 1.6 0.01 3.1 0.03 2.2 
Dusp1 1.1 0.009 2.2 0.1 3.1 0.05 2.2 
Arl6ip1 -1.8 0.1 4.8 0.0002 3.4 0.0006 2.1 
Hist1h1c 1.8 0.00001 2.2 0.000005 2.2 0.0008 2.1 
Cyr61 1.6 0.0008 1.7 0.003 2.9 0.003 2.1 
Srpx2 1.5 0.0001 2.5 0.004 2.2 0.02 2.1 
Inhba 2.6 0.003 1.5 0.004 2 0.0009 2.0 
Dusp6 1.7 0.03 1.5 0.0001 2.9 0.001 2.0 
Iap 1 0.003 1.1 0.0009 3.8 0.003 2.0 
Rgs16 1.8 0.02 2.2 0.04 1.9 0.01 2.0 
Nuak1 1.7 0.6 1.9 0.7 2.4 0.1 2.0 
Hist2h2aa1 1.5 0.0001 1.9 0.001 2.3 0.005 1.9 
Gm773 3.8 0.0004 1 0.01 1 0.08 1.9 
Phlda1 3 0.05 1.1 0.002 1.7 0.002 1.9 
Fxyd5 3.1 0.04 1.6 0.05 1.1 0.04 1.9 
Tspan6 1.4 0.0001 1.7 0.07 2.6 0.4 1.9 
Hist2h2aa2 1.5 0.2 2 0.4 2.2 0.2 1.9 
Pdk4 1.2 0.002 2.4 0.06 2 0.6 1.9 
Myl9 1.1 0.001 1.5 0.0003 3 0.001 1.9 
Tfrc 1.8 0.01 1.9 0.04 1.8 0.05 1.8 
Table 4.2 Top 33 genes with the largest fold-changes from the microarray data showing the fold-
change increase (in pink) of all the three stable cell lines along with their p-value (in blue). 
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Microarray analysis comparing NIH-3T3/pcDNA3.1 cells with the stably 
transfected cells (7.2, 9.6 and 10.2 that express eEF1A2) also resulted in a long list of 
downregulated genes. 
Table 4.3 shows a list of the 32 most downregulated genes, where the cutoff 
point was an average fold-change decrease of 1.7 and lower, whereas table 4.4 shows 
the same genes along with their individual fold-change decrease and their 
significance in the three stable cell lines separately. The most downregulated five 
genes are Rhox5, Renbp, Ppap2c, H60a and Itga11 with only Ppap2c being 
previously associated with cancer in the literature (Tanyi et al., 2003).  
The reproductive homeobox-5 (RHOX5) gene encodes a transcription factor 
which showed the most decreased fold-change in the microarray list with 4.9. Loss of 
Rhox5 in mice causes increased male germ-cell apoptosis, reduced sperm count, and 
reduced sperm motility (Maclean et al., 2005). The authors reported that the reduced 
sperm count is probably due to apoptosis as cell proliferation was not significantly 
affected. Rhox5 is expressed in Sertoli cells promoting survival and differentiation of 
the adjacent male germ cells. In the microarray list, Rhox5 was the most 
downregulated gene. Since this gene has not been studied in breast cancer 
previously, its downregulation might play a similar apoptotic role as it does in male 
germ-cells and therefore act as a good therapeutic target in cancer. Its 
downregulation was statistically significant in all three stable cell lines: 7.2 (p-value 
0.0004, FC -2.1), 9.6 (p-value 0.005, FC -2.0) and 10.2 (p-value 4E-06, FC -11) 
(Table 4.4). 
The second most downregulated gene that showed a 3.1 fold-change decrease 
is Renbp (Renin Binding Protein). Renbp is involved in the regulation of the renin-
angiotensin system which plays an important role in cardiovascular and renal 
physiology and disease. Therefore downregulation of this gene would have a 
negative impact especially on the renal and cardiovascular systems. RENBP is 
mapped to Xq28 and its downregulation was statistically significant in all three 
stable cell lines: 7.2 (p-value 2.73E-06, FC -3.3), 9.6 (p-value 0.002, FC -1.7) and 
10.2 (p-value 1.72E-06, FC -4) (Table 4.4). 
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Ppap2c (phosphatidic acid phosphatase type 2C) is the third most 
downregulated gene in the microarray list with a fold-change decease of 2.3. The 
protein encoded by this gene is a member of the phosphatidic acid phosphatase 
(PAP) enzyme family. PPAP2C is significantly overexpressed in ovarian carcinoma 
(Tanyi et al., 2003), bladder, lung, and prostate cancers compared with normal 
tissues (Flanagan et al., 2009). Flanagan et al. also reported that PPAP2C is 
particularly highly expressed in breast carcinoma. Therefore its downregulation 
might be associated with decreased risk of breast tumorigenesis. Ppap2c is mapped 
to 19p13.3 and its downregulation was statistically significant only in 7.2 (p-value 
5.67E-06, FC -4.4) but not in 9.6 (p-value 0.06, FC -1.0) nor in 10.2 (p-value 0.2, FC 
-1.3) stable cell lines (Table 4.4). 
Histocompatibility 60a (H60a) gene showed a fold-change decrease of 2.2 in 
the microarray list making it the forth most downregulated gene. H60a is an MHC 
class I-like glycoprotein and is one of the ligands for the natural killer cell receptor 
NKG2D. Downregulation of H60a was statistically significant only in 9.6 (p-value 
0.002, FC -4.1) but not in 7.2 (p-value 0.2, FC -1.5) nor in 10.2 (p-value 0.6, FC -
1.1) stable cell lines (Table 4.4). 
ITGA11 (Integrin alpha-11), mapped to 15q23, is a protein that in humans is 
encoded by the ITGA11 gene. It is a cell surface adhesion receptor mediating cell-
adhesion to extra cellular matrix or to other cells. It showed a 2.2 fold-change 
decrease in the microarray list of genes from the NIH-3T3 stable cell lines expressing 
EEF1A2. Since this gene is important in cell-adhesion, its downregulation as 
detected in this study would probably facilitate cell detachment mediating cell 
migration. Downregulation of Itga11 was statistically significant in the two stable 
cell lines 7.2 (p-value 2.26E-05, FC -2.7) and 9.6 (p-value 2.47E-05, FC -2.7) but not 
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Stable cells NIH-3T3/1A2 7.2 NIH-3T3/1A2 9.6 NIH-3T3/1A2 10.2 
Average FC 
Gene Symbol FC p-value FC p-value FC p-value 
Il1rl1 -1.4 0.006 -2 0.004 -2.0 0.02 -1.7 
Kcnab1 -1.4 0.006 -2 0.0002 -1.7 0.002 -1.7 
Adi1 -1.3 0.08 -1.5 0.01 -2.2 0.003 -1.7 
2300002D11Rik -1.4 0.0005 -1.9 0.0005 -1.7 0.003 -1.7 
Ramp3 -1.1 0.2 -1.8 0.0002 -2.2 0.0003 -1.7 
LOC100044411 -2.3 0.003 -1.6 0.04 -1.2 0.2 -1.7 
B230343A10Rik -1.5 0.0006 -1.6 0.001 -2.0 0.0001 -1.7 
Atp6ap2 -1.5 0.01 -1.3 0.04 -2.3 0.001 -1.7 
Soat1 -1.2 0.1 -1.9 0.0003 -2.1 0.004 -1.7 
Ptn -2.1 0.002 -1.2 0.1 -2 0.0009 -1.7 
Rpl31 -1.0 0.7 -1.7 0.01 -2.5 0.001 -1.7 
Bdh2 -1.6 0.0002 -1.7 0.02 -2.0 0.008 -1.8 
Cenpa -1.6 0.001 -1.7 0.002 -2.0 0.002 -1.8 
Dbp -1.5 0.002 -1.3 0.02 -2.5 0.0001 -1.8 
Ctsk -2.5 0.00001 -1.7 0.0003 -1.2 0.04 -1.8 
Ramp3 -1.2 0.002 -1.9 0.0001 -2.4 0.0003 -1.8 
Gstm2 -2.3 0.00003 -1.1 0.5 -2.1 0.003 -1.8 
Csrp2 -1.5 0.01 -2.1 0.001 -1.9 0.004 -1.8 
Actr3b -1.0 0.8 -2.1 0.001 -2.4 0.002 -1.8 
2810417K24Rik -1.5 0.2 -2.2 0.02 -2 0.0004 -1.9 
EG633692 -1.5 0.03 -1.4 0.05 -2.7 0.002 -1.9 
Uap1l1 -1.7 0.001 -1.6 0.0004 -2.4 0.0002 -1.9 
Dhcr24 -1.5 0.05 -2.7 0.004 -1.5 0.03 -1.9 
Prkg2 -1.2 0.04 -2.0 0.002 -2.7 0.0002 -2.0 
Spon2 -1.5 0.04 -3.0 0.001 -1.4 0.09 -2.0 
Gsta4 -1.2 0.1 -2 0.003 -3 0.0007 -2.0 
Cyp2c55 -2.1 0.0009 -1.6 0.007 -2.5 0.001 -2.1 
Itga11 -2.7 0.00002 -2.7 0.00002 -1.1 0.8 -2.2 
H60a -1.5 0.2 -4.1 0.002 -1.1 0.6 -2.2 
Ppap2c -4.4 0.00001 -1 0.06 -1.3 0.2 -2.3 
Renbp -3.2 0.000003 -1.7 0.002 -4 0.000002 -3.1 
Rhox5 -2.1 0.0004 -2.0 0.005 -11 0.000004 -4.9 
 
Table 4.4 The 32 most downregulated genes from the microarray data showing the fold-change 







Roles of EEF1A2 & PTK6 in Breast Cancer 
Chapter 4: Pathways affected by the overexpression of EEF1A2 118
4.2.1.3 Expression level of upregulated breast cancer genes 
Real-time PCR was carried out on the four stable cell lines to establish the 
validity of the microarray results (Described in section 3.2.3). Expression level of all 
five breast cancer-associated genes in the NIH-3T3 stable cell lines (Serpine2, Egr1, 
Aldh3a1, Tpd52 and Dusp6) were analyzed (Table 4.5, Figures 4.8 & 4.9). Figure 4.8 
is shown based on the expression level of each gene in all the stable cell lines, 
whereas figure 4.9 shows the same results but arranged so that it shows the 
expression level of all five genes in a single stable cell line instead.   
Table 4.5 Analyzing gene expression level of Serpine2, Egr1, Aldh3a1, Tpd52 & Dusp6 in the 
stable cell lines using the 2−∆∆Ct method. (Ct gene= average Ct values of the gene studied, Ct ref 
genes= average Ct values of all the reference genes, ∆CT= difference in CT values). 
NIH-3T3 cells Ct gene Ct ref genes ∆CT ∆∆CT 2^-∆∆CT 
Serpine2 
NIH-3T3 37.09 27.93 9.16 0 1 
7.2 30.96 28.16 2.80 -6 82 
9.6 37.09 27.68 9.41 0 1 
10.2 30.91 27.86 3.05 -6 69 
Egr1 
NIH-3T3 31.77 27.93 3.84 0 1 
7.2 30.16 28.16 2.00 -2 4 
9.6 30.18 27.68 2.50 -1 3 
10.2 30.19 27.86 2.32 -2 3 
Aldh3a1 
NIH-3T3 35.63 27.93 7.70 0 1 
7.2 30.70 28.16 2.55 -5 36 
9.6 33.92 27.68 6.25 -1 3 
10.2 32.37 27.86 4.50 -3 9 
Tpd52 
NIH-3T3 35.82 27.93 7.89 0 1 
7.2 35.27 28.16 7.11 -1 2 
9.6 35.62 27.68 7.94 0 1 
10.2 33.14 27.86 5.28 -3 6 
Dusp6 
NIH-3T3 31.73 27.93 3.80 0 1 
7.2 30.96 28.16 2.80 -1 2 
9.6 31.30 27.68 3.62 0 1 
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As shown in figure 4.8 and table 4.6 below, the expression level of all five 
genes in the three stable cell lines from the microarray data (7.2, 9.6 and 10.2) 
corresponded to the expression level detected by real-time PCR. NIH-3T3 cells do 
not express EEF1A2 under normal conditions. In the stable cell lines (Figure 4.8) 
EEF1A2 expression level was the lowest in 7.2 cells and the highest in 10.2 cells. 
Serpine2 –which showed the highest average fold-change increase (FC 19.6) in the 
microarray list of genes- showed an increased expression in 7.2 and 10.2 cells but it 
was not detected in 9.6 cells. These results are similar to the fold-change increase 
detected in the microarray data. Egr1, Tpd52 and Dup6 are not normally expressed in 
NIH-3T3 cells. In the stable cells lines, all three genes showed a slight increase in the 
expression level detected in the microarray data and confirmed by the real-time PCR 
results. As for Aldh3a1 -which showed an average fold-change increase of 2.4- it 
showed the highest fold-change increase in the 7.2 cells (FC ~ 4) and slightly lower 
(FC ~ 2) in the 10.2 cells.   
 
Table 4.6 Average fold-change of all 5 breast cancer-associated genes in all three stable cell lines 
along with their real-time PCR expression level. 
Stable cells 7.2 cells 9.6 cells 10.2 cells 
Average FC 
Gene FC qPCR FC qPCR FC qPCR 
Serpine2 24.7 82 -1.0 1 35.3 69 19.6 
Egr1 1.7 4 3.5 3 3.4 3 2.9 
Aldh3a1 3.6 36 1.5 3 2.0 9 2.4 
Tpd52 1.1 2 1.5 1 4.1 6 2.2 
Dusp6 1.7 2 1.5 1 2.9 3 2.0 
 
4.2.1.4 Protein detection of top 5 breast cancer-associated 
genes from the microarray data in the stable cell lines 
Serpine2, Egr1, Aldh3a1, Tpd52 and Dusp6 are five genes that showed an 
increased fold-change expression in the microarray data. This was confirmed by 
detecting the same expression at the mRNA level using real-time PCR. To detect 
whether those 5 genes were expressed at the protein level, Western blots were carried 
out on the 7.2, 9.6 and 10.2 stable cell lines (Figure 4.10). MCF7 breast cancer cells 
were used as a control as they are known to express many proteins in cancer. 
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Figure 4.10 Western blots on NIH-3T3/pcDNA3.1, 7.2, 9.6 and 10.2 stable cell lines detecting a) 
Serpine2, b) Egr1, c) Aldh3a1, d) Tpd52 and e) Dups6. MCF7 breast cancer cells were used as a 
control as they usually express EEF1A2 and other cancer-related proteins. Each experiment was 
carried out in triplicate hence the three lanes of proteins for each of the stable cell lines. 
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SERPINE2 protein was expressed in all stable cells lines including MCF7 
cells (Figure 4.10a). Its expression in the 9.6 cells at the mRNA level was similar to 
the control cells yet as shown from the microarray results, 7.2 and 10.2 cells showed 
an increased expression when compared to the control cells (Table 4.6 and figure 
4.8).  
EGR1 which did not show an average fold-change increase as high as 
Serpine2, was detected at the protein level in all stable cell lines but was slightly 
decreased in 7.2 cells (Figure 4.10b). The expression level however from the real-
time PCR results (Table 4.6) did not show a high increase in the three stable cell 
lines when compared to the control cells nor was the expression level different 
between those three cells.  
ALDH3A1 showed an increased fold-change at the mRNA level in both 7.2 
and 10.2 stable cell lines. The opposite was observed in Western blots. ALDH3A1 
was not detected in 7.2 and 10.2 cell lines but a band was seen in the 9.6 cells (Figure 
4.10c). This might probably be due to the antibody detecting/cross-reacting with 
another protein. Aldh3a1 is not usually detected in MFC7 cells as shown.  
TPD52 and DUSP5 also showed a fold-change increase at the mRNA level in 
the microarray data and were slightly increased in the 10.2 cells when real-time PCR 
was carried out (Table 4.6). These two proteins are not normally expressed in NIH-
3T3 cells. As shown in figures 4.10d and 4.10e, neither were detected at the protein 
level in the NIH-3T3 cells nor in any of the stable cell lines. Both these proteins are 
expressed in MCF7 cells.  
 
 
4.2.2 Effect of EEF1A2 expression in NIH-3T3 transiently 
transfected cells 
NIH-3T3 cells were transiently transfected with the same EEF1A2 expression 
construct used in the stable cell lines. This was done to determine whether EEF1A2 
would affect the same genes (Serpine2, Egr1, Aldh3a1, Tpd52 and Dusp6) in the 
transiently transfected cells when compared to the stable cell lines. 
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EEF1A2 construct (construct details described in Chapter 2, section 2.2.6.2 
and figure 2.1) was transfected into NIH-3T3 cells and cells were collected 24 and 48 
hours after transfection. Real-time PCR was carried out as described in section 2.2.5 
to detect the expression level of all the five breast cancer-associated genes (Table 
4.7).  
Table 4.7 Analyzing gene expression level of Serpine2, Egr1, Aldh3a1, Tpd52 & Dusp6 in NIH-
3T3 cells transiently transfected with EEF1A2 using the 2−∆∆Ct method. 
NIH-3T3 cells Ct gene Ct ref genes ∆CT ∆∆CT 2^-∆∆CT 
Serpine2 
NIH-3T3 35.42 29.22 6.2 0 1 
NIH-3T3/EEF1A2 24h 33.72 28.64 5.09 -1 2 
NIH-3T3/EEF1A2 48h 33.96 29.7 4.26 -2 4 
Egr1 
NIH-3T3 32.76 29.22 3.54 0 1 
NIH-3T3/EEF1A2 24h 32.71 28.64 4.07 1 1 
NIH-3T3/EEF1A2 48h 32.93 29.7 3.23 0 1 
Aldh3a1 
NIH-3T3 34.51 29.22 5.29 0 1 
NIH-3T3/EEF1A2 24h 32.32 28.64 3.68 -2 3 
NIH-3T3/EEF1A2 48h 33.70 29.7 4 -1 2 
Tpd52 
NIH-3T3 36.88 29.22 7.66 0 1 
NIH-3T3/EEF1A2 24h 36.91 28.64 8.27 1 1 
NIH-3T3/EEF1A2 48h 36.46 29.7 6.76 -1 2 
Dusp6 
NIH-3T3 32.34 29.22 3.12 0 1 
NIH-3T3/EEF1A2 24h 31.47 28.64 2.83 0 1 
NIH-3T3/EEF1A2 48h 34.30 29.7 4.6 1 0 
 
 
Tables 4.7 and 4.8, and figure 4.11 show the real-time PCR expression level 
analysis from the transient transfection of eEF1A2 in NIH-3T3 cells 24 and 48 hours 
post-transfection. Cell viability was >95% and apoptosis was minimal. As expected, 
the expression level of EEF1A2 was high 24 hours after transfection and was slightly 
decreased 48 hours later. Surprisingly, Serpine2 which showed the highest 
expression level in the stable cell lines in both the microarray data and real-time PCR 
results, showed no significant expression at the mRNA level in the transiently 
transfected cells whether 24 or 48 hours after transfection.  
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ALDH3A1 is not normally expressed in NIH-3T3 cells. In the stable cell 
lines, ALDH3A1 showed an increased expression, however, in the transiently 
transfected cells, no expression was observed. 
EGR1, TPD52 and DUSP6 did not show a change in expression level 
whether in the transiently transfected cells or in the stable cell lines expressing 
EEF1A2.  
Proteins were extracted from these transiently transfected NIH-3T3 cell lines 
and Western blots were carried out. As expected, SERPINE2, EGR1, ALDH3A1, 
TPD52 and DUSP6 proteins were not detected (data not shown). This was not 
surprising as no mRNA was detected when real-time PCR was carried out. To further 
assess and monitor the efficiency of the transient transfection, cells could be co-
transfected with the Green Fluorescent Protein (GFP). This would be followed by 
using fluorescence-activated cell sorting (FACS) or the fluoresence microscope to 
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4.2.3 Effect of EEF1A2 expression on PTK6 
EEF1A2 and PTK6 are both located on 20q13.3 and are less than 50kb apart. 
Since both are overexpressed in 60% of breast cancer patients and are considered to 
be oncogenes, it is thought that one gene would be the driver of the other on this 
amplicon. This hypothesis was examined first in the stable cell lines expressing 
EEF1A2 and then in two transiently transfected cells that do not express EEF1A2 nor 
PTK6 under normal conditions: NIH-3T3 and BT549 breast cancer cell line. 
 
4.2.3.1 Effect of EEF1A2 expression on PTK6 in stable cell lines 
As shown in section 4.2.1.2, table 4.8 below and figure 4.12, EEF1A2 was 
expressed in the NIH-3T3 stably transfected cells 7.2, 9.6 and 10.2. The expression 
level of PTK6 was analyzed in these cells and showed no significant increase at the 
PTK6 mRNA level using real-time PCR. Since the database indicates the presence of 
few PTK6 splice variants, it is not certain if these primers would recognize other 
unidentified isoforms. In the microarray list however, there was only one probe for 
PTK6 which showed an average fold-change increase of 0.3 which was not 
statistically significant in any of the stable cell lines.  
As shown below in table 4.8, even though eEF1A2 is not known to be 
detected in NIH-3T3 cells, the 2−∆∆Ct value always gives a value of one. This is 
because the amount of eEF1A2 was first normalised to the reference genes and then 
expressed relatively to the expression level in NIH-3T3 cells (=1). 
 
Table 4.8 Analyzing gene expression level of EEF1A2 &PTK6 in NIH-3T3 cells stably 
transfected with EEF1A2 using the 2−∆∆Ct method. 
Sample ID Ct EEF1A2 Ct ref genes ∆Ct ∆∆Ct 2^-∆∆Ct 
NIH-3T3 38.53 27.93 10.60 0 1 
NIH-3T3/1A2 7.2 33.07 28.16 4.91 -6 52 
NIH-3T3/1A2 9.6 32.55 27.68 4.87 -6 53 
NIH-3T3/1A2 10.2 31.98 27.86 4.12 -6 89 
Sample ID Ct PTK6 Ct ref genes ∆Ct ∆∆Ct 2^-∆∆Ct 
NIH-3T3 37.00 27.93 9.07 0 1 
NIH-3T3/1A2 7.2 35.36 28.16 7.20 -2 4 
NIH-3T3/1A2 9.6 37.00 27.68 9.32 0 1 
NIH-3T3/1A2 10.2 35.94 27.86 8.08 -1 2 
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Figure 4.12 Expression of EEF1A2 and PTK6 in NIH-3T3 stable cell lines showing no significant 
change in PTK6 expression. EEF1A2 and PTK6 transcripts were normalized to the reference genes 
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4.2.3.2 Effect of EEF1A2 expression on PTK6 in transiently 
transfected cells 
 
4.2.3.2.1 Transient transfection of EEF1A2 into NIH-3T3 fibroblast 
cells 
The EEF1A2 construct was transfected into NIH-3T3 cells as described in 
section 2.2.6 and the expression level of both eEF1A2 and PTK6 was analyzed. The 
expression level of eEF1A2 was increased after 24 hours and decreased slightly by 
48 hours whereas no significant change in PTK6 expression was observed (Table 4.9 
and figure 4.13). 
Table 4.9 Analyzing gene expression level of EEF1A2 & PTK6 in NIH-3T3 cells transiently 
transfected with EEF1A2 using the 2−∆∆Ct method. 
NIH-3T3 cells Ct gene Ct ref genes ∆CT ∆∆CT 2^-∆∆CT 
EEF1A2 
NIH-3T3 35.43 29.22 6.21 0 1 
NIH-3T3/EEF1A2 24h 29.75 28.64 1.11 -5 34 
NIH-3T3/EEF1A2 48h 31.73 29.70 2.03 -4 18 
PTK6 
NIH-3T3 38 29.22 8.78 0 1 
NIH-3T3/EEF1A2 24h 38 28.64 9.36 1 1 
NIH-3T3/EEF1A2 48h 38 29.70 8.30 0 1 























Figure 4.13 Transient transfection of EEF1A2 in NIH-3T3. Expression of EEF1A2 shows no 
significant change in PTK6 expression 24hrs and 48hrs after transfection. EEF1A2 and PTK6 were 
normalized to the reference genes (Tbp, B2M and 18s rRNA) and then expressed relatively to the 
expression level in NIH-3T3 cells.  
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4.2.3.2.2 Transient transfection of EEF1A2 into BT549 breast 
cancer cells 
The EEF1A2 construct was transfected into the breast cancer cell line BT549. 
This cell lines also does not express either EEF1A2 or PTK6 under normal 
conditions. The expression level of both genes was detected using real-time PCR. 
EEF1A2 showed an increased expression 24 hours after transfection whereas no 
PTK6 expression was observed (Table 4.10 and figure 4.14). 
 
Table 4.10 Analyzing gene expression level of EEF1A2 & PTK6 in BT549 breast cancer cells 
transiently transfected with EEF1A2 using the 2−∆∆Ct method. 
BT549 cells Ct gene Ct ref genes ∆Ct ∆∆Ct 2^-∆∆Ct 
EEF1A2 
BT549 cells 36.75 30.21 6.54 0 1 
BT549/EEF1A2 26.11 28.57 -2.45 -9 510 
PTK6 
BT549 cells 34.51 30.27 4.24 0 1 
BT549/EEF1A2 33.59 28.69 4.90 1 1 
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Figure 4.14 Transient transfection of EEF1A2 in BT549 breast cancer cell line. Expression of 
EEF1A2 shows no significant change in PTK6 expression. EEF1A2 and PTK6 were normalized to the 
reference genes (PUM1 and TBP) and then expressed relatively to the expression level in BT549 cells. 
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Western blots were also carried out to check for the protein expression in 
these cells. Since the V5-tag is part of the EEF1A2 construct, an anti-V5 antibody 
was used to check for the expression of EEF1A2. As shown below, even though 
there was an unequal protein loading in the wells, V5 was detected in the BT549 




Figure 4.15 Western blot on BT549 breast cancer cells transiently transfected with EEF1A2. 
Anti-V5 tag antibody was used to detect the presence of EEF1A2. No protein was detected in BT549 
cells nor in the MOCK cells whereas a protein band was detected in the BT549 cells transiently 
transfected with EEF1A2. MCF7 cells were used as a negative control as it was not transfected and 
therefore the V5 tag would not be detected. 
 
PTK6 was not detected in BT549, MOCK cells nor in the cells transfected 
with EEF1A2 (Figure 4.16). This confirms the real-time PCR results where EEF1A2 
expression did not affect the expression of PTK6. PTK6 was detected in MCF7 cells 
as two protein bands. This is always the case in this cell line as those two protein 




Figure 4.16 Western blot on BT549 breast cancer cells transiently transfected with EEF1A2 to 
detect a change in PTK6 expression.  No PTK6 protein was detected in BT549 cells nor in the 
MOCK cells or in the BT549 cells transiently transfected with EEF1A2. MCF7 cells were used as a 








Roles of EEF1A2 & PTK6 in Breast Cancer 
Chapter 4: Pathways affected by the overexpression of EEF1A2 132
4.3 Discussion 
 
4.3.1 Pathways affected by EEF1A2 expression 
 
Microarray data analysis on NIH-3T3 cells stably transfected with EEF1A2 
(section 4.2.1) showed a list of up- and down-regulated genes that were affected by 
the expression of EEF1A2 (Tables 4.1 and 4.3). As shown in section 4.2.1.2, many of 
these genes are associated with different types of cancers; either as oncogenes or 
tumor suppressor genes and therefore would be involved in cancer-related pathways. 
To determine pathways that are affected by the overexpression of EEF1A2, 
the “DAVID Pathway Viewer” was used (Huang da et al., 2009). This tool displays 
the genes on pathway maps to facilitate biological interpretation in a network context. 
From a list of the 500 most upregulated genes that were loaded, three main pathways 
from Biocarta were shown to be affected by the overexpression of EEF1A2. These 
pathways are the p53 signaling pathway (Figure 4.17), PML transcriptional regulation 
pathway (Figure 4.18) and the VEGF, Hypoxia, and Angiogenesis pathway (Figure 
4.19). 
In the p53 pathway (Figure 4.17), the four upregulated genes from the 
microarray data are Gadd45a (FC 1.5), Mdm2 (FC 1.4), p21 (FC 1.3) and Rb1 (FC 
1.2). As discussed in section 4.3.1, Kato et al. have shown that EEF1A was one of the 
genes upregulated by the overexpression of p53 (Kato et al., 1997). 
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Figure 4.17 p53 pathway showing four upregulated genes from the microarray data where NIH-
3T3 cells were stably transfected with EEF1A2. Genes upregulated in the study are circled in 
yellow: Gadd45, Mdm2, p21 and Rb (Biocarta). 
 
Growth arrest and DNA-damage-inducible protein (Gadd45) genes function 
as stress sensors that modulate the response of mammalian cells to genotoxic and/or 
physiological stress and modulate tumor formation. These proteins bind to stress 
modulators such as p21 and p38 kinases.  
HDM2 gene, the human homologue of murine double minute (mdm2) 
oncogene, blocks the function of p53 by binding to its transcriptional activation 
domain (discussed in section 1.1.5.1.4) (Figure 4.17). 
P21, also known as cyclin-dependent kinase inhibitor 1 or CDK-interacting 
protein 1 is a protein that in humans is encoded by the CDKN1A gene. Its expression 
is tightly controlled by the tumor suppressor protein p53 as it functions as a regulator 
of cell cycle progression. The retinoblastoma protein (Rb) is a tumor suppressor 
protein that is dysfunctional in many types of cancers (discussed in section 1.1.4.2). 
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Another pathway affected by the overexpression of EEF1A2 is the PML 
transcriptional regulation pathway (Figure 4.18) which has three of the upregulated 
microarray genes, one of them is RB along with PML and FAS.  
 
Figure 4.18 Regulation of transcriptional activity by PML. The three upregulated genes from the 
microarray list where NIH-3T3 cells were stably transfected with EEF1A2 are circled in yellow: RB, 
PML and Fas (Biocarta). 
 
Both PML and FAS showed a fold-change increase of 1.3 in the microarray 
list of upregulated genes. Promyelocytic leukemia (PML) protein functions as a 
transcription factor and tumor suppressor. As shown in figure 4.18, its expression is 
cell-cycle related and it regulates the p53 response to oncogenic signals. The gene is 
often involved in the translocation with the retinoic acid receptor alpha (RARα) gene 
associated with acute promyelocytic leukemia (APL).  
Fas (TNF receptor superfamily, member 6) encodes a receptor that contains a 
death domain therefore it plays an important role in the regulation of programmed 
cell death. It has also been implicated in the pathogenesis of various malignancies and 
diseases of the immune system. As shown in figure 4.17, Fas activates downstream 
substrates that inhibit growth. 
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The third pathway involved in the overexpression of EEF1A2 is the VEGF, 
hypoxia, and angiogenesis pathway (Figure 4.19). Three upregulated genes from the 
microarray list are involved in this pathway: VEGF and FAK both showed a 1.3 fold-
change increase and EIF2B that had a 1.2 fold-change increase. VEGF (Vascular 
endothelial growth factor) is a protein involved in angiogenesis. It plays an important 
role in inflammation and during normal and pathological angiogenesis, a process that 
is associated with wound healing, embryonic development, and growth and metastasis 
of solid tumors when overexpressed. Interestingly, as discussed in section 4.3.1, 
VEGF –like EEF1A2- has been associated with motor neuron degeneration in mice 
(Sathasivam, 2008).  
FAK (Focal Adhesion Kinase), also known as PTK2 is a non-receptor tyrosine 
kinase involved in cell motility, proliferation and apoptosis (Figure 4.19). Chan et al. 
reported that when FAK was blocked, breast cancer cells became less metastastic due 
to decreased mobility (Chan et al., 2009).  
EIF2B (Eukaryotic Translation Initiation Factor 2B) is another upregulated 
gene that is involved in this pathway. It is one of the initiation factors (IFs) associated 
with severe autosomal recessive neurodegenerative disease, described in young 
children as CACH (childhood ataxia with central nervous system 
hypomyelination)/VWM (leukoencephalopathy with vanishing white matter) 
syndrome. In the microarray list of genes, it showed a fold-change increase of 1.2.  
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Figure 4.19 VEGF, Hypoxia, and Angiogenesis pathway. The three upregulated genes from the 
microarray data where NIH-3T3 cells were stably transfected with EEF1A2 are circled in yellow: 
VEGF, FAK and IFs (Biocarta). 
 
Overexpression of EEF1A2 has also shown to downregulate genes as shown 
in table 4.3. Using the same “DAVID Pathway Viewer” tool, 200 downregulated 
genes from the microarray list were analyzed to determine if any were involved in 
cancer-related pathways. One pathway that was associated with EEF1A2 expression 
was the B Cell Survival Pathway (Figure 4.20). 
 
Roles of EEF1A2 & PTK6 in Breast Cancer 
Chapter 4: Pathways affected by the overexpression of EEF1A2 137
 
Figure 4.20 The B-cell survival pathway. The two downregulated genes from the microarray data 
where NIH-3T3 cells were stably transfected with EEF1A2 are circled in yellow: Survivin and FBI1 
(Biocarta). 
 
Two of the downregulated genes that are involved in this pathway are 
SURVIVIN and FBI1. Survivin, also known as BIRC5 (baculoviral inhibitor of 
apoptosis repeat-containing 5) showed a 1.6 fold-change decrease in the microarray 
list. It inhibits caspase activation leading to negative regulation of apoptosis. Since it 
is downregulated in this study, this would lead to caspase activation and thus promote 
apoptosis. 
FBI1 is a proto-oncogenic protein, which represses tumor suppressor ARF 
gene transcription. FBI1 also represses transcription of the Rb gene, a tumor 
suppressor gene important in cell cycle (Jeon et al., 2008). It showed a 1.4 fold-
change decrease in the NIH-3T3 stable cell lines expressing EEF1A2. As shown in 
figure 4.8, FBI1 is associated with cell proliferation. Therefore as its expression 
decreases by the effect of EEF1A2 overexpression, FBI1 downregulation could lead 
to reduced cell proliferation. Together with the downregulation of SURVIVIN, this 
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could lead to increased survival as reported by other groups (discussed in section 
4.3.1). 
 
4.3.2 Effect of EEF1A2 on cancer-related pathways 
A number of reports have indicated that eEF1A2 may play an important role 
in tumorigenesis and therefore act as an oncogene. Amiri et al. reported that eEF1A2 
is an activator of the protein kinase Akt in a phosphatidylinositol-3 kinase (PI3K)-
dependant manner (Amiri et al., 2007) whereas Li et al. showed that knockdown of 
Eef1a2 expression in PCT cell lines affected the JAK/STAT pathway suggesting that 
eEF1A2 may play an important role in the induction or progression of plasma cell 
neoplasms in mice and humans (Li et al., 2010).  
To examine which other genes/cancer-related pathways are affected by 
EEF1A2 expression, microarray analysis was carried out on NIH-3T3 stable cell lines 
generated in our lab that express eEF1A2. As shown in table 4.1, many upregulated 
genes were associated with different types of cancer. However, most of the 
downregulated genes are not known to be associated with tumorigenesis (Table 4.3). 
As shown in the p53 pathway (Figure 4.17), the oncogene Mdm2 is 
upregulated in the NIH-3T3 stable cells expressing EEF1A2 along with p21 and 
Gadd45. P21 overexpression blocks the effects of the Rb tumor suppressor gene 
while Mdm2 and Gadd45 are associated with tumor formation. The overexpression of 
EEF1A2 would eventually lead to the increased activity of those three genes and 
therefore make EEF1A2 an important therapeutic target in cancer. Interestingly, Kato 
et al. have shown that EEF1A was one of the genes upregulated by the 
overexpression of p53 (Kato et al., 1997). The authors reported that since p53 also 
plays a role in G2/M checkpoint regulation then this suggests that EEF1A might be a 
key factor in the regulation of cell cycle at G2/M. They have suggested that since p53 
upregulates the EEF1A gene, this provides new insights into the mechanism of the 
cell cycle and cell death, and it might also be an important target in cancer therapy. 
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Figure 4.18 shows the PML transcriptional regulation pathway which involves 
two upregulated genes from the microarray list PML and FAS. PML protein functions 
as a transcription factor and tumor suppressor. It is also associated with acute 
promyelocytic leukemia (APL). Therefore upregulation of this gene might decrease 
the risk of cancer development. The Fas receptor on the other hand activates 
downstream substrates that inhibit growth by promoting apoptosis. Therefore Fas 
could be an important therapeutic target in cancer treatment where its ligands would 
act as antagonists increasing its apoptotic activity and therefore reducing tumor size. 
 The third pathway that is affected by the overexpression of EEF1A2 is the 
VEGF, Hypoxia, and Angiogenesis pathway (Figure 4.19). The overexpression of the 
initiation factor EIF2B and VEGF would lead to the activation of the PI3K/Akt 
pathway that in turn leads to cell survival. This has been previously reported by Amiri 
et al. They reported that eEF1A2 is an activator of the protein kinase Akt in a 
phosphatidylinositol-3 kinase (PI3K)-dependant manner (Amiri et al., 2007). The 
same group showed that the expression of eEF1A2 in BT549 cells stimulated the 
formation of filopodia in these human breast cancer cell lines and in non-transformed 
Rat2 cells. Filopodia production enhances cell invasion and migration and therefore 
indicates the importance of eEF1A2 in promoting tumor development through 
phosphatidylinositol signalling, actin remodeling and cell motility (Amiri et al., 
2007). However, even though Amiri et al. suggested the involvement of eEF1A2 in 
tumorigenesis, other groups reported that high eEF1A2 protein expression was 
associated with increased survival (Pinke et al., 2008; Ruest et al., 2002). FAK is 
another gene in this pathway that is upregulated. It is involved in cell motility, 
proliferation and apoptosis (Figure 4.19). Chan et al. reported that when FAK is 
blocked, breast cancer cells became less metastatic due to decreased mobility (Chan 
et al., 2009).  
Interestingly, Oosthuyse et al. showed for the first time that manipulation of 
the VEGF gene in mice resulted in a new role for VEGF in the pathogenesis of motor 
neuron degeneration (Oosthuyse et al., 2001). 60% of mice with the homozygous 
deletion died before or around birth from vascular abnormalities in the lung whereas 
Roles of EEF1A2 & PTK6 in Breast Cancer 
Chapter 4: Pathways affected by the overexpression of EEF1A2 140
the remaining 40% that survived, begun to show symptoms of motor neuron 
degeneration at around five months of age. The authors suggested that insufficient 
VEGF leading to vascular abnormalities may put motor neurons at risk of late-onset 
neurodegeneration brought on by chronic ischemia (Oosthuyse et al., 2001). Since 
EEF1A2 is a translation factor also reported to be involved in motor neuron 
degeneration (section 1.3.1.1). These results further demonstrate the importance of 
EEF1A2 as a therapeutic target that could affect the downstream substrates and 
reduce cell proliferation and tumor development. 
Figure 4.20 shows the B-cell survival pathway which involves two 
downregulated genes from the microarray list FBI1 and Survivin. FBI1 is a proto-
oncogene which represses two tumor suppressors ARF and Rb. FBI1 is associated 
with cell proliferation. Therefore as its expression decreases by the effect of EEF1A2 
overexpression, FBI1 downregulation could lead to reduced cell proliferation. On the 
other hand, as shown in figure 4.20, FBI1 is another downstream substrate of the 
PI3K pathway but not through Akt.  
The data reported by Li et al. (Discussed on page 136) showed that 
knockdown of Eef1a2 expression in PCT cell lines indicate that eEF1A2 may play an 
important role in the induction or progression of plasma cell neoplasms in mice and 
humans. In this study, we show that overexpression of EEF1A2 –rather than its 
knockdown- downregulates FBI1 which is downstream of PI3K but not through the 
Akt pathway (Figure 4.20). These results are the opposite of what Li et al. have 
reported. This could be due to the fact that FBI1 is not affected by Akt but rather 
affected directly by PI3K (PI3K-FBI1 pathway).  
Survivin, which is another gene downregulated in this pathway (Figure 4.20), 
inhibits caspase activation leading to negative regulation of apoptosis. Since it is 
downregulated in this study, this would lead to caspase activation and thus promoting 
apoptosis.  
With both FBI1 and Survivin being downregulated and therefore leading to 
reduced cell proliferation and apoptosis with the overexpression of EEF1A2, these 
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results differ from the reports previously published by other groups that showed 
eEF1A2 having anti-apoptotic properties and that high eEF1A2 protein expression 
was associated with increased survival (Pinke et al., 2008; Ruest et al., 2002).  
Other microarray gene expression studies done by different groups on breast 
cancers showed different up- and down-regulated genes then the ones shown in our 
study (Ma et al., 2003; Sotiriou et al., 2006). Sotiriou et al. examined whether 
histologic grade was associated with gene expression profiles of breast cancers and 
whether such profiles could be used to improve histologic grading. Unlike our study 
(Tables 4.1 & 4.3), the five most upregulated genes in their study were UBE2C, 
RACGAP1, KPNA2, C10orf3 and PTTG1 whereas the five most down-regulated 
genes were TBC1D17, FLJ21628, SMARCA2, DIXDC1 and KIF13B (Sotiriou et al., 
2006). Another microarray analysis was generated by combining the use of laser 
capture microdissection and DNA microarrays. They generated in situ gene 
expression profiles of the premalignant, preinvasive, and invasive stages of human 
breast cancer (Ma et al., 2003). The top five genes with increased expression both in 
high tumor grade and the ductal carcinoma in situ- invasive ductal carcinoma (DCIS-
IDC) transition were IDH2, FLJ10540, KNSL1, ANKT and PRO2000 (Ma et al., 
2003).  
These breast cancer up-/down-regulated genes were not similar to the genes 
which showed a change in expression from our microarray data (section 4.2.1.2). This 
is most likely because the change of gene expression in our study is due to the effect 
of eEF1A2 expression in the NIH-3T3 transfected cells. 
 
4.3.3 Effect of EEF1A2 on cancer-related genes 
Table 4.1 shows the top 33 upregulated genes from the microarray list of 
which 14 genes were associated with different types of cancer. Five of the genes that 
were associated with breast cancer were studied in this project. These genes are: 
Serpine2, Egr1, Aldh3a1, Tpd52 and Dusp6. To confirm the microarray data, real-
time PCR was carried out on the stable cell lines to assess their expression level. 
Serpine2 showed the highest average fold-change increase in the microarray data 
(19.6) and as shown in table 4.5 and figure 4.9, its expression level was high in both 
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stable cell lines 7.2 and 10.2 but not in 9.6. This might be due to the EEF1A2 
construct being incorporated within the Serpine2 gene and therefore would have 
altered it expression. This could explain why there was a fold change increase in 7.2 
and 10.6 but not in 9.6 cells. Another explanation would be a technical artefact in the 
microarray chip, however, since real-time PCR results also showed a reduced 
SERPINE2 expression at the mRNA level in the 9.6 cells, the more valid hypothesis 
would be that the EEF1A2 construct was integrated within the Serpine2 gene. All 
other genes showed a fold-change increase between 2 and 3. Expression level of all 
these genes which were assessed by real-time PCR confirmed the microarray results. 
Surprisingly, when the same NIH-3T3 cells were transiently transfected with the 
same EEF1A2 construct, no change in the expression level of these five genes was 
detected (Table 4.7 & figure 4.11). This might explain the indirect role EEF1A2 plays 
in cancer which is the activation of cancer-related pathways which in turn activates 
downstream intermediates such as SERPINE2. In the transiently transfected cells, no 
increase of expression in those five genes was detected as cells were collected 24, 48 
and 72 hours after transfection which might not be the time scale long enough for 
these intermediates to be activated and therefore become overexpressed as observed 
in the stable cell lines. 
Western blots were carried out to detect the protein level of the five 
upregulated gene in the stable cell lines (Figure 4.10). Even though SERPINE2 
protein was expressed in all three stable cells along with the control cells, the protein 
expression was not as high as was detected at the mRNA level when the real-time 
PCR was carried out. Surprisingly, ALDH3A1 which showed an increased expression 
at the mRNA level in both the microarray data and in real-time PCR in 7.2 and 10.2 
cells, showed no protein expression in these two stable cell lines (Figure 4.10c). This 
might be the result of miRNAs either degrading ALDH3A1 mRNA or binding to the 
mRNA and inhibiting protein translation. As for the bands detected in 9.6, the 
antibody is probably cross-reacting with another protein. 
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EGR1, TPD2 and DUSP6 only showed 2-3 fold-change increase in the 
microarray data and a slight increase was detected at the mRNA level when real-time 
PCR was carried out (Table 4.5 and figure 4.8). The expression level did not show a 
high increase in the three stable cell lines when compared to the control cells nor did 
the expression level show much difference between those three cells. Western blots 
showed no expression at the protein level of TPD52 and DUSP6; this is consistent 
with the fact that NIH-3T3 do not usually express these proteins but is in contrast to 
the results of the microarrays. Egr1 however was expressed in all the stable cell lines 
but not at a higher level as that in the parental cells. 
These results provide evidence that EEF1A2 is involved in many cancer-
related pathways by indirectly activating many genes. This signifies its role as an 
oncogene as previously reported (Lee and Surh, 2009) and would therefore be a good 
therapeutic target for the treatment of breast cancer. 
 
4.3.4 Effect of transformation on cells 
NIH-3T3 cells are mouse fibroblast cell lines that do not express EEF1A2 
under normal conditions. However, as discussed in section 4.2.1.1, these cells 
developed an oncogenic phenotype when stably transfected with EEF1A2. 
Microarray analysis on these stable cell lines generated a list of many upregulated 
genes which are associated with different types of cancers (Table 4.1). A few were 
well documented in the literature as being associated with breast cancer as previously 
mentioned.  
Serpine2 is one of the genes associated with breast cancer and showed the 
largest increase in the microarray list. In another study conducted by Bergeron et al., 
Serpine2 was also the most upregulated gene with more than 28 fold-change increase 
in cells overexpressing activated MEK1 when compared to cells expressing the wild 
type MEK in the rat intestinal epithelial cells (Bergeron et al., 2010). MEK1 is one of 
the kinases that is known to be associated with different types of cancers. The 
overexpression of SERPINE2 was furthermore confirmed by carrying out real-time 
PCR. The authors also reported that SERPINE2 protein is secreted; they confirmed its 
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presence by carrying out Western blots after spinning down the proteins collected 
from the culture medium they grew in. This was not carried out when our stable cell 
lines were growing in culture in preparation for the microarrays experiment but cells 
were harvested and protein was extracted directly from the cells. It is possible that 
this is the reason for the discrepancy in the results.  
In another study where microarrays were conducted on NIH-3T3 cells stably 
transfected with the Rho oncogene, Serpine2 showed a fold-change increase of only 
0.15 (Berenjeno et al., 2007). However, they also reported an upregulation of four of 
the same genes that were upregulated in our microarray study with approximately 
similar fold-change increases. These genes are DUSP6, GADD45 and MDM2 (Figure 
4.17) and VEGF (Figure 4.19). 
Another study reported the upregulation of many cancer-associated 
genes/pathways detected by microarray data when NIH-3T3 cells were transfected 
with Kaposin A (Chen et al., 2009). A few of the upregulated genes that were 
involved in the cancer pathways were also the same that were upregulated in our 
microarray data. Kaposin A is a product of the Kaposi sarcoma-associated herpes 
virus (KSHV) which when transfected into the NIH-3T3 cells caused these cells to 
develop oncogenic properties, inducing cell proliferation and tumorigenesis. In the 
p53 pathway, they reported the upregulation of p21, Mdm2 and Gadd45. These are 
the same upregulated genes detected in our microarray data that showed an 
overexpression in the p53 pathway (Figure 4.17). Interestingly, Chen et al., have also 
shown the upregulation of VEGF in the Kaposin A expressing NIH-3T3 cells. Other 
pathways that have been upregulated in their study are the PI3K/Akt, STAT and 
MAPK pathways (Chen et al., 2009).  
Since the same pathways have been shown to be upregulated by different 
genes stably transfected into NIH-3T3, this shows that EEF1A2 is not the only gene 
affecting these cancer-related pathways and that there are other substrates that are 
involved. Being a translation elongation factor, EEF1A2 will probably affect the 
translation of other proteins that in turn activates/upregulates these pathways. The 
other explanation for the upregulation of the same genes in NIH-3T3 cells is that 
these genes could simply reflect the general state of transformation of cells. To 
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further understand whether EEF1A2 targets specific transcripts, SILAC (Stable 
Isotope Labeling by Amino acids in cell Culture) would be a useful tool to detect the 
proteins upregulated in our stable cell lines (Chapter 5, Future Directions). 
 
4.3.5 Effect of EEF1A2 expression on PTK6 and vice versa 
EEF1A2 and PTK6 are less than 50kb apart on 20.q13.3 and share many 
common properties. Both are overexpressed in 60% of breast cancers (Barker et al., 
1997; Kulkarni et al., 2007), are reported to be potential oncogenes (Lee and Surh, 
2009; Zhang et al., 2005), they promote cell growth, migration and inhibit apoptosis 
by activating the PI3K/AKT pathway (Kamalati et al., 2000; Li et al., 2010) and both 
were reported to be associated with increased survival (Aubele et al., 2007; Pinke et 
al., 2008). Showing all those similar properties, it was hypothesized that EEF1A2 and 
PTK6 act in tandem to increase the risk of developing breast cancer and that one of 
them acts as the driver while the other is the passenger. 
This was first examined in the NIH-3T3 stable cell lines that express EEF1A2. 
As shown in figure 4.12, no significant increase was detected in PTK6 expression. 
Similar results were found in the NIH-3T3 cells which were transiently transfected 
with EEF1A2. EEF1A2 expression was detected 24 hours after transfection and 
slightly decreased 48 hours later but PTK6 showed no change in expression (Figure 
4.13). The same experiment was repeated where EEF1A2 was transfected into the 
breast cancer cell lines BT549. As shown in the other cell line, no significant change 
in PTK6 expression was detected as confirmed by Western blots (Section 4.2.3.2.2, 
figure 4.15). 
Since EEF1A2 expression seems to have no effect on the expression level of 
PTK6, it was hypothesized that the opposite might be true where PTK6 might affect 
the expression level of EEF1A2. This hypothesis was considered after we established 
that the overexpression of PTK6 was due to its increased gene copy number in the 
primary breast tumors while EEF1A2 did not show a copy number as high as PTK6 
(Chapter 3). Therefore, to determine whether PTK6 affects EEF1A2 expression, the 
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same cell lines which were transfected with the EEF1A2 construct were now 
transfected with the PTK6 construct: NIH-3T3 and BT549. NIH-3T3 cell line showed 
a slight increase in the expression of PTK6 while BT549 showed a high PTK6 
expression with no significant change in EEF1A2 expression. When Western blots 
were carried out on these cells, PTK6 was not detected even though it showed an 
increased expression at the mRNA level detected by real-time PCR (Tables and 
figures are given in Appendix C). We cannot therefore be confident that PTK6 
expression has no effect on the expression level of EEF1A2. The construct used was a 
LacZ-PTK6 construct which should express the LacZ/PTK6 fusion protein. 
Excluding construct errors (no mutations, correct orientation), one of the reasons why 
cells that showed an increased PTK6 expression did not show PTK6 at the protein 
level might be that the fusion protein has a different conformation that the PTK6 
antibody could not recognize. Also, PTK6 is not normally expressed in these two cell 
lines and therefore when they are transfected and thus do express PTK6 at the mRNA 
level, miRNAs might degrade the mRNA or bind to it inhibiting translation and 
protein expression. 
These results clearly show that our initial hypothesis that EEF1A2 and PTK6 
act in tandem is not correct. Based on the studies done so far, we suggest that 
EEF1A2 and PTK6 act independently and that the expression of one does not affect 
the expression of the other and therefore each act through a different mechanism in 
breast tumorigenesis.  
These results of EEF1A2 expression in several breast tumors and breast 
cancer cell lines further confirm the role of EEF1A2 in breast tumorigenesis. As 
shown in this chapter, EEF1A2 contributes to breast cancer development by indirectly 
activating several downstream intermediates which in turn promotes cell division and 
invasion. This shows that EEF1A2 could be an important therapeutic target for the 
treatment of breast cancer. On the other hand, another set of downregulated genes 
reduce cell proliferation and promote apoptosis, thus supporting reports published by 
other groups reporting that high eEF1A2 protein expression was associated with 
increased survival (Pinke et al., 2008; Ruest et al., 2002). 
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Chapter 5: Discussion 
 
5.1 Summary of Results 
 
EEF1A2 and PTK6 are two genes located on 20q13.3. Several studies reported the 
amplification of this region in a number of tumor types including breast cancer. EEF1A2 
and PTK6 being less than 50kb apart and sharing many common properties, it was 
hypothesized that EEF1A2 and PTK6 act in tandem through the same mechanism in breast 
cancer and that one of these genes could be the driver in this amplicon.  
To test this hypothesis - whether EEF1A2 and PTK6 act in tandem or independently 
(chapter three), the copy number changes in the genes encoding EEF1A2 and PTK6 was 
related to their expression level using IHC on primary breast tumors TMAs from around 
300 patients, 55 of which were analyzed for copy number changes. Being in the same small 
genomic region, it was hypothesized that both genes would have an increased copy number 
in the tumors that strongly co-expressed both proteins. Surprisingly, as shown in table 3.3 
and figure 3.11, PTK6 showed an increased copy number in those tumors but not EEF1A2. 
Two other genes –KCNQ2 and SRMS- flanking both EEF1A2 and PTK6 were also tested 
for gene copy number in a smaller group of tumors but showed a normal gene copy number 
(Table 3.4 and figure 3.14). These results need to be expanded by using a larger set of 
tumors but from these data, it is clear that PTK6 is the only gene amplified to any 
significant degree.  
Also, in those 300 breast tumors that were analyzed, no significant statistical 
correlation was found between eEF1A2 and any of the histopathological parameters studied 
(grade and size of tumors, ER status, PR status, lymph node involvement, treatment 
modality (chemotherapy alone or chemotherapy and hormonal therapy) and disease free 
survival). On the other hand, PTK6 overexpression was associated with only low grade 
tumors and the estrogen receptor positive tumors. No correlation was found with tumor 
size, lymph node status or with disease-free survival of patients.  
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To expand on this work, EEF1A2 and PTK6 were analyzed to understand whether 
either affects the expression of the other. As shown in the results’ chapters where the 
expression of both genes was analyzed when either is expressed in cell lines, PTK6 
expression is clearly not affected by the expression of EEF1A2. Gene copy number 
analyses on breast tumors have shown that PTK6 is amplified in this region but not 
EEF1A2. This led us to the conclusion that each has a different mechanism contributing to 
breast cancer development. This shows that our initial hypothesis that one of those genes is 
the driver while the other is the passenger is clearly not correct.   
EEF1A2 has also been analyzed for its oncogenicity effect to establish its role as a 
therapeutic target. As shown in chapter four, the overexpression of EEF1A2 led to the 
upregulation of many cancer-associated genes. We also demonstrated that EEF1A2 could 
contribute to breast cancer development by indirectly activating several downstream 
intermediates which in turn promotes cell division and invasion. This shows that EEF1A2 
could be an important therapeutic target for the treatment of breast cancer. On the other 
hand, another set of downregulated genes reduce cell proliferation and promote apoptosis, 
thus supporting reports published by other groups reporting that high eEF1A2 protein 
expression was associated with increased survival (Pinke et al., 2008; Ruest et al., 2002). 
 
 
5.2 Future Directions 
 
5.2.1 Effect of EEF1A2 expression on protein synthesis 
Microarray data analysis on NIH-3T3 stable cell lines expressing EEF1A2 have 
shown that EEF1A2 is potentially responsible for the indirect upregulation of many cancer-
related genes/pathways. Being a translation elongation factor, EEF1A2 probably affects 
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Justyna Janikiewicz –a previous PhD student in our lab- measured the rate of global 
protein synthesis in all these stable cell lines expressing eEF1A2 along with control cells. 
This involved metabolic [35S] methionine/cysteine labelling of the cell lines stably 
expressing eEF1A2. The radiolabeled amino acids will incorporate into the newly 
synthesized polypeptides which are then measured for radioactivity levels. Justyna showed 
that the rate of protein synthesis in the stable cells is marginally lower than the control cells 
despite the increased growth rate and the colony and focus formation (Janikiewicz, 2010). 
This suggests that the oncogenic properties of eEF1A2 might derive from other non-
canonical functions of this protein or from affecting translation of specific messages rather 
than global translation. 
To further test this and to understand whether EEF1A2 targets specific transcripts, it 
would be interesting to perform SILAC (Stable Isotope Labeling by Amino acids in cell 
Culture) on one of the stable cell lines expressing EEF1A2 in comparison to the control 
cells. SILAC is a powerful and accurate technique for proteome-wide quantitation by mass 
spectrometry.  
The basic principle of SILAC is exposing a cell line to a given amino acid that will 
take it up from the growth medium and metabolically incorporate it into its proteome. This 
concept is exploited by passaging cell cultures in media containing either a normal (light) 
or a heavy form of a selected amino acid, most frequently Lysine and Arginine, where the 
light and heavy amino acids differ only in mass as a result of different isotopic content. 
Once fully labeled (after 5 to 7 doublings), cells can be collected and pooled together 
before performing any preparative procedures, thus eliminating quantitation inaccuracies 
introduced during sample handling. Finally, the proteome of the two differently labeled cell 
cultures (the control cells and one of the stable cell lines) will be analyzed in the same 
liquid chromatography-mass spectrometry (LC-MS/MS) run and the origin of the proteins 
or peptides can readily be discriminated based on the mass shift introduced by the different 
isotopic content conveyed by the labeled amino acid on these stable cell lines. We can then 
compare the protein expression generated from SILAC with the mRNA gene expression 
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5.2.2 EEF1A2 knockdown in breast cancer cell lines 
Even though normal mouse and human plasma cells do not express eEF1A2, it has 
been reported to be overexpressed in plasma cell neoplasms of both mice and humans (Li et 
al., 2010). In mouse plasmacytomas (PCT), eEF1A2 appears to contribute to cell 
transformation by affecting cell cycle progression and inhibiting apoptosis. A previous 
study showed that cultured myotube cells overexpressing eEF1A2 had enhanced cell 
growth and were resistant to apoptosis (Ruest et al., 2002) whereas Li et al. showed that 
phosphorylation of STAT3 in the JAK/STAT pathway was delayed and PI3K expression 
(part of the PI3K-AKT pathway) was reduced when Eef1a2 was knocked down in PCT cell 
lines (Li et al., 2010). The authors suggested that eEF1A2 may play an important role in the 
induction or progression of plasma cell neoplasms in mice and humans. 
It would be interesting to test the same concept but using breast cancer cell lines 
instead of mouse cell lines to check whether the knockdown of EEF1A2 would affect the 
same pathways in human cells. EEF1A2 would be knocked down in breast cancer cells that 
normally express EEF1A2. Since breast tumors respond differently to treatment based on 
the Estrogen Receptor (ER) status, the RNAi technique would be used on an ER+ and ER- 
breast cancer cell lines. Once the knockdown was achieved and confirmed by various 
methods (Western blots, real-time PCR), a microarray gene expression analysis would be 
performed. This would generate a list of upregulated and downregulated genes that might 
be involved in many cancer-related pathways. This will further shed light on the role of 
EEF1A2 as an oncogene and therefore will establish its role as a therapeutic target for 
breast cancer treatment.  
To further expand on this, it would be interesting to know whether the same 
concept applies on breast tumors. Perou et al. used microarrays and clustering to identify 
patterns of gene expression in human mammary epithelial cells in primary human breast 
tumors (Perou et al., 1999). This was followed by IHC on proteins encoded by a 
particular gene in a cluster. They showed that one cluster was found to correlate with 
variation in cell proliferation rates, another with Interferon (IFN) response. These reports 
supported the usefulness of studying variation in gene expression patterns in human 
cancers to classify breast cancer.  
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5.2.3 Role of MicroRNAs in EEF1A2 expression 
Most studies have shown that miRNAs downregulate gene expression by binding to 
the 3’UTR and either degrading the mRNA or binding to the mRNA and therefore 
inhibiting translation. However, in 2008, Dahiya et al. have reported the overexpression of 
eEF1A2 in the ovarian cancer cell line BG-1 when transfected with the miRNA let-7f 
(Dahiya et al., 2008).  
We established from this project (Chapter 3) that EEF1A2 gene copy number –
unlike PTK6- does not correlate with its expression level in human breast tumors, therefore 
other factors might contribute to the overexpression of eEF1A2. It would be of interest to 
determine if miRNAs play a role in EEF1A2 expression. This could be done by 
transfecting different miRNAs into breast cancer cell lines that express eEF1A2 
endogenously. miRNAs could be identified using different databases such as 
“www.microrna.org” .This will then be followed by measuring the expression of eEF1A2 
and that particular miRNA by real-time PCR to determine whether the miRNA has an 
effect on EEF1A2 expression. This will shed light on whether miRNAs affect the 
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5.3 Conclusion 
 
This study shed light on the function of two breast cancer-associated genes –
EEF1A2 and PTK6- on the 20q13.3 region. We clearly show that even though both genes 
are less than 50kb apart and share many oncogenic characteristics, both are associated with 
breast cancer through different mechanisms. As many other amplified regions in cancer, a 
specific gene is usually the driver of neighboring genes. Collins et al. have shown that 
analysis of a 1-Mb region on 20q13.2 produced evidence for five genes of which ZNF217 
is probably the driver (Collins et al., 1998). On the other hand, GC analysis of a 1.2-Mb 
region of amplification at 20q13.2 have identified 6 genes of which prefoldin 4 (PFDN4) 
was identified as the driver gene (Collins et al., 2001). Since both ZNF217 and PFDN4 are 
amplified in the same region, the authors reported for the first time the presence of a 
duplicon on the 20q13.2 breast cancer amplicon (Collins et al., 2001). We show however 
that this is not the case with EEF1A2 and PTK6 and that neither is the driver nor the 
passenger in this region as only PTK6 was amplified. EEF1A2 expression on the other 
hand led to the upregulation of many cancer associated genes/pathways making it a 
possible therapeutic target for cancer. Because EEF1A2 can activate multiple signaling 
pathways, further studies are needed to understand which signal is a key signal to control 
accelerated tumorigenesis by EEF1A2. 
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Figure A.2 Illustration of melting curves analysis. Melting curve
genes D5S478 and D11S913 primer sets were performed in order to
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Appendix B: Let-7f miRNA effect on eEF1A2 expression  
To examine whether let-7f miRNA might play a role in eEF1A2 overexpression in 
breast cancer, let-7f miRNA was transfected into the breast cancer cell line BT549 which is 
a cell line that does not express eEF1A2 under normal conditions. This was done to 
determine whether let-7f alone could trigger the overexpression of eEF1A2. Cells were 
collected 24, 48 and 72 hours after transfection. mRNA was isolated to detect the 
expression level of eEF1A2, and miRNA was purified to detect the expression level of the 
miRNA let-7f. Finally, protein was extracted to check for the expression of eEF1A2 by 
Western blotting, as miRNAs can exert their effect at the level of mRNA degradation 
and/or translational repression. Real-time PCR was performed as described above. The 
reference genes used for the mRNA were PUM1 (Pumilio homolog 1) and TBP (TATA-
box binding protein) whereas the reference gene used for the miRNA was U6 (Perkins et 
al., 2007; Szabo et al., 2004; Yamagata et al., 2009). The reference genes were selected 
based on previous reports on RT-qPCR studies and were used as endogenous controls to 
estimate the amount and integrity of the total RNA in each reaction. Reference genes in 
general always show a Ct value lower than that of the studied transcript. This correspnds to 
higher mRNA/miRNA abundance (ie the lower the Ct value, the higher the gene/transcript 
expression). This experiment was repeated three times to take into account experiment 
variability and ultimately to confirm results. The first and second transfections showed a 
slight increase in the expression level of both EEF1A2 and let-7f with no significant 
correlation (p-value 0.2) between the two (Figures B.1 and B.2 & tables B.1 and B.2). In 
the third transfection, let-7f showed an increased expression 48 hours post-transfection 
with a slight increase in EEF1A2. The expression of both EEF1A2 and let-7f decreased 
after 72 hours (Figure B.3 and table B.3). No significant association was found between the 
two (p-value 0.1). Surprisingly, even though EEF1A2 was expressed in the transfected cells 
at the mRNA level, Western blots showed no eEF1A2 expression at the protein level 24, 48 
and 72 hours post-transfection (Figure B.4). Unfortunately, due to the variability in the 
eEF1A2 and let-7f expression in each of the three repeated experiments, these results 
cannot be considered conclusive and would need to be followed up by more experiments 
either in a different cell line or by using another miRNA that might affect the expression 
level of EEF1A2 and therefore might help in the explanation of the role EEF1A2 plays in 
breast cancer.  
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Table B.1 Analyzing gene expression level of EEF1A2 & let-7f miRNA in BT549 breast cancer cell line 
transiently transfected with let-7f using the 2−∆∆Ct method (Experiment #1). 
Cells Ct gene Ct Ref G ∆CT ∆∆CT 2^-∆∆CT 
BT549 (EEF1A2) 32.52 34.60 -2.09 0 1 
BT549/Let-7f 24h 32.03 34.92 -2.89 -1 2 
BT549/Let-7f 48h 31.42 34.84 -3.42 -1 3 
BT549/Let-7f 72h 31.75 34.41 -2.65 -1 1 
BT549 (Let-7f) 35.77 28.07 7.71 0 1 
BT549/Let-7f 24h 33.82 27.42 6.40 -1 2 
BT549/Let-7f 48h 34.08 27.47 6.60 -1 2 
BT549/Let-7f 72h 34.46 27.81 6.65 -1 2 
 
 
Effect of Let-7f miRNA transfection into BT549 




















Figure B.1 First transfection: Effect of let-7f miRNA on eEF1A2 expression in BT549 breast cancer cell 
line. EEF1A2 and let-7f were normalized to the reference genes (PUM1 and TBP for EEF1A2, U6 for let-7f 
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Table B.2 Analyzing gene expression level of EEF1A2 & let-7f miRNA in BT549 breast cancer cell line 
transiently transfected with let-7f using the 2−∆∆Ct method (Experiment #2). 
Cells Ct gene Ct Ref G ∆CT ∆∆CT 2^-∆∆CT 
BT549 (EEF1A2) 35.58 35.64 -0.06 0 1 
BT549/Let-7f 24h 33.29 35.27 -1.98 -2 4 
BT549/Let-7f 48h 33.65 34.97 -1.32 -1 2 
BT549/Let-7f 72h 33.53 34.70 -1.17 -1 2 
BT549 (Let-7f) 36.05 27.66 8.39 0 1 
BT549/Let-7f 24h 33.71 26.99 6.72 -2 3 
BT549/Let-7f 48h 33.58 26.76 6.82 -2 3 
BT549/Let-7f 72h 33.51 27.10 6.41 -2 4 
 
 
Effect of let-7f expression on EEF1A2 in BT549 





















Figure B.2 Second transfection: Effect of let-7f miRNA on eEF1A2 expression in BT549 breast cancer 
cell line. EEF1A2 and let-7f were normalized to the reference genes (PUM1 and TBP for EEF1A2, U6 for 
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Table B.3 Analyzing gene expression level of EEF1A2 & let-7f miRNA in BT549 breast cancer cell line 
transiently transfected with let-7f using the 2−∆∆Ct method (Experiment #3). 
Cells Ct gene Ct Ref G ∆CT ∆∆CT 2^-∆∆CT 
BT549 (EEF1A2) 38.41 36.01 2.40 0 1 
BT549/Let-7f 24h 38.07 35.54 2.53 0 1 
BT549/Let-7f 48h 35.82 35.71 0.11 -2 5 
BT549/Let-7f 72h 37.51 35.75 1.76 -1 2 
BT549 (Let-7f) 36.05 27.66 8.39 0 1 
BT549/Let-7f 24h 33.71 26.99 6.72 -2 1 
BT549/Let-7f 48h 33.58 26.76 6.82 -2 7 
BT549/Let-7f 72h 33.51 27.10 6.41 -2 6 
Effect of the miRNA Let-7f transfection on EEF1A2 




















Figure B.3 Third transfection: Effect of let-7f miRNA on eEF1A2 expression in BT549 breast cancer 
cell line. EEF1A2 and let-7f were normalized to the reference genes (PUM1 and TBP for EEF1A2, U6 for 
let-7f miRNA) and then expressed relatively to the expression level in BT549 cells. 
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stern blot on BT549 cells transfected with let7-f to detect a change in EEF1A2 
 EEF1A2 was detected in BT549 cells or in the MOCK cells or in the BT549 cells transiently 
 let-7f. MCF7 cells were used as a positive control. GAPDH was used as a loading control. 
Roles of EEF1A2 & PTK6 in Breast Cancer 
Appendix 159
Appendix C: Effect of PTK6 expression in transiently transfected cells 
Transient transfection of EEF1A2 into NIH-3T3 cells and BT549 cells showed no 
effect of EEF1A2 expression on PTK6 expression (section 4.2.3). In this section, the 
opposite was examined with PTK6 being transfected into NIH-3T3 cells and BT549 to 
assess any changes in the EEF1A2 expression level. This was done to determine if the 
amplification and resulting overexpression of PTK6 shown in chapter three is the driver of 
overexpression of EEF1A2 in breast cancer. This would explain the co-overexpression of 
the two genes in so many individual tumors.  
 
C.1 Transient transfection of PTK6 into NIH-3T3 fibroblast cells 
The PTK6 construct was kindly provided by Micaela Aubele and Natalie Ludyga 
from the German Research Center for Environmental Health in Neuherberg, Germany 
(Figure C.1). The construct (which has the Lac-Z sequence and would therefore express 
PTK6-lacZ fusion protein) was transfected into NIH-3T3 cells and the expression level of 
EEF1A2 was analyzed. As shown in table C.1 and figure C.2, PTK6 level was slightly 
increased 24 hours after transfection and gradually decreased 48 and 72 hours later. 
EEF1A2 however did not show an increase in expression at the mRNA level as did PTK6.  
 
Figure C.1 LacZ-PTK6 expression construct. Construct and figure provided by Micaela Aubele and 
Natalie Ludyga from the German Research Center for Environmental Health in Neuherberg, Germany. The 
lacZ-PTK6 fusion vector was constructed by recombination of the pENTR221 hORF vector and the 
pSCREEN-iT/lacZ-DEST vector (Invitrogen) using the LR clonase II enzyme. attB sites immediately 
following the lacZ ORF for fast and efficient recombination to generate the lacZ/PTK6 gene fusion. The 
CMV promoter is used for strong expression of the lacZ-PTK6 gene fusion. 
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Table C.1 Analyzing gene expression level of EEF1A2 & PTK6 in NIH-3T3 cell line transiently 
transfected with PTK6 using the 2−∆∆Ct method. 
NIH-3T3 cells Ct gene Ct ref genes ∆CT ∆∆CT 2^-∆∆CT 
EEF1A2 
NIH-3T3 35.73 27.62 8.11 0 1 
NIH-3T3/PTK6 24h 35.87 27.65 8.22 0 1 
NIH-3T3/PTK6 48h 35.3 26.95 8.35 0 1 
NIH-3T3/PTK6 72h 35.54 25.63 9.9 2 0 
PTK6 
NIH-3T3 33.65 27.62 6.03 0 1 
NIH-3T3/PTK6 24h 31.23 27.65 3.58 -2 5 
NIH-3T3/PTK6 48h 32.18 26.95 5.23 -1 2 
NIH-3T3/PTK6 72h 31.58 25.63 5.95 0 1 
 
 
























Figure C.2 Transient transfection of PTK6 in NIH-3T3. Expression of PTK6 shows no change in EEF1A2 
expression 24, 48 and 72 hrs after transfection of the PTK6 construct. EEF1A2 and PTK6 were normalized to 
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 3T3     MOCK    3T3/1A2    3T3/1A2  3T3/1A2   MCF7 
                                 24hrs        48hrs     72hrs 
  PTK6 (52kD) 
A western blot was carried out to check for the expression of PTK6 in these NIH-
3T3 transfected cells (Figure C.3). PTK6 was not detected in the cells showing an increase 
in expression in the real-time PCR results as NIH-3T3 cells do not normally express this 
protein (Table C.1 & figure C.2). It was, however, detected as two protein bands in MCF7 
cells when Western blots were carried out.  
 
 
      
                                   
 
Figure C.3 Western blot o
PTK6 expression.  No PT
cells transiently transfected
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n NIH-3T3 cells transiently transfected with EEF1A2 to detect a change in 
K6 protein was detected in BT549 cells nor in the MOCK cells or in the BT549 
 with EEF1A2 24, 48 and 72 hours post transfection. MCF7 cells were used as a 
s detects two PTK6 protein bands that might indicate the presence of different 
s used as a loading control. 
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C.2 Transient transfection of PTK6 into BT549 cells 
The same PTK6 construct was transfected into BT549 breast cancer cells to assess 
the change in EEF1A2 expression as was shown in the NIH-3T3 cells (Table 4.9 and figure 
4.1). Real-time PCR analysis showed no increase in EEF1A2 expression and only slight 
increase in PTK6 expressing cells 24, 48 and 72 hours post-transfection (Table C.2 and 
figure C.4).  
Table C.2 Analyzing gene expression level of EEF1A2 & PTK6 in BT549 breast cancer cells transiently 
transfected with PTK6 using the 2−∆∆Ct method. 
BT549 cells Ct gene Ct ref genes ∆CT ∆∆CT 2^-∆∆CT 
EEF1A2 
BT549 35.22 30.21 5.01 0 1 
BT549/PTK6 24h 37.32 36.16 1.16 -4 14 
BT549/PTK6 48h 37.72 35.73 2.00 -3 8 
BT549/PTK6 72h 37.96 35.56 2.40 -3 6 
PTK6 
BT549 33.16 30.21 2.95 0 1 
BT549/PTK6 24h 30.61 36.16 -5.55 -9 362 
BT549/PTK6 48h 30.70 35.73 -5.02 -8 251 
BT549/PTK6 72h 31.30 35.56 -4.26 -7 148 
Effect of PTK6 transfection on EEF1A2 in 























Figure C.4 Transient transfection of PTK6 in BT549 breast cancer cells. Expression of PTK6 shows no 
change in EEF1A2 expression using real time PCR. EEF1A2 and PTK6 were normalized to the reference 
genes (PUM1 and TBP) and then expressed relatively to the expression level in BT549 cells. 
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Western blots were carried out to check for the expression of PTK6 in BT549 
transfected cells (Figure C.5). PTK6 expression was not detected in the transfected cells 
even though it was shown to be increased at the mRNA level when real-time PCR was 
carried out. Since this is a LacZ-PTK6 construct, it should express the LacZ/PTK6 fusion 
protein which might have a conformation different from PTK6 and therefore would hinder 
the PTK6 antibody from recognizing it. This might be one of the reasons why the PTK6 
antibody did not detect PTK6 protein in the Western blot. Another reason would be that 
there is a fault in the construct itself especially if the sequence was not in the correct 
orientation or if there were mutations in the sequence. 
 
 
   
                                 
 
Figure C.5 Western blot on BT549 breast cancer c
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